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Telomeres are the terminal nucleoprotein structures of chromosomes, protecting 
chromosomal ends from nuclease attack and recombination. Dysfunctional telomeres trigger 
genomic instability that underlies tumourigenesis. Poly (ADP-Ribose) Polymerase 1 (PARP-1), 
an important player in the base excision repair pathway, is a regulator of telomere length and 
telomeric end-capping function. In this study, we wanted to investigate the role of PARP-1 at the 
telomeres under conditions of DNA damage.  Sodium arsenite, the DNA damaging agent used in 
this study, is a potent environmental toxicant and a known inducer of oxidative damage. We 
identified that PARP-1 is a critical factor required for mouse cells to withstand arsenite-induced 
chromosomal aberrations and cell death. PARP-1 was also observed to have an essential function 
in defence against telomere attrition and resultant genomic instability.  
Interestingly, our microarray analysis revealed differential expression of copper 
metabolism and copper binding proteins following arsenite-induced DNA damage. Additionally, 
a link between copper metabolism and PARP-1 has been recently demonstrated where, copper 
was able to inhibit PARP-1 activity. Copper is a key component of enzymatic anti-oxidative 
defence systems yet under conditions of copper excess, it can be a key inducer of ROS. Defects 
in copper homeostasis are implicated in pathophysiologies such as cancer. Gene set enrichment 
analysis indicated that genes involved in copper metabolism were significantly differentially 
expressed in the absence of PARP-1 and following arsenite treatment. We thus investigated if 
copper metabolism may directly have a role in DNA damage response in mammalian cells.  
Copper supplementation reduced the levels of double strand breaks induced by genotoxicants in 
normal MEFs. Yet, in copper metabolism disease conditions such as Menkes and Wilson’s 
vii 
 
diseases, patient lymphoblastoid cells displayed increased levels of DSBs and genomic 
instability. These findings reiterate the importance of tight regulation of copper levels in the 
cellular milieu for proper biological function.  
We then further explored if specific factors in the copper metabolism pathway may affect 
the susceptibility to DNA damage. Antioxidant protein 1 (ATOX1), a copper chaperone, was 
down regulated in PARP-1 deficient MEFs. Furthermore, ATOX1 was recently established to be 
a copper-dependent transcription factor. While the antioxidant effects of ATOX1 have been 
demonstrated, its role in DNA damage response or the maintenance of genomic stability has not 
been clearly elucidated. We identified that Atox1 mRNA levels rose in response to hydrogen 
peroxide and arsenite exposure. Hence, we investigated the effect of ATOX1 deficiency in MEFs 
under conditions of genotoxicant-induced DNA damage. Increased DNA damage was observed 
in Atox1 deficient MEFs when challenged with sodium arsenite and radiation. The absence of 
ATOX1 was also responsible for increased levels of ROS as well as DSB sustained by the cells. 
In addition, genes in the DNA damage signalling, oxidative stress and anti-oxidant defence 
pathways were differentially expressed in the absence of ATOX1. Given that oxidative processes 
are major sources of DNA damage, we propose that the antioxidant properties of ATOX1 may 
protect genomic integrity. Although the nature of PARP-1 and ATOX1 interaction has not yet 
been elucidated, this study proposes a new paradigm for how copper metabolism impacts cellular 
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CHAPTER 1  
Introduction 
1.1 Review of Literature 
1.1.1 Genomic Instability 
Although genetic variation is an essential feature of evolution, genomic instability 
in normal cells may underlie tumourigenic progression (Hanahan and Weinberg, 2000). 
Genomic instability is characterised by the increased tendency of cells to acquire 
spontaneous, extensive and progressive changes in the genome (Lengauer et al., 1998). 
Genomic instability can be classified into chromosomal instability (CIN), referring to 
changes in chromosome number that lead to chromosome gain or loss, micro- and 
minisatellite instability (MIN), which leads to repetitive-DNA expansions and 
contractions [reviewed in (Aguilera and Gómez-González, 2008)], CpG Island 
Methylator phenotypes (CIMP) [reviewed in (Jass, 2007)] and a putative type that has 
been suggested to be point mutation instability (PIN) (Bielas et al., 2006). Some 
mutations in normal somatic cells predispose cells to further genomic changes, 
perpetuating genomic instability and subsequently cancer. These include alterations in 
genes regulating DNA repair, cell-cycle control mechanisms, and direct molecular 
modifications in dominantly transforming cellular proto-oncogenes [reviewed in 
(Aguilera and Gómez-González, 2008)]. Molecular mechanisms maintaining genomic 
stability are deficient in cancer, further aggravating the accumulation of genetic 
mutations and deficiencies of diverse mechanisms beyond repair [reviewed in (Meeker 
and Argani, 2004)]. 
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1.1.1.1 Telomere-mediated genomic instability 
The view that telomere dysfunction can serve as a potent driving force in the 
production of complex chromosomal rearrangements and aneupliody was first shown in 
maize where dicentric chromosomes induced prolonged breakage-fusion-bridge (BFB) 
cycles (McClintock, 1938, 1941). Telomeres are highly regulated, terminal 
ribonucleoprotein structures that shield the ends of linear chromosomes (Blackburn, 
1991). Telomeres are composed of guanine-rich hexameric DNA repeats and specific 
telomere binding proteins (Figure 1A) (Blackburn, 1991). Telomeres prevent the natural 
ends of chromosomes from being recognised as double strand breaks and protect the 
chromosomes from degradation and chromosomal fusions (Blackburn, 1991; Greider, 
1991). They also function in meiotic and mitotic pairing, as well as chromosome 
segregation during meiosis and mitosis, (Pandita et al., 2007) with key roles in nuclear 
organization and transcriptional silencing (Blackburn, 1991; Greider, 1990, 1991). The 
physical structure of the telomeres is believed to be in the form of a telomere loop (T 
loop) and displacement loop (D-loop) structure where the C terminal portion of telomeres 
folds back on itself to form the large T-loop and the 3' G-strand binds to the double-
stranded telomere repeat sequence of the 5'-end strand, forming a D-loop (Figure 
1B)(Greider, 1999). The protective function of telomeres is attributed to this physical 
conformation.  
1.1.1.1.1 Telomeres 
Telomere synthesis and maintenance are mediated by the telomerase enzyme. The 
telomerase complex is composed of an RNA component (hTR or hTERC; Figure 1C) 
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(Greider and Blackburn, 1985) with a sequence complementary to the telomeric repeats 
(Greider and Blackburn, 1989), and a catalytic component, the telomerase reverse 
transcriptase (hTERT) enzyme (Nakamura et al., 1997). With the RNA component as a 
template, TERT reverse transcribes and adds hexanucleotide telomeric repeats onto the 3’ 
end (Greider and Blackburn, 1989; Yu et al., 1990), maintaining telomere length. 
Telomerase, however, is expressed only in germ cells, stem cells (Wright et al., 1996) 
and re-expressed in majority of cancer cells (Kim et al., 1994). A small proportion of 
cancer cells utilise a telomerase independent mechanism termed alternative lengthening 
of telomere (ALT) employing homologous recombination for the maintenance of 
telomeres (Bryan et al., 1995). In the absence of telomerase, 50-150 bp of DNA is lost 
from the telomeres with each cell division (Harley et al., 1990; Hastie et al., 1990; Levy 
et al., 1992; Olovnikov, 1971, 1973). This phenomenon, known as the end replication 
problem (Figure 2), is due the unidirectional DNA polymerases not being able to fill the 
gap left by the primer on the terminal end of the lagging strand (Harley et al., 1990; 
Hastie et al., 1990; Levy et al., 1992). The terminal gap is further enlarged by the action 
of putative 5' to 3' exonucleases, which degrade 130-210 nucleotides (Hug and Lingner, 
2006). The gaps left by the primers at the ends of the chromosome result in net 
shortening of the telomeres with each replication cycle (Harley et al., 1990; Hastie et al., 
1990; Olovnikov, 1971, 1973; Watson, 1972) (Figure 2). Telomere loss is further 
aggravated by a variety of endogenous and exogenous factors such as oxidative stress, 






















Figure 1: Telomere structure.  
The fluorescence image shows the location of a telomere within a chromosome. Mammalian telomeres 
consist of TTAGGG repeats with a single-stranded 3’ overhang of the G-rich strand. (A) Specific 
protein complexes bind to the double- and single-stranded telomeric DNA. (B) The single-stranded 
overhang can invade the double-stranded portion of the telomere, forming protective loops — such as t-
loops and D-loops — at the invasion site. (C) The telomerase complex (which contains the telomerase 
RNA template and the reverse transcriptase (TERT) interacts with the overhang and is regulated by 
telomeric proteins. Other factors that can interact with telomeres are listed. Bidirectional arrows 






Figure 2: The telomeric end replication problem.                                              
The replication forks move in opposite directions.  Since DNA polymerases only elongate in the 5′ to 3′ 
direction, each fork contains a leading and a lagging strand. Lagging strand synthesis cannot be 
completed because the removal of primers thus causing net loss of DNA base pairs from the lagging 




Studies demonstrated the formation of tumours in mice with telomere dysfunction 
(Artandi et al., 2000; Blasco et al., 1997; Chin et al., 1999; Rudolph et al., 1999). 
Following this, several studies have highlighted the role of telomeres in inducing 
genomic instability and thus promoting tumourigenesis (de Lange, 2005; Desmaze et al., 
2003; Meeker and Argani, 2004; Meeker et al., 2004; Murnane, 2006; O'Hagan et al., 
2002). Hence, when telomeres are shortened to a critical length or when the secondary 
structure is compromised, the telomeres are unable to effectively protect the terminal 
ends. This causes the cell to elicit a DNA damage response, leading to cell cycle arrest 
and subsequently cell death (Wright and Shay, 1992). Telomere protection and 
maintenance are essential for prevention of genomic imbalances through BFB cycles 
[reviewed in (Feldser et al., 2003)], a major cause of structural chromosomal instability. 
These BFB cycles permit the accumulation of gross changes in the genome that underlie 
tumourigenic progression (Figure 3).  

















Figure 3: Breakage-fusion-bridge cycles. 
Telomere attrition renders the chromosomal ends prone to fusions resulting in prolonged BFB cycles 




DNA damage response involves a set of mechanisms that come into play when 
cells are exposed to genotoxic stress. It consists of genes involved in DNA damage 
processing, cell cycle control and apoptosis control. Additionally, proteins involved in 
chromosomal repair have also been found to have key roles in telomere maintenance. 
Ataxia telangiectasia mutated (ATM), one of the first DNA damage signalling molecule 
to be activated by DNA damage, has been shown to have a role in telomere maintenance 
(Metcalfe et al., 1996). Accelerated telomere loss, telomeric fusions and extra-
chromosomal telomeric fragments have been observed in cells from ataxia telangiectasia 
patients or ATM defective mice (Hande et al., 2001). Furthermore, human 
RAD50/NBS1/MRE11(MRN) complex and ATM have been identified in complexes 
with telomere binding protein TRF1 (Wu et al., 2007). Cells deficient in functional 
RAD50 and MRE11 in Drosophila, also display dysfunctional telomeres (Ciapponi et al., 
2004; Ciapponi et al., 2006; Wu et al., 2007). Proteins involved in non-homologous end-
joining (NHEJ), which include DNA-dependent protein kinase catalytic subunit (DNA-
PKcs), Ku 70 and Ku 80, have also been demonstrated to have key functions in telomere 
maintenance and function (Boulton and Jackson, 1996; d'Adda di Fagagna et al., 2001; 
Gilley et al., 2001; Hande et al., 1999). A model of telomere-mediated genomic stability 
has been proposed where the telomeres and DNA repair factors work to maintain the 
telomeres in equilibrium. The telomeres are affected by telomere loss at each cell cycle as 
well as proper capping function of the telomere-associated proteins. However, when this 
equilibrium is affected, telomere dysfunction leads to genomic instability and 
tumourigenesis (Hande, 2004) (Figure 4).  
1.1.1.1.3 DNA repair proteins in telomere maintenance 
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Figure 4: Model of telomere-mediated genomic instability.  
The flow chart highlights how DNA damage-signalling molecules and DNA repair factors may play a 
significant role in the maintenance of telomere equilibrium and in the event of this equilibrium not 




1.1.2 Inducers of genomic instability 
 
1.1.2.1 Oxidative stress 
 
Reactive Oxygen Species (ROS) are intermediates formed during oxidative 
metabolism, inflammatory responses as well as from exposure to environmental insults 
such as ultraviolet, ionising radiation and during oxidative metabolism of xenobiotic 
agents by p450s (Dawson et al., 1993; Griendling et al., 1994; Mohazzab et al., 1994; 
Rajagopalan et al., 1996). ROS production can be further exacerbated by the presence of 
‘free’ metals, such as iron, copper and manganese, that are released from metalloprotein 
complexes (van der Vliet, 2008). ROS include the super oxide anion (O2-), hydroxyl 
radicals (OH-) and hydrogen peroxide (H2O2). When the levels of ROS are not kept in 
check, oxidative stress ensues, causing damage to cellular components and the activation 
of other cellular processes (Figure 5). Oxidative stress-induced cellular damage can result 
in decreased efficiency of DNA replication, transcription and DNA repair [reviewed in 
(Mates and Sanchez-Jimenez, 1999)]. This condition of oxidative stress is thought to be 
behind a whole range of human pathologies from cardiovascular diseases (Gackowski et 
al., 2001; Yet et al., 2001); [reviewed in (Lee and Blair, 2001)], neurological diseases 
(Alam et al., 1997; Lezza et al., 1999), cancer [reviewed in (Rossman and Goncharova, 
1998)] and aging [reviewed in (Beal, 2002; Sohal et al., 2002)].  
Reactive oxygen species may interact with cellular components including DNA, leading 
to modification and potentially toxic by-products. DNA lesions formed by oxidative 
damage include DNA adducts, potentially mutagenic oxidised bases and DNA breaks 
[reviewed in (Cooke et al., 2003)]. Oxidative stress can result in increased levels of single 
strand breaks at the telomeres and accelerated telomere shortening (Saretzki et al., 2003; 
11 
 
Serra et al., 2003; von Zglinicki et al., 2000; von Zglinicki et al., 1995). Telomeres are 
also more prone to oxidative damage (Henle et al., 1999; Oikawa and Kawanishi, 1999) 
and are deficient in the repair of oxidatively generated single-strand breaks (Petersen et 
al., 1998). A proposed model to link oxidative stress to telomere attrition and replicative 
senescence is that t-loop formation hinders access of repair proteins to telomeres. This 
leads to accumulation of abasic sites and single-strand breaks due to oxidative damage. 
These may then accelerate telomere shortening by transient stalling of replication and in 
high numbers could destabilise the telomeric loop structure. As a result, the single-
stranded G-rich overhang, normally protected within the terminal loop structure, is 
exposed to the nucleoplasm (von Zglinicki et al., 2000). Free G-rich telomeric single 
strands are a strong inducer of the p53 pathway. Antioxidant enzymes and antioxidants 
retard telomere attrition (Kashino et al., 2003; Serra et al., 2003). Cells also gained an 
extension in lifespan when grown in low oxygen (Packer and Fuehr, 1977).  
Oxidative stress can thus bring about genomic instability by its effects on the 
telomeres, which can perpetuate BFB cycles. Apart from this, studies have identified that 
oxygen metabolism itself is a major source of endogenous double strand breaks and 
genomic instability (Karanjawala et al., 2002). The increase of ROS levels induced by 
expression of the superoxide dismutase 1 (Sod1) transgene was also shown to increase 
chromosome instability in primary adult and embryonic fibroblast cell cultures and this 
effect can be modulated by oxygen tension (Karanjawala et al., 2002). Additionally, 
reduced oxidative DNA damage was observable in primary fibroblasts cultured at 
physiological oxygen concentration, assessed by delayed onset of senescence (Chen et 
al., 1995). While ROS can directly affect signalling pathways to initiate tumourigenesis 
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(Arbiser et al., 2002; Arnold et al., 2001; Irani et al., 1997; Maciag et al., 2004), 






Figure 5: ROS levels determine cellular outcomes.  
Induction of ROS at lower levels leads to activation of signaling pathways responsible for regulating 
cellular proliferation and growth. Conversely, high levels of ROS generation can lead to DNA damage, 




1.1.2.2  Arsenic-induced oxidative stress  
Arsenic is a major environmental concern with inorganic arsenic classified as a 
human carcinogen by the US Environmental Protection Agency (U.S. Environmental 
Protection Agency,  2000). Human exposure to arsenical compounds occurs through both 
industries and natural sources. Although workers involved in industries utilizing arsenical 
compounds such as in vineyards, ceramics, glass-making, smelting, pharmaceuticals, 
refining of metallic ores, pesticide manufacturing and application, wood preservation, or 
semiconductor manufacturing are exposed to arsenical compounds, contaminated 
drinking water is the predominant source of acute and chronic arsenic exposure globally 
(Gebel, 2001). It has been found that millions of people are at risk of drinking water 
contaminated by arsenic with large numbers of contaminated sites having been identified, 
especially in developing countries (Hoque et al., 2000; Leonard and Lauwerys, 1980). 
Several epidemiological studies have identified a clear association between arsenic 
exposure and the increased incidence of cancer in the internal organs of individuals who 
chronically consume arsenic-contaminated drinking water (Anetor et al., 2007; Cantor 
and Lubin, 2007; Smith et al., 1992). Interestingly, arsenite has traditionally been in use 
as an anti-cancer drug in both Western medicine and traditional Chinese medicine. 
Arsenic-based compounds were reported to induce complete remission in patients with 
refractory acute promyeliotic leukaemia (Soignet et al., 1998).  
Although several epidemiological studies have documented the sources of 
exposure and the global impact of arsenic contamination, the underlying mechanisms of 
arsenic toxicity have not been completely elucidated.  Arsenic induces oxidative stress 
both in vitro and in vivo. Arsenic induced heat shock or stress proteins such as haeme 
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oxygenase, and c-fos oncogene in vitro and in vivo, implicating oxidative damage as an 
underlying basis of genotoxic effects [(Brown and Rush, 1984); reviewed by (Del Razo et 
al., 2001)]. The mutagenic response of arsenite was also partly mediated by ROS (Hei et 
al., 1998; Kessel et al., 2002) (Figure 6). Antioxidant enzymes, catalase and SOD 
reduced the extent of arsenite–induced DNA damage (Nordenson and Beckman, 1991; 
Wang and Huang, 1994). Antioxidants such as vitamin E, methylamine and benzyl 
alcohol also decreased the extent of cell death in human fibroblasts by arsenite (Lee and 
Ho, 1994).  
Spin trap agents that protect against oxidative stress were effective in protecting 
against arsenite-induced telomere attrition and apoptosis, suggesting that reactive oxygen 
species may play an important role in the shortening of telomeres and apoptosis induced 
by arsenic (Zhang et al., 2003). Liu et al demonstrated that arsenic-induced oxidative 
stress promoted telomere attrition, chromosome end-to-end fusions, and apoptotic cell 
death with antioxidant, N-acetylcysteine, effectively preventing arsenic-induced 
oxidative stress, telomere erosion, chromosome instability, and apoptosis (Liu et al., 
2003). Low concentrations of less than 1 µM arsenite increase telomerase activity, 
maintain or elongate telomere length, and promote cellular proliferation in HaCaT and 
HL-60 cells (Zhang et al., 2003). On the other hand, high concentrations of arsenite 
(more than 1 µM) decreased telomerase activity, telomere length and induced apoptosis 
(Zhang et al., 2003). In mouse embryonic fibroblasts (MEFs) lacking telomerase RNA 
component (mTERC-/-) with long (early passage) and short (late passage) telomeres, the 
differences in DNA damage, chromosome instability, and cell survival at varying time 
points of arsenite exposure imply that short dysfunctional telomeres impair the repair of 
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oxidative damage caused by arsenite (Newman et al., 2008). Hence, arsenic compounds 
may have a critical role in inducing telomere-mediated genomic instability. Apart from 
this, arsenic compounds induced genomic instability in the form of increased 
chromosomal aberrations, sister-chromatid exchanges, and micronuclei formation in both 
human and rodent cells in culture (Barrett et al., 1989; Hartmann and Speit, 1994; Jha et 
al., 1992) and in cells of exposed humans [(Vega et al., 1995); reviewed in (Rossman, 
2003)]. Other than oxidative stress, DNA repair inhibition capacity  as well as properties 
of inorganic arsenic in the pentavalent state to replace phosphate in several reactions  
may be additional mechanisms contributing to arsenic-induced genotoxicity (Li and 
Rossman, 1989a). Part of the DNA repair inhibition properties of many arsenical 
compounds including arsenite, MMA(III), DMA(III), TMA(III), and dimethylarsine can 
be attributed to the affinity for proteins with thiol and free sulfhydryl groups, which are 
common in DNA-binding proteins, transcription factors, and DNA-repair proteins (Li and 
Rossman, 1989b)(Delnomdedieu et al., 1993, 1994; Scott et al., 1993). Arsenic-induced 










Figure 6: Hypothesis for induction of oxidative DNA adducts and protein cross-links by arsenic. 
Solid lines indicate well-established pathway. Dotted lines indicate tentative pathways. It is not fully 
understood how arsenite induces nitric oxide (NO) in a calcium dependent process, which then reacts 
with superoxide (O2-) to produce peroxynitrite (ONOO-). O2- is converted to hydrogen peroxide (H2O2) 
by superoxide dismutase. H2O2 produced can react with Fenton metal ions to produce hydroxyl radicals 
capable of causing oxidative DNA damage. H2O2 may also induce such damage by the overproduction 




 1.1.2.3 Radiation  
A broad range of potentially mutagenic lesions in DNA is induced by ionising 
radiation despite its well known role in cancer therapy (Hutchinson, 1985; Ward, 1988) 
(Figure 7). Radiation also induced innate genomic instability in the form of chromosomal 
rearrangements, chromosomal bridge formation, chromatid breaks and gaps and 
micronuclei (Grosovsky et al., 1996; Kaplan et al., 1997; Murnane, 1996; Suzuki et al., 
1998) that persist in surviving cells following the initial radiation exposure. Furthermore, 
ionising radiation produces damage directly and indirectly through the production of 
ROS [reviewed in (Mikkelsen and Wardman, 2003)]. DNA double-strand breaks (DSBs) 
are generally accepted to be the most biologically significant lesion by which ionising 
radiation cause cancer and hereditary disease (Rothkamm and Lobrich, 2003). As a form 
of ionising radiation, gamma rays cause serious damage when absorbed by living tissue 
resulting in cellular damage, radiation sickness and increased incidence of cancer. 
Radiation-induced genomic instability (RIGI) is a non-targeted radiation effect of 
inducing genomic instability in the progeny of irradiated cells (Maxwell et al., 2008).  
Additionally, radiation exposure induced the activation of inflammatory cells, generating 

















Figure 7: Induction of DNA damage by radiation.  
Radiation causes biological effects by energy transfer. Part of the transfer induces excitation, which is 
usually rather harmless, part induces ionisation. In the aqueous cell environment ionised molecules 
create reactive radicals like OH• and H• and hydrated electrons. A multitude of reactions with oxygen 
and organic matter generates novel highly reactive compounds, that can react with vital biomolecules 




1.1.3 Mechanisms for preventing genomic instability 
 
Given the impact of ROS on the stability of cellular systems, organisms have 
evolved enzymes such as SOD, glutathione and catalase which physiologically combat 
the effects of ROS. SOD converts the highly reactive superoxide to H2O2 and water. 
H2O2 is then subsequently converted to water and oxygen by catalase (McCord and 
Fridovich, 1969). Antioxidant amino acids, vitamins and polyphenols bind free radicals 
to form less reactive intermediates and hence limiting damage to the cellular components 
(Akashi et al., 2001; Lass et al., 2002; Rassaf et al., 2002; Redmond et al., 1996; Wu and 
Morris, 1998). As a second line of defense, incorporation of damaged bases into DNA is 
prevented by enzymes that hydrolyse oxidised deoxyribonucleotide triphosphates such as 
8-oxo-7, 8-dihydroguanine triphosphates to the corresponding monophosphates (Sakumi 
et al., 1993). However, despite such mechanisms, endogenous damage still occurs hence 
requiring specific repair mechanisms. Base excision repair (BER), transcription-coupled 
repair (TCR), global genome repair (GGR), mismatch repair (MMR), translesion 
synthesis (TLS), homologous recombination (HR) and non-homologous end-joining 
(NHEJ) all contribute to repair of oxidative DNA damage [reviewed in (Hoeijmakers, 
2001; Slupphaug et al., 2003)]. These mechanisms integrate with other cellular processes 




1.1.3.1 Poly (ADP-ribose) polymerase 1 (PARP-1) 
Human poly (ADP-ribose) polymerase 1 (PARP-1), a key player of the BER 
pathway, is a 113 kDa enzyme encoded by the Parp-1 gene on chromosome 1q41–42. 
PARP-1 is part of a family of enzymes that mediate poly (ADP-ribosyl)ation of proteins 
(Chambon et al., 1963). The catalytic centre in the C-terminus of PARP-1 termed the 
“PARP signature sequence” is highly conserved between species in PARP-1 and found in 
other members of the PARP family (Shall and de Murcia, 2000). PARP-1 and PARP-2 
are nuclear, but other PARP family member such as PARP-3, tankyrase-1, tankyrase-2, 
and vault PARP were also identified in other cell compartments. While PARP-1 and 
PARP-2 are activated by DNA strand breaks, the mechanisms that regulate the activity of 
other cellular PARPs are poorly understood (Meyer-Ficca et al., 2005). PARP-1 catalyses 
the synthesis of over 90 % of cellular poly (ADP-ribose) following DNA damage 
(Meyer-Ficca et al., 2005). PARP-1 is implicated during DNA repair as a recruiting 
molecule by directly recognising the lesion and then recruiting the BER machinery to the 
site of damage and regulating DNA access and activity of DNA repair enzymes like 
XRCC1 [X-ray repair cross-complementing factor; (Meyer-Ficca et al., 2005; von Kobbe 
et al., 2004)] and Werner syndrome nuclear protein [WRN; (von Kobbe et al., 2004)]. 
PARP-1 binds to single strand breaks (SSB), activating the enzymatic activity to add 
ADP-ribose units from nicotinamide adenine dinucleotide (NAD)
 
hydrolysis to many 
nuclear proteins including itself as the major substrate. Subsequently, the molecule 
becomes more charged, dramatically decreasing PARP’s affinity for SSBs (de Murcia 
and Menissier de Murcia, 1994). Mammalian cells also possess depolymerising activity 
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for removing the ADP-ribosyl residues from the modified proteins via the poly (ADP 
ribose) glycohydrolase enzyme [PARG; (V Rolli, 2000)].  
PARP-1 has a critical role in ensuring the genomic stability of the cell [reviewed 
in (Masutani et al., 2003)(Bürkle et al., 2002)]. Cells over-expressing human PARP-1 
displayed fewer sister-chromatid exchanges (SCE) upon treatment with alkylating agents 
than in control cells (Meyer et al., 2000). Conversely, genetic disruption of the Parp-1 
gene renders mice hypersensitive to genotoxic agents and results in genomic instability as 
measured by high SCE frequencies and, in the absence of a functional p53 gene, 
increased tumour formation (Shall and de Murcia, 2000). In addition to increased SCE 
frequency, PARP-1 knockout mouse cells displayed increased levels of micronuclei after 
DNA damage (Wang et al., 1997). PARP-1 null mutation in mice caused high levels of 
aneuploidy, chromosomal fragmentation and fusion as well as chromosome loss and gain 
(Gomez et al., 2006; Pleschke et al., 2000; Wang et al., 2007). Other studies have shown 
that PARP-1 deficiency due to chemical inhibition or dominant negative mutations cause 
genomic instability in human cells (guilar-Quesada et al., 2007; Seimiya, 2006; Smith 
and de Lange, 2000). Over expression of a dominant negative PARP-1 DNA binding 
domain, which reduces PARP-1 dependent poly (ADP-ribosyl)ation, sensitised cells 
towards γ-irradiation and alkylating agents (Molinete et al., 1993). All these studies 
emphasise the important role of PARP-1 in the maintenance of genomic stability.  
 PARP-1 has an additional function as a transcription factor [Reviewed in (Kraus, 
2008). Recent studies show key abilities of PARP-1 to affect expression of other DNA 
repair genes (Hegan et al., 2010). It is not fully understood how the transcriptional 
function of PARP-1 affects the maintenance of genomic stability. Apart from this, 
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correlative data implicate the role of PARP-1 in cancer (Barnett et al., 2010; Barton et al., 
2009; Tentori et al., 2007; Tong et al., 2007) and ageing [reviewed in (Beneke and 
Burkle, 2007). Furthermore, major progress has been made in the employment of low-
molecular weight PARP inhibitors as monotherapeutic agents or in support of 
mainstream chemotherapy or radiotherapy [reviewed in (Mangerich and Burkle, 2011)]. 






1.1.3.1.1 Role of PARP-1 at the telomeres 
The role of PARP-1 in telomere maintenance was first reported by Fagagna et al. 
where embryonic fibroblasts and primary cells derived from PARP-1 deficient mice had 
shortened telomeres as compared to the wild type litter mates   without any change in the 
intrinsic telomerase activity (d'Adda di Fagagna et al., 1999). These mice were also found 
to have increased chromosomal instability. Some studies reported that telomere lengths 
were normal although increased genomic instability was observed in the PARP-1 
deficient mice (Samper et al., 2001). However, it was suggested that this difference could 
have been attributed to mice of different genetic background and variable mutations of 
the same gene displaying different effects (Hande, 2004). 
Since then, PARP-1 was identified to preferentially bind telomere repeat-binding 
factor 2 (TRF2), under conditions of DNA damage (Beneke et al., 2008; Gomez et al., 
2006). Increased telomere dysfunction and subsequent genomic instability was also 
evident in PARP-1 deficient murine embryonic stem cells and MEFs upon DNA damage 
(Gomez et al., 2006). Tong et al identified that PARP-1 cooperates with p53 in the 
maintenance of genomic stability with a functional interplay at the telomeres (Tong et al., 
2001). Similarly, haploinsufficiency of PARP-1 in the absence of breast tumour 
associated gene 1 (BRCA1), a known effector of the homologous end-joining pathway, 
was associated with increased telomere dysfunction and genomic instability (Wang et al., 
2007). Combined deficiency of PARP-1 and haploinsufficiency of Ku80, a component of 
the non homologous end joining (NHEJ) repair pathway in MEFs resulted in increased 
genomic instability in comparison to the cells deficient in only PARP-1 or Ku80 (Tong et 
al., 2002).  Hence, it is evident that PARP-1 plays a significant role at the telomeres and 
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this role involves interaction with other repair pathways, although the specific mechanism 
is not fully elucidated.  
Tankyrase 1 is another poly (ADP-ribose) polymerase that has been shown to 
have a role at the telomeres is. It is a telomere specific member of the PARP family, that 
interacts with and  prevents binding of TRF1 protein to telomeres, which in turn 
facilitates addition of telomeric repeats by telomerase (Smith and de Lange, 2000). 
Furthermore, PARP inhibition, in addition to telomerase inhibition has been shown to 




Study Cell type Effect on telomeres Effect on genomic stability 
De Murcia et al.,1997 PARP-1-/- mice with 
irradiation/ alkylating agents. 
Not investigated Increased genomic instability with 
high mortality. 
d’ Adda di Fagagna et al.,  
1999 
PARP-1-/- mice. Telomere shortening Increased genomic instability.  
Samper et al., 2001 PARP-1-/- mice. Normal telomere length  Increased genomic instability. 
    
    
Tong et al, 2001 PARP-1-/-p53-/-MEFs. Heterogeneous telomere  
length 
Increased genomic instability. 
Tong et al., 2002 PARP-1-/-Ku80+/- Mice. Not investigated Increased genomic instability 
(telomere-associated genomic 
instability). 
Espejel et al., 2004 PARP-1-/-mTERC-/- mice. Normal telomere length No increase in genomic instability. 
 PARP-1-/- mice. Normal telomere length No increase in genomic instability. 
Gomez et al., 2006 PARP-1-/- mouse embryonic 
stem cells and MEFs with 
DNA damage. 
No change in telomere 
length 
Increased genomic instability. 
Aguilar-Quesada et al., 
2007 
ATM-/- MEFs with PARP 
inhibitor and ionising 
radiation. 
Not investigated Increased genomic instability 
(decreased repair efficiency). 
Wang et al., 2007 PARP-1+/-p53-/- MEFs. Increased telomere 
shortening 
Increased genomic instability. 
Beneke S, 2008 COM3 hamster cells and 
HeLa, IMR90 human cells 
with pharmacological 
inhibitor for PARP and 




Tong and Hande 
(unpublished) 
PARP-1-/-Ku80+/- mice. Shortened telomeres Increased genomic instability 
(telomere-associated genomic 
instability). 
Table 1: Effect of PARP-1 deficiency on telomere maintenance and chromosome-genomic instability.  
The table highlights the various studies that have investigated the role of PARP-1 at the telomeres.   
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1.1.4 Copper metabolism and disease 
In all living organisms, copper ion is required as an essential trace element and a 
cofactor for enzymes which depend on copper for their function in diverse biological 
processes. Biological roles include mitochondrial function, neurotransmitter biosynthesis, 
oxidative stress defense, and iron transport (Frieden, 1986). However, excess copper in 
the body is toxic and have deleterious effects. Unbound free copper ions readily react 
with H2O2 in the cells to yield hydroxyl radicals, responsible for inducing intracellular 
oxidative stress, lipid peroxidation, protein malfunction and DNA damage (Hochstein et 
al., 1980; Salhany et al., 1978). Specialised copper homeostasis mechanisms highly 
regulate the uptake, transport and removal of copper inside the cell (Camakaris et al., 
1999) (Figure 9). Copper is transported into the cell by a plasma membrane transport 
protein, copper transporter 1 (Ctr1) and is bound to a specific class of proteins inside the 
cell known as copper chaperones. Copper chaperones pass copper to specific proteins 
such as Cu/Zn superoxide dismutase (SOD1) (Valentine and Gralla, 1997), cytochrome 
oxidase in the mitochondria (Cox, 1995) or to copper transporting ATPases in the Golgi 
apparatus for later incorporation to the cuproenzymes or for secretion.  
Genetic and nutritional studies have illustrated the essential nature of copper 
binding proteins where alterations in their levels are associated with severe pathology 
(Prohaska and Gybina, 2004). Mutations in the copper transporting ATPases, Menkes 
P_type ATPase (ATP7A) and Wilson P_type ATPase (ATP7B) result in Menkes disease 
(Chelly et al., 1993; Vulpe et al., 1993) and Wilson’s disease (Bull et al., 1993) 
respectively. ATP7A controls the absorption of copper from dietary intake in the 
intestines. Under normal conditions, the protein resides in the Golgi apparatus to 
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transport copper to the cuproenzymes which are secreted. However, under conditions of 
excess copper in the cell, the protein moves to the plasma membrane of the cell and aids 
in excreting the excess copper (Dierick et al., 1997; Petris et al., 1996; Yamaguchi et al., 
1996). Thus the defective form of this protein (Menkes disease) is characterised by 
reduced dietary copper transport from intestinal enterocytes into the bloodstream with 
accumulation in intestines and kidneys and unusually low levels in the brain and other 
tissues. The clinical manifestations arise due to the deficiencies in the activity of the 
essential cuproenzymes.  
On the other hand, Wilson’s disease is caused by a genetic mutation in the Atp7b 
gene. It results in the inability of the liver to pump copper ions to the bile, causing liver 
damage (Bull et al., 1993). ATP7B, an ATP-driven copper efflux pump in hepatocytes, 
transports copper to ceruloplasmin, which then transports it to other parts of the body via 
the blood stream. However, under conditions of elevated copper levels, ATP7B leaves 
the Golgi and transfers copper into vesicles to be excreted through the bile (Roberts and 
Cox, 1998). As this route is the only physiological mechanism for copper excretion from 
the body, defects in this gene result in copper accumulation and eventually cause cellular 
necrosis and leakage of copper into the plasma and deposition of copper in extra hepatic 
tissues, including the limbus of the cornea and the basal ganglia of the brain (Culotta, 
2001).  
Copper levels are different in cancers as compared to the normal surrounding 
tissue (Gupta et al., 1991; Margalioth et al., 1983). In tumour cells with acquired 
resistance to the anticancer drug, cisplatin (CDDP), cellular accumulation of CDDP is 
often impaired. The transporters of the copper homeostasis system in the process of 
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uptake and efflux of CDDP have been implicated in causing resistance. In particular, the 
absence of Ctr1 impaired the capacity of cells to accumulate CDDP and thus increase the 
degree of resistance of cancer cells to the cytotoxic effects of this drug (Holzer et al., 
2006; Holzer et al., 2004; Ishida et al., 2002; Lin et al., 2002). Copper-containing 
ATPases, ATP7A and ATP7B affect the efflux or vesicular sequestration of CDDP and 
are regulators of the cytotoxic effect of CDDP (Katano et al., 2002; Komatsu et al., 2000; 
Safaei and Howell, 2005; Samimi et al., 2004).  
 
1.1.4.1 PARP- 1 and Copper metabolism  
 
It was demonstrated that in rat brain, low concentrations of 5µM copper stimulate 
the activity of purified PARP. Further increases in copper concentration to 50 µM 
inhibited the enzymatic activity till the polymerase activity appeared to be fully inhibited 
(Zaalishvili et al., 1990). This was supported by another study, which demonstrated that 
copper induced the inhibition of activity in isolated PARP-1 (Schwerdtle et al., 2007). 
Here the authors reported that at cytotoxic concentrations of copper, oxidative DNA base 
modifications and DNA strand breaks were induced. However, at lower non cytotoxic 
concentrations, copper inhibited the repair of oxidative DNA damage and inhibited poly 
(ADP-ribosyl)ation upon H2O2 treatment. In cultured cells, copper induced strong 
inhibition of PARP-1 activity (Schwerdtle et al., 2007). The authors pointed out the 
importance of copper doses in the differential biological effects that were observed. 
Copper mis-regulation has also been implicated in diseases including cancer which are 
characterised by genomic instability (Gupta et al., 1991; Inutsuka and Araki, 1978; 






















Figure 8: Intracellular uptake and transport of copper.  
Copper is readily taken up into the cells by Ctr1 and then passed on to copper chaperones which then 
traffic copper to the various copper-dependent pathways. Excess copper is excreted by the liver into bile 




1.1.5 Copper chaperone, Antioxidant protein 1 (ATOX1) 
ATOX1 is an 8 KDa metallochaperone that delivers copper to ATP7A and 
ATP7B copper transporters (Huffman and O'Halloran, 2000; Lin et al., 1997; Pufahl et 
al., 1997; Wernimont et al., 2000). Originally isolated as an antioxidant protein in 
Saccharomyces cerevisiae (Lin and Culotta, 1995; Lin et al., 1997), ATOX1 also 
functions in a high affinity iron uptake pathway in yeast. Human ATOX1 maps to 
chromosome 5q32 (Boultwood et al., 2000).  Marked increase in intracellular free copper 
content was observed in Atox1 deficient mouse embryonic fibroblasts due to the impaired 
copper efflux (Hamza et al., 2001). Copper levels in the liver and brain however, are 
decreased by 50 % in Atox1 deficient MEFs, consistent with an impaired efflux of copper 
from enterocytes (Hamza et al., 2001). In addition, Atox1-/- mice have diminished activity 
of secretory copper enzymes lysyl oxidase, dopamine monooxygenase, and tyrosinase, 
leading respectively to, impaired connective tissue integrity, impaired temperature 
regulation, and hypopigmention (Jeney et al., 2005).  
ATOX1 is present at high levels in neurons and may protect these cells from 
oxidative stress (Kelner et al., 2000). Oxygen toxicity of yeast mutants lacking SOD1 can 
be suppressed by ATOX1 expression (Lin and Culotta, 1995; Lin et al., 1997). SOD1 and 
ATOX1 are thus thought to have additive and independent roles in protecting against 
superoxide damage (Lin and Culotta, 1995). The antioxidant effect of ATOX1 has been 
proposed to be important in protecting against cancer progression (Lin and Culotta, 
1995). Atox1 deficiency also contributed to CDDP resistance (Safaei et al., 2009). 
Interestingly, ATOX1 has been shown to be reduced in metastatic colorectal cancers as 
compared to non-metastatic colorectal cancer cell lines (Humar et al., 2002). 
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Furthermore, chemoprevention trials against human colon polyp recurrence in colon 
cancer patients using selenomethionine have indicated an increase in Atox1 levels which 
may be associated with the mechanism of chemoprevention by selenomethionine (Goulet 
et al., 2007). Atox1 also belongs to the locus of hyper-methylated genes in ovarian 
cancers that are associated with a bad prognosis and hence may be useful as a tumour 
biomarker (Wei et al., 2006).  
ATOX1 was found to regulate cell proliferation as a copper dependent 
transcription factor, by regulating the expression of cyclin D1 (CCND1) (Itoh et al., 
2008). A conserved KKTGK motif in the C-terminus of Atx1, previously identified as 
essential for antioxidant function in yeast  may function as nuclear localisation signal 
(NLS) to recruit ATOX1 into the nucleus (Hamza et al., 2001). ATOX1 was also 
established as a positive regulator of Sod3 gene which functions as an antioxidant and 
expressed highly in the vasculature (Jeney et al., 2005). Hence, ATOX1 may thus be a 




1.2 Rationale and Thesis objectives 
DNA damage sensors, DNA repair factors and cell cycle regulators coordinate to 
maintain genome integrity, which is critical in the survival of an organism (Aguilera and 
Gómez-González, 2008). The base excision repair (BER) pathway is one of the primary 
mechanisms for the repair of oxidative DNA lesions (Klungland et al., 1999). PARP-1 
plays an active role in the base excision repair pathway (Dantzer et al., 1999). It is 
activated upon binding to DNA strand breaks, and mediates poly (ADP-ribosyl)ation of 
downstream proteins. PARP-1 deficient mice have shortened telomeres and high levels of 
chromosomal instability (d'Adda di Fagagna et al., 1999). Telomeres are the terminal 
nucleoprotein structures of chromosomes, which function in protecting chromosomal 
ends from nuclease attack and recombination (de Lange, 2002). Dysfunctional telomeres 
trigger genomic instability through breakage-fusion-bridge cycles that underlie 
tumourigenesis. PARP-1 was also found to have a synergistic role together with other 
repair proteins in the maintenance of telomere-chromosomal integrity (Tong et al., 2002; 
Tong et al., 2001). Arsenite is a significant environmental concern worldwide with 
chronic exposure to inorganic arsenite associated with hepatic injury, peripheral 
neuropathy and a wide variety of cancers (Ding et al., 2000; Germolec et al., 1998; 
Morales et al., 2000; National Research Council, 1999; Simeonova and Luster, 2000; 
Steinmaus et al., 2000). A key mediator of arsenite toxicity is by the induction of reactive 
species (Shi et al., 2004).  In this study, we sought to investigate the role of PARP-1 in 




With the establishment of a role of PARP-1 in telomere-mediated genomic 
stability following arsenite-induced damage, we sought to identify the molecular changes 
that are associated with this role of PARP-1. We profiled genome-wide gene expression 
in PARP-1 proficient and deficient MEFs with arsenite treatment by microarray. 
Functional gene annotation was then undertaken to classify differentially expressed genes 
into specific pathways based on their biological function. This was followed up with 
Gene set enrichment analysis (GSEA) to determine if these pathways show statistically 
significant, concordant differences between two biological states i.e. the presence and 
absence of PARP-1 when subject to arsenite treatment. We identified that genes involved 
in copper metabolism and homeostasis were significantly affected when PARP-1 was 
absent. Interestingly, copper has been shown to induce the inhibition of activity in 
isolated poly (ADP-ribose) polymerase-1 (PARP-1) (Schwerdtle et al., 2007). Copper is 
an essential trace element in all living systems with multiple key roles in normal 
physiology. Paradoxically it is both a key component of enzymatic anti oxidative defense 
systems and yet capable of generating reactive oxygen species in its unbound form 
(Vulpe and Packman, 1995). Defects in copper homeostasis are directly responsible for 
human diseases and are implicated in additional pathophysiologies (Keen et al., 1998; 
Kumar et al., 2004; Prodan et al., 2006). Mutations in the Atp7a or Atp7b genes, encoding 
P-type copper transporting ATPase pumps expressed in extra hepatic tissues or in the 
liver, respectively, cause Menkes and Wilson’s diseases (Culotta, 2001).  They are 
characterised by pathological hyper-accumulation or deficiency of copper (Ferenci, 2004; 
Kaler, 1998; Kodama et al., 1999; Oder et al., 1991). Conditions of either disturbed 
homeostasis or overload of copper may exert genotoxic effects. In this study, we 
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attempted to investigate how copper metabolism can affect DNA damage response in 
mammalian cells. For this, we used normal MEFs supplemented with copper as well as 
lymphoblastoid cells from Menkes and Wilson’s disease patients.  
Apart from this, we ranked the genes in the copper metabolism pathway identified 
by microarray, based on the extent of differential expression. Copper chaperone, 
Antioxidant protein 1 (Atox1) was significantly down regulated in PARP-1 deficient 
MEFs. ATOX1 is incidentally the primary metallochaperone responsible for delivery of 
copper to ATP7A and ATP7B (Hamza et al., 1999). In yeast, ATOX1 is important for 
protection against oxidative damage (Lin and Culotta, 1995). Recently, ATOX1 was 
demonstrated to have further roles as a transcription factor regulating cell proliferation 
and antioxidant factors (Itoh et al., 2008; Itoh et al., 2009). Interestingly, ATOX1 levels 
were reduced in metastatic colorectal cancers as compared to non-metastatic colorectal 
cancer cell line (Humar et al., 2002). Given the role of PARP-1 in DNA damage repair 
and chromosome stability, we investigated whether ATOX1 has an analogous function 
in mammalian cells.  
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1.3 Significance of the study:  
 
1. PARP-1 has been implicated in tumourigenesis and aging. PARP-1 inhibitors in 
combination with other DNA-damaging agents have found utility as anti-cancer 
agents. Hence, the findings of this study will further aid in understanding the 
myriad roles of PARP-1.  
2. Mixtures of copper chelators with copper salts have been found to act as efficient 
proteasome inhibitors and apoptosis inducers, specifically in cancer cells. In 
addition, copper chelators act as anti-angiogenic molecules in the treatment of 
several types of cancers. Given the role of copper in such pathology, it is of 
interest to further dissect out the role of copper in DNA repair and genomic 
stability which have key functions in tumourigenic progression.   
3. This study improves the understanding of the molecular nature of copper 
metabolism, DNA damage and repair in the outcome of Menkes and Wilson’s 
Diseases. This would help in better planning of diagnosis and treatment of these 
two diseases. 
4. Our study points to a role of ATOX1 in maintaining genomic integrity. Since 
ATOX1 has been found to be down-regulated in colon cancer and is associated 
with cisplatin resistance in cancer therapy, understanding the effects of Atox1 





• To study the role of PARP-1 in regulating telomere mediated genomic stability 
following arsenite-induced oxidative damage.  
• To investigate the changes in gene expression when PARP-1 is absent. 
• To investigate the effects of copper levels on DNA damage. 
• To analyse DNA damage-repair and genome instability in primary fibroblasts and 
lymphoblastoid cell lines derived from Wilson’s and Menkes copper metabolism 
disease patients following DNA damage. 
• To determine spontaneous as well as oxidative stress-induced genomic instability 




Methods and Materials 
 
2.1 Cell Lines used in this study: 
 
2.1.1 Mouse embryonic fibroblasts (MEFs) used in this study:  
PARP-1+/+ and PARP-1-/-
 
MEFs (A kind gift from Professor Zhao-Qi Wang, Leibniz 
Institute for Age Research, Germany). 
Atox1+/+ and Atox1-/- MEFs (A kind gift from Professor Jonathan Gitlin, Washington 
University at St. Louis, USA). 
2.1.2 Human cells used in this study: 
Primary human lung fibroblasts (IMR-90, Coriell repositories, USA) 
Normal human lymphoblastoid cells (Coriell repositories) 
Menkes disease patient human lymphoblastoid cells (Coriell repositories) 
Wilson’s disease patient human lymphoblastoid cells (Coriell repositories) 
Human peripheral blood-derived lymphocytes 
Human peripheral blood lymphocytes were isolated from heparinised venous 
blood obtained from healthy donors using Ficoll-Hypaque (GE Healthcare Bio-Sciences, 
Singapore) density gradient centrifugation and centrifuged at 500g, without brakes for 30 
minutes at room temperature. The lymphocyte layer above the Ficoll was gently aspirated 
and washed three times with sterile 1 x PBS and the number of cells were counted using 
hemocytometer. All MEFs were cultured in Dulbecco’s Modified Essential Medium 
(DMEM; Sigma-Aldrich, Singapore) supplemented with 10 % foetal bovine serum (FBS; 
Hyclone, USA) and 1 % streptomycin/ penicillin in a humidified 5 % CO2/ 95 % air 
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incubator. Human fibroblasts were cultured in Minimum Essential Medium (MEM; 
Gibco, USA) supplemented with 10 % Fetal Bovine Serum (FBS), 100 Units/ml 
penicillin/streptomycin, 1 % vitamins, 2 % essential amino acids and 1 % non-essential 
amino acids (All supplements were obtained from Gibco). Human lymphoblasts and 
lymphoblastoid cells were cultured in Roswell Park Memorial Institute (RPMI) 1640 
medium (Gibco) supplemented with 10 % FBS (Hyclone) and 1 % 
Penicillin/Streptomycin (Hyclone). 
 
2.2 Chemicals utilised  
 
2.2.1  Sodium arsenite 
  
Stock solution of sodium arsenite (NaAsO2; Sigma-Aldrich) at 1 mg/ml was 
prepared in double distilled water and sterilised by passing through 0.22 μm syringe 
filter. Cells were treated with doses of between 0 to 3.0 μg/ml of sodium arsenite. Twenty 
four hour and 48 hour treatments were used for telomere length, cell cycle analysis, 
chromosomal aberration and micronucleus analysis. Two hour treatment was used for 
γH2AX foci staining.  
 
2.2.2 Hydrogen peroxide 
 
Hydrogen peroxide (H2O2; Kanto Chemical Co. Inc., Japan) treatment was carried 
out for γH2AX foci analysis. One hundred millimolar H2O2 stock solution was freshly 
prepared in Phosphate Buffered Saline (PBS, National University Medical Institutes 
(NUMI)) prior to treatment. Cells were treated with doses of 25 µM, 50 µM and 100 µM 




2.2.3 Gamma radiation 
Radiation exposure was carried out at the Department of Radiation Oncology, 
National Cancer Centre, Singapore (Gamma ® 40 extractor with the central dose rate of 
1.16 Gy/minutes). Radiation doses between 0 to 2 Gy were used in this study. Following 
radiation exposure, the cells were allowed to cycle for a further 24 hours prior to fixing 
for metaphase preparation and fixing for micronucleus assay. For other experiments, cells 
were harvested 30 minutes following radiation exposure.  
2.2.4  Copper pre-treatment 
Dose response experiments were carried in doses between 1 to 100 µM. For 
subsequent experiments, pre-treatment with 10 µM copper chloride (CuCl2; Sigma-
Aldrich) for 24 hours was employed prior to arsenite, radiation or H2O2 exposure.  
2.2.5  Bathocuproine sulphonate pre-treatment 
Cells were pre-treated with 200 µM bathocuproine sulphonate, a copper chelator, 
(BCS; Sigma-Aldrich) for 24 hours prior to radiation or H2O2 exposure. This dose was 
based on an earlier study by Hamza et al. (Hamza et al., 2003). 
2.3 Cytotoxicity Assays 
 
2.3.1  Crystal Violet Assay  
 
Crystal violet solution stains DNA of the adhered cells. Upon solubilisation of the 
stain, it can be read with an ELISA plate reader to determine the relative amounts of cell 
survival by comparison of fluorescence with the untreated controls. Medium was 
aspirated from treated cells with an ultra-fine tipped pipette, to prevent detachment of 
cells. The cells were washed in PBS and a volume of 500 μl of 0.1 % crystal violet (CV) 
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staining solution (Sigma-Aldrich) in 20 % ethanol (NUMI) was added. Cells were 
allowed to stain for 15 minutes. After staining, the extracellular dye was removed by 
rinsing the cell monolayer with distilled water thoroughly. The remaining cell-attached 
dye was dissolved in 1 ml of 1 % Sodium Dodecyl Sulfate (SDS; NUMI) in PBS, and the 
absorbance was recorded at 595 nm by an ELISA plate reader (TECAN SpectrophorPlus, 
USA).   
2.3.2 Tetrazolium salt 3-(4, 5-dimethylthiazol-2-yl)-2, 5- diphenyltetrazolium bromide 
(MTT) assay 
 
3-(4, 5-Dimethylthiazol-2-yl)-2, 5 Diphenyltetrazolium assay (MTT; Sigma-
Aldrich, Singapore) is a colorimetric assay that measures the reduction of yellow 3-(4, 5-
dimethythiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT) by mitochondrial 
succinate dehydrogenase. The MTT enters the cells and passes into the mitochondria 
where it is reduced to an insoluble, coloured (dark purple) formazan product. The cells 
are then solubilised with an organic solvent and the released, solubilised formazan 
reagent is measured spectrophotometrically. Since reduction of MTT can only occur in 
metabolically active cells, the level of activity is a measure of the viability of the cells. 
Equal numbers of cells were plated in 96 well culture plates (Nunc, Denmark). 
Following appropriate treatment, 50 µl of the MTT solution (4 mg/ml in plain RPMI) was 
added to each well. The cells were incubated at 37°C for 2 hours in the dark. The plate 
was then centrifuged and the supernatant was discarded. The resulting formazan crystals 
were dissolved by the addition of 190 µl of dimethylsulfoxide (DMSO; Sigma-Aldrich) 
and 10 µl of Sorenson’s glycine buffer and the absorbance of each well were measured at 
570 nm in a plate reader (TECAN SpectrophorPlus). Cell survival was estimated based 
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on the difference in the absorbance values between the controls and the treated 
categories. 
 
2.4 DNA damage analysis 
 
2.4.1  Alkaline Single Cell Gel Electrophoresis Assay (Comet Assay)  
 
The Comet assay is a sensitive method for quantifying extent of DNA damage. 
Alkaline conditions at pH greater than 13, allow for the detection of single stranded, 
double-stranded breaks, apurinic and apyridiminic sites as well as alkali adducts. Cells 
are lysed and then denatured under alkali conditions to unwind the DNA and hydrolyse 
the damaged sites. The cells are then subjected for electrophoresis. Electrophoresis 
induces the cleaved DNA fragments to migrate further under the electric field forming a 
characteristic comet-like shape. Undamaged nuclei remain in the nucleoidal shape.  
Treated cells were harvested and washed in PBS. The cells were then resuspended 
in Hank’s Balanced Salt Solution (HBSS; Gibco) with 10 % DMSO; Sigma-Aldrich) and 
0.5 M ethylenediaminetetraacetic acid (EDTA; Sigma-Aldrich). Ten percent of the cell 
suspension was suspended in melted low melting point agarose (Trevigen, USA) and 50 
μl of this suspension was added to comet assay slides (Trevigen). The agarose was 
allowed to solidify at 4 °C. The slides were then left in lysis solution (Trevigen) for 1 
hour at 4 °C. These slides were then left for denaturation for 40 minutes in the dark, in 
chilled alkaline electrophoresis buffer (pH 13.0- 13.7) consisting of 24 g sodium 
hydroxide pellets (Merck Chemicals, Singapore), 0.5 M EDTA and distilled water. 
Electrophoresis was subsequently carried out for 25 minutes at 25 Volts. The slides were 
dried and stained with SYBR green dye (Molecular Probes, USA) and observed under 
Zeiss Axioplan 2 imaging fluorescence microscope (Carl Zeiss, Germany) equipped with 
43 
 
triple band filter. Images were captured using Comet Analysis Software (Metasystems, 
Germany). Fifty comets per sample were analysed to obtain mean tail DNA.  
Experiments were repeated twice.   
2.4.2 γH2AX foci quantitation 
γH2AX foci detection is a sensitive assay indicative of double strand breaks 
sustained by the cells. Phosphorylated H2AX histone is one of the first detectable 
markers of double strand breaks (Sedelnikova et al., 2002). For this experiment 10,000 
cells were seeded on 22 mm x 22 mm cover slips. The cells were fixed with 4 % 
formaldehyde (Merck) following treatment. The cells were then washed with 1XPBS and 
subsequently permeabilised with 0.2 % of Triton-X 100.  Cells were blocked in 5 % 
Bovine Serum Albumin (BSA, Amresco, USA). Cells were then incubated with mouse 
monoclonal γH2AX primary antibody (Upstate Biotechnology, USA) at 37ºC for 1 hour. 
Cells were washed in 1XPBS and incubated with goat anti-mouse IgG conjugated with 
fluorescein isothiocyanate (FITC; Molecular probes, USA). The cover slips were then 
mounted on slides (Fisher, UK) with DAPI in vectashield (Vectashield, UK). γH2AX 
foci were quantitated in 50 nuclei per sample under the Axioplan 2 imaging fluorescence 




2.5 Genotoxicity Assays 
2.5.1  Chromosomal aberration analysis 
Chromosomal aberration analysis involves the visualisation of chromosomes to 
analyse numerical and structural abnormalities. 
2.5.1.1 Metaphase preparation 
For all the MEFs used in this study, cells were then treated with 0.1 µg/ml 
Karyomax colcemid solution (Gibco) for 4-6 hours to arrest the cells at metaphase stage 
following 24 hour arsenite treatments or a further 24 hour incubation after radiation 
exposure. The MEFs were then incubated with a hypotonic solution of pre-warmed 0.03 
M sodium citrate (Fischer Scientific, USA) at 37 ºC for 20 minutes. This was followed by 
fixation in Carnoy’s fixative (3:1 methanol: Acetic acid (NUMI). Metaphase spreads 
were then prepared by dropping the fixed samples onto clean, dry slides and were left to 
air dry overnight in preparation for the next step of hybridisation. 
2.5.1.2 Peptide Nucleic Acid Fluorescence In Situ Hybridisation (PNA-FISH) 
Fluorescence In Situ Hybridisation (FISH) is a cytogenetic approach that allows 
for the direct visualisation and localisation of selected DNA regions. The metaphase 
spreads were hydrated in 1XPBS (1st Base, Singapore) and fixed in 4 % 
paraformaldehyde (Merck). The slides were subjected to 0.5 % pepsin (Sigma-Aldrich) 
treatment at 37ºC for 5 minutes following the PBS hydration and again subjected to 
fixation by 4 % formaldehyde. Serial ethanol dehydration (70 %, 90 % and 100 %; 
Merck) was performed and the slides were allowed to air dry. Hybridisation mix was 
prepared in the dark. The telomeres were hybridised with telomere-specific PNA probe 
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(CCCTAA)3 labelled with Cy3 (Applied Biosystems, USA). Denaturation was performed 
at 80 ºC for 3 minutes and hybridised in the dark for 2 hours. Excess probes were washed 
away and the slides were then dehydrated in a series of ethanol (70 %, 90 % and 100 %), 
and allowed to air dry in the dark. The chromosomes were then counter-stained with 4’6-
diamidino-2-phenylindole (DAPI; Vectashield). The metaphase spreads were then 
captured with Zeiss Axioplan 2 imaging fluorescence microscope (Carl Zeiss and 
analysed using ISIS imaging software (Metasystems).  
2.5.2 Cytokinesis Blocked Micronucleus Assay 
Chromosomes unattached to the spindle during mitosis and broken chromosomal 
fragments form micronuclei in the cytoplasm during mitotic division.  Cytokinesis 
Blocked Micronucleus (CBMN) assay involves the detection of damage by quantification 
of micronuclei formation in cells arrested at the cytokinesis stage. Following appropriate 
treatment, cells were then subjected to 4 μg/ml cytochalasin B (Sigma-Aldrich) treatment 
for 22 hours. The cells were then harvested by trypsinisation and centrifuged for 800 rpm, 
8 minutes. The cells were then resuspended in 6 ml of cold hypotonic 0.03 M of sodium 
citrate for MEFs or 0.075 M of potassium chloride for the human lymphoblastoid cells. 
The cells were then immediately centrifuged at 800 rpm for 8 minutes and subsequently 
fixed with 400 ml of formaldehyde in 6 ml of Carnoy’s fixative (acetic acid/methanol, 
1:3). The cells were then stored at 4ºC till analysis. The fixed cells were dragged onto 
clean dry slides and stained with 30 μg/ml of acridine orange (Calbiochem, USA), which 
differentially stains cytoplasm and nuclei. Two sets of 1000 binucleated cells were scored 
for the presence of micronuclei (MN) with an Axioplan 2 imaging fluorescence 
microscope (Carl Zeiss).  
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2.6 Gene expression analysis 
2.6.1 Microarray analysis 
Cells were subjected to appropriate treatment and the total RNA was extracted 
(RNeasy Kit, Qiagen, USA). Double stranded cDNA was synthesised from 5 µg of total 
RNA using Superscript system (Invitrogen) primed with T7-(dT)-24 primer. For biotin 
labelled cRNA synthesis, in vitro transcription reaction was performed in the presence of 
T7 RNA polymerase and biotinylated ribonucleotides (Enzo Diagnostics, USA). The 
cRNA product was purified (RNeasy Kit, Qiagen), fragmented, and hybridised to 
Affymetrix GeneChip® Mouse Genome 430 2.0 or Illumina Human B chip Ref 8 version 
2 (Illumina Inc, USA) in a Gene chip hybridisation oven 640 (Affymetrix, USA) as per 
the Gene Chip Expression Analysis manual (Affymetrix). After 16 hours of hybridisation 
the gene chips were washed and stained using the Affymetrix Fluidic station and scanned 
by Gene Array Scanner (Affymetrix/Agilent Technologies).  Image data were normalised 
and statistically analysed using Gene Spring 7.3 (Silicon Genetics, USA). Genes that 
displayed significant (p < 0.05; One-way ANOVA) differential expression were 
annotated according to Gene Ontology- Biological process. Subsequent data analysis 
involved Agglomerative average-linkage hierarchical clustering for finding different 
patterns and levels of gene expression. 
2.6.2  Real Time Reverse Transcription Polymerase Chain Reaction array 
Real Time Reverse Transcription Polymerase Chain Reaction array 
(SABiosciences, USA) was undertaken to analyse the expression of genes in the DNA 
damage signalling pathway as well as oxidative stress and anti-oxidant defense pathways. 
47 
 
2.6.2.1  RNA extraction 
RNA was extracted using Qiagen RNeasy® Mini Kit (Qiagen, USA) as per the 
manufacturer’s instructions. To ensure the quality of the extracted RNA A260:A230 and 
A260:A280 ratios were evaluated by UV spectrometry. The ribosomal band integrity was 
also determined (Agilent E-gene bio analyser, USA). 
2.6.2.2 cDNA synthesis 
cDNA synthesis was carried out using RT² First Strand Kit (SABiosciences) as 
per the manufacturer’s instructions. Double distilled water was added to the cDNA 
synthesised and stored at _20 ºC until PCR was carried out. 
2.6.2.3 Real time PCR 
 
 The experimental cocktail was prepared by mixing RT2 qPCR Master Mix 
(SABiosciences), 100 ng cDNA and double distilled water. Two different pathways were 
analysed- DNA damage signalling pathway, Mouse 
(http://www.sabiosciences.com/rt_pcr_product/HTML/PAMM-029A.html) and 
Oxidative stress and Antioxidant defense, Mouse 
(http://www.sabiosciences.com/rt_pcr_product/HTML/PAMM-065A.html). Using a 
multi channel pipette the cocktail was loaded onto the PCR array plates which are pre-
coated with specific pre-designed and optimised primers for each gene in the specific 
pathway. Pipette tips were changed before each addition in order to prevent cross 
contamination. The PCR array plate then was carefully and tightly sealed with optical 
adhesive films. The plate was then centrifuged briefly in order to prevent any bubbles. 
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The plate was then run in the Roche 480 Real-time thermal cycler (Roche, USA). The 
thermal cycler has 2 programs and is displayed below; 
Program 1, a two-step cycling program 









Program 2, a three-step cycling program 











2.6.2.4 Analysis of PCR data 
 
Data analysis was based on the ΔΔCt method. This involved the comparison of 
the Ct values of the samples of interest with RNA from normal tissue. The Ct values of 
both the RNA from normal tissue and the samples of interest are normalised to an 
appropriate endogenous housekeeping gene. The integrated web-based software package 
provided by the SABiosciences for the PCR Array System 
(http://www.sabiosciences.com/pcr/arrayanalysis.php) was used to perform all ΔΔCt 
based fold-change calculations from the uploaded raw threshold cycle data. 
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2.7  Superoxide measurement 
Formation of superoxide can be measured by use of dihydroethidine (HE). HE is a 
redox-sensitive probe to detect intracellular superoxide anion. Cells are freely permeable 
to HE. HE can be directly oxidised to ethidium bromide (EB) by superoxide anion 
produced by the cell. Intracellular EB is fluorescent (610 nm) with 488 nm excitation. 
ROS subsequently oxidise it to form a fluorescent compound that can be detected by flow 
cytometry.  
Treated cells were harvested by trypsinisation and washed with PBS. The cells 
were stained with staining solution containing 10 µM HE (Molecular Probes, USA) in 
500 µl plain RPMI and incubated for 15 minutes at 37 °C in the dark. After incubation, 
the cells are washed in plain RPMI and then resuspended in 0.5 ml of plain RPMI and 
analysed by flow cytometry at excitation wavelength at 488 nm and emission wavelength 
of 525 nm (Beckman-Coulter Epics Altra). A minimum of 10000 events per sample was 
collected and analysed using WinMDI software. Experiments were repeated thrice. 
 
2.8 Cell Cycle Analysis  
 
To analyse the DNA content at the different stages of the cell cycle, the treated 
cells were harvested, washed in PBS solution and fixed in 3 ml of ethanol. Following 
fixation overnight at -20 °C, the cells were centrifuged at 1200 rpm for 5 minutes and the 
resulting cell pellets re-suspended in PBS with propidium iodide (PI, Sigma-Aldrich) and 
100 μg/ml of RNAse A (Roche, USA; 2 mg PI and 2 mg RNase A/100 ml 0.1 % BSA in 
1×PBS) overnight at 4 °C. Samples were then analysed by flow cytometry. A minimum 




2.9  Telomere length analysis by Flow-FISH 
Cells were washed in PBS containing 0.1 % BSA (Calbiochem) and placed in 1.5 
ml Eppendorf tubes. One million cells were used per sample. Cells were centrifuged and 
resuspended in 1 ml PBS with 0.1 % BSA and each sample was divided equally among 
two Eppendorf tubes. Following centrifugation for 15 seconds at 13000 rpm in an 
Eppendorf microfuge (Picofuge, Germany), the supernatant was removed and the cell 
pellets were resuspended in hybridisation mixture containing 70 % deionised formamide 
(Gibco), 20 mM Tris, pH 7.0, 1 % BSA and either 0.3 µg/ml telomere-specific FITC 
conjugate (CCCTAA)3 PNA probes (Perseptive Biosystems, USA). The volume of 
hybridisation mixture was adjusted to 100 µl/105 cells with a minimum volume of 200 µl 
and maximum of 500 µl. Samples were subjected to heat denaturation of DNA for 10 
minutes at 80 ºC in a thermomixer (Eppendorf, Germany) followed by hybridisation for 2 
hours at room temperature in the dark. Cells were spun down, the supernatant removed 
and the cells were washed twice with 1 ml of wash buffer containing 70 % formamide 
(Gibco), 10 mM Tris, 0.1 % BSA and 0.1 % Tween 20 (Sigma-Aldrich). Washes were 
then performed with wash solution containing PBS, 0.1 % BSA, 0.1 % Tween 20. The 
initial centrifugation and all subsequent wash steps were performed in a Benchman TJ-6 
centrifuge at 16 ºC for 7 minutes at 3000 rpm except for the last wash (5 minutes, 2000 
rpm). Cells were resuspended according to cell numbers (100 µl per 105 cells) in PBS 
with 0.1 % BSA, 10 µg/ml RNase A (Boehringer Mannheim, USA), 0.06 µg/ml 
propidium iodide (Sigma-Aldrich) and incubated for 2 hours at room temperature, before 
flow cytometry analysis. To ensure consistency of data between experiments, the flow 
cytometer was calibrated with FITC labelled fluorescent beads (Flow cytometry 
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standards, USA) in PBS with 0.1 % BSA at the start of each experiment. The resulting 
calibration curve was used for correction of experimental fluorescence values in each 
experiment. 
 
2.10 Bioinformatics analysis 
 
2.10.1 Functional gene annotation analysis 
The list of differentially expressed genes obtained by microarray in PARP-1+/+ 
and PARP-1-/- MEFs upon arsenite treatment was uploaded on to the DAVID 2008 
bioinformatics resources web based software (http://david.abcc.ncifcrf.gov/) for 
functional gene annotation.  The genes were classified according to biological process 
based on gene ontology. From this, genes involved in copper metabolism or copper 
binding proteins were identified. The list of genes involved in DNA damage signalling 
was obtained from SABiosciences PCRarray (PAMM-029) so as to allow for comparison 
of gene sets with those used in PCRarray in Atox1+/+ and Atox1-/- MEFs. Similarly, genes 
from the oxidative stress and antioxidant defense pathway were from the gene list 
identified by SABiosciences PCRarray (PAMM-065).  We then used Pathway studio 5.0 
software to undertake gene set enrichment analysis (GSEA). This analysis allows for the 
calculation of probability that particular biological pathways were significantly affected 
when PARP-1 is absent. This analysis was carried out to ascertain if the copper 
metabolism pathway, DNA damage signalling pathway and oxidative stress and 






2.10.2 Identification of Atox1 consensus sequences and binding motifs in promoter 
sequences of potential target genes. 
 
Based on the PCRarray data, transcriptional targets were investigated using 
bioinformatics approaches. Since ATOX1 is known to act as a transcription factor, 
searching for Atox1 consensus sequences (Muller et al., 2008) in the promoter sites of 
potential targets will allow for elucidation of possible transcriptional targets. The 
promoter sequences (5 kb) upstream of the transcription start site from transcripts were 
downloaded from NCBI database using EZ-Retrieve tool available at 
(http://siriusb.umdnj.edu:18080/EZRetrieve/index.jsp). Atox1 response element is the 
directed repeat 1(DR1) type of element, which is given as TGAAA N TGAAA (Muller 
and Klomp, 2009) while the Atox1 consensus motif is given as GAAAGA (Itoh et al., 
2008). To search for the ATOX response elements and binding motifs in the promoter 
region, a text mining and pattern search program, Exact Sequence and Pattern Search 
(ESPSearch) was used. ESPSearch analyses a DNA, RNA, or protein sequence for 
specific target sequences and is more specific for searching directed repeats (Watt and 
Doyle, 2005). The program was set to search out genomic sequences in the promoter 
region containing either the Atox1 response element or consensus motif. In this study the 
mismatch per segment was set to 1 to allow the program to search for all Atox1 response 
elements having 1 mismatch in either of the segment. This corresponds to the 
identification of Atox1 response elements in the genomic sequence with only a maximum 





2.11 Real Time Reverse Transcriptase Polymerase Chain Reaction for 
ATOX1 and PARP-1 
 
Real time RT-PCR was used to validate Atox1 and Parp-1 expression in the 
MEFs used in this study. Total RNA was harvested using Qiagen RNeasy® Mini Kit 
(Qiagen) as per the manufacturer’s instructions. To ensure the quality of the extracted 
RNA A260:A230 and A260:A280 ratios were evaluated by UV spectrometry. Extracted 
RNA was reversed transcribed with Transcriptor First Strand cDNA Synthesis Kit 
(Roche). Template-primer reaction was prepared with 1 μg total RNA and 2 μl random 
hexamers (to make a final concentration of 60 μM) made up to 13 μl with PCR-grade 
H2O, denatured at 59°C for 10 minutes in a thermal block cycler with heated lid, and 
cooled immediately on ice. A master mix containing 4 μl 5×Transcriptor Reverse 
transcriptase Reaction Buffer, 20 U Protector RNase Inhibitor, deoxynucleotide (dNTP) 
mix of 1 mM each and 10 Units Transcriptor reverse transcriptase was prepared and 7 μl 
of this master mix was mixed into the template-primer reaction by pipetting. The RT 
reaction was carried out at 25°C for 10 minutes, then 50°C for 60 minutes. The enzyme 
was inactivated at 85°C for 5 minutes and the reaction was stopped on ice. LightCycler® 
480 SYBR Green I Master PCR mix (Roche) was used to quantify specific mRNA 
expression of ATOX1 normalised to Gapdh mRNA expression. A master mix containing 
2 μl 100×diluted cDNA, 6 μl PCR-grade H2O and 10 μl of the provided 2×Master Mix 
per reaction was prepared and aliquoted into each well. Two microlitres of PCR primers 
(5 μM each of forward and reverse) were added into each well. A negative control with 
the cDNA replaced with dH2O was included in each run. The reaction was carried out 
under the following conditions: 5 minutes initial hold at 95°C, 45 cycles of 95°C for 10 
seconds, 59°C for 10 seconds and 72°C for 15 seconds, with a 1-minute hold at 65°C 
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before cooling to 40°C. All primers were run simultaneously with Gapdh primers in 
duplicate. Data were analysed with LightCycler® 480 software version 1.2.9.11. Relative 
quantification of the genes was calculated using normalised relative ratio (ETCpT (C) – 
CpT (S) × ERCpR (S) – CPR (C)) where E: efficiency value specific for each set of 
primers calculated from performing a standard curve with serial dilutions of cDNA, Cp: 
Crossing over point, T: target gene, R: reference (housekeeping) gene, C: calibrator 
(control), S: samples with the respective primer).  
Details of the primer sequences are as follows:  
Gapdh:  Forward: 5’- atcttccaggagcgagaccc-3’ 
Reverse: 5’- gagcccttccacaatgccaa-3’ 
Atox1:  Forward: 5’- gggaggagtggagttcaaca-3’ 
Reverse: 5’- tggactggactgagcagttg-3’ 
Parp-1: Forward: 5’- aaggcggagaagacattggg-3’ 
Reverse: 5’- ttcatctgttccatccacctcg-3’ 
  
2.12 Statistical Analysis 
Statistical comparisons between and among the groups were made using 2-way 
ANOVA, Student’s t-test and contingency tables analysis (Chi-square test and Fisher’s 
exact test) using Microsoft Excel 2003 (Microsoft Corporation, USA).  The difference 







3.1 Role of PARP-1 in regulating telomere-mediated genomic 
stability following arsenite-induced oxidative stress.  
 
3.1.1  Cells lacking PARP-1 displayed elevated DNA damage.  
PARP-1 is one of the first proteins to be activated in response to DNA damage 
(Meyer-Ficca et al., 2005). We investigated the role of PARP-1 in responding to sodium 
arsenite-induced damage in PARP-1+/+ and PARP-1-/- MEFs. The levels of DNA damage 
incurred were measured by alkaline single-cell gel electrophoresis (Comet assay). 
Normal undamaged nuclei form a nucleoidal shape whereas damaged DNA forms a 
characteristic comet-like shape when subjected to electrophoresis (Figure 9A and B).  
The comet assay was carried out in alkaline conditions (pH >13), to detect all types of 
DNA damage, including double-strand breaks, single-strand breaks, and alkali labile 
sites. PARP-1-/- cells reflected enhanced DNA damage induction compared with PARP-
1+/+ cells after arsenite treatment (Figure 10A and B). DNA damage induced by 30 
minutes of treatment of arsenite was 5 to 6-fold (p < 0.001, two-way ANOVA test and 
Student’s t-test) more in PARP-1-/- MEFs than PARP-1+/+ cells. Similarly, arsenic 
exposure for 24 hours resulted in an increased tail moment, indicating the impaired repair 






Figure 9 A, B: SYBR Green–stained comets following the comet assay in PARP-1+/+ and PARP-1-/- 
MEFs following arsenite treatment.  
Representative images of (A) SYBR Green–stained undamaged nuclei and (B) damaged nuclei with 













Figure 10 A, B: DNA damage as measured by the comet assay in PARP-1+/+ and PARP-1-/- MEFs 
following arsenite exposure. 
PARP-1+/+ (Black bars) and PARP-1-/- (White bars) MEFs were treated with 1.5 µg/ml and 3.0 µg/ml of sodium 
arsenite for 30 minutes (A; block columns) and for 24 hours (B; Dotted columns). The extent of DNA damage 
measured as tail moment (product of tail length and fraction of DNA) differed between PARP-1-deficient and 
PARP-1 proficient cells. Error bars indicate standard error. Two sets of 50 comets per sample were analysed.  
*p < 0.05 as compared to untreated PARP-1+/+ MEFs,  
++ p < 0.05 as compared to respective untreated controls and with As3+- treated PARP-1+/+ MEFs. 








































A PARP-1+/+ MEFs with 30min arsenite 
 PARP-1-/- MEFs with 30min arsenite 
Sodium arsenite concentration (µg/ml) 
 
Sodium arsenite concentration (µg/ml) 
 
++ 
PARP-1+/+ MEFs with 24 h arsenite 
 PARP-1-/- MEFs with 24 h arsenite 
58 
 
3.1.2 Absence of PARP-1 enhances chromosomal instability. 
PARP-1 has been established to have a critical role in ensuring the genomic 
stability of the cell when challenged with DNA damaging agents [reviewed in (Masutani 
et al., 2003)]. Micronuclei analysis, a reliable indicator of chromosomal damage and 
genomic instability (Fenech, 2002a, b), was used to investigate if PARP-1 deficiency 
affects the response to arsenite-induced damage. PARP-1-/- cells exhibited a 2 to 3-fold 
increase (p < 0.05, chi square test/Fisher’s exact test) in the number of binucleated cells 
with micronuclei (Figure 11) at 24 and 48 hours after sodium arsenite treatment 
compared with PARP-1+/+ cells (Figure 12A and B). FISH using telomeric PNA probe 
was employed to analyse the types of chromosomal aberrations induced. Typical fusions, 
such as Robertsonian fusion-like structures and ring like structures (Figure 13), were 
detected in the arsenite-treated PARP-1-/- MEFs. Higher numbers of chromosome 
aberrations were detected in PARP-1-/- MEFs at 1.5 µg/ml dose at both the time points 
(Figure 14A and B). However, arsenite treatment did not increase the frequency of 
chromosome end-to- end fusions in PARP-1 null cells, but the frequency of gross 
chromosome aberrations (which includes end-to-end fusions, chromosome breaks, and 
fragments) observed was higher in PARP-1-/- cells than PARP-1+/+ cells (Table 2). 
Statistically significant increase (p < 0.05, chi square test) in the total number of 
chromosome aberrations was observed at a dose of 1.5 µg/ml in PARP-1-/- MEFs at both 





Figure 11: Binucleated cells from PARP-1+/+ and PARP-1-/- MEFs following arsenite treatment by 
cytokinesis-blocked micronucleus assay.  
(A) Undamaged binucleated cell differentially stained with acridine orange. (B) Damaged binucleated 













Figure 12 A, B: Micronuclei induction measured by the cytokinesis-blocked micronucleus assay in 
PARP-1+/+ MEFs and PARP-1-/- MEFs following arsenite treatment. 
PARP-1+/+ MEFs (Black columns) and PARP-1-/- MEFs (White columns) were treated with 1.5µg/ml and 3.0µg/ml 
of sodium arsenite for (A) 24 hours (Block columns) and (B) 48 hours (Dotted columns). Micronuclei formation, a 
biomarker of chromosomal instability, was analysed as the percentage of micronuclei formed. Error bars indicate 
standard error.  A total of 1,000 binucleated cells were scored.  
* p < 0.05 as compared to untreated PARP-1+/+ MEFs,. 
++ p < 0.001 as compared to untreated samples as well as with As3+-treated PARP-1+/+ MEFs.  
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As3+ concentration Treatment time 
No. of 
metaphases 
analysed Fusions Breaks 
Total 
aberrations 
ctrl   - 50 0 1 1(0.02/cell) 
1.5 24 hours 50 3 0 3(0.06/cell) 
3 24 hours 50 2 1 3(0.06/cell) 
1.5 48 hours 50 2 1 3(0.06/cell) 
3 48 hours 50 2 1 3(0.06/cell) 
PARP-1-/- 
As3+ concentration Treatment time 
No. of 
metaphases 
analysed Fusions Breaks 
Total 
aberrations 
ctrl   - 50 1 0 1(0.02/cell) 
1.5 24 hours 50 4 2 6(0.12/cell) 
3 24 hours 50 1 1 2(0.04/cell) 
1.5 48 hours 50 2 3 5(0.1/cell) 
3 48 hours 50 2 1 3(0.06/cell) 
 
Figure 13 A, B: Telomere PNA-FISH analysis on metaphase spreads from PARP-1+/+ and PARP-1-
/- MEFs following arsenite exposure. 
Chromosomal DNA was stained with DAPI (Blue) and telomeres were hybridised with Cy3-labeled telomere probe 
(Red). Arrow points to a (A) Robertsonian fusion-like configuration without telomeres at the fusion point in PARP-
1-/- MEFs following arsenic treatment. Partial metaphase spread in a partial metaphase spread from PARP-1-/- 
MEFs, arrow points to a (B) ring-like structure resulting from loss of telomeres on sister chromatids in a 
chromosome.  
Table 2: Chromosomal aberrations observed in PARP-1+/+ and PARP-1-/- MEFs following arsenite 
treatment. 
PARP-1+/+ and PARP-1-/- MEFs were treated with 1.5 and 3.0 µg/ml of arsenite for periods of 24 hours and 48 
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Figure 14 A, B: Chromosome aberrations detected by telomere PNA-FISH analysis in PARP-1+/+ 
MEFs and PARP-1-/- MEFs following arsenite treatment. 
PARP-1+/+ (Black columns) and PARP-1-/- MEFs (White columns) were treated with 1.5 µg/ml and 3.0 µg/ml 
sodium arsenite for (A) 24 hours (Block columns) and (B) 48 hours (Dotted columns). 50 metaphase spreads were 
analysed per sample. Frequency of chromosome aberrations per cell is given.  Chromosome alterations detected 
include fragments, breaks, and end-to-end fusions. 
*p < 0.05 as compared to compared to PARP-1+/+ cells.   
(chi square test and Fisher’s exact test.) 
* 
* 
Sodium arsenite concentration (µg/ml) 
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3.1.3 Arsenite-induced telomere attrition was greater in PARP-1-/- mouse embryonic 
fibroblasts.  
 
Chromosomes with critically short telomeres are unstable and often result in end-
to-end fusions and chromosomal aberrations. Aberrations such as Robertsonian fusion-
like structures and ring like structures displayed by arsenite-treated PARP-1-/- MEFs are 
indicators of telomere loss and dysfunction. Earlier studies by our group have also 
implicated PARP-1 in telomere maintenance (d'Adda di Fagagna et al., 1999; Tong et al., 
2001). Additionally, arsenite is a potent inducer of oxidative stress which can accelerate 
telomere shortening (Kessel et al., 2002; Saretzki, 2002; von Zglinicki, 2002). In this 
study, the effect of arsenite-induced oxidative stress on telomere length in PARP-1+/+ and 
PARP-1-/- MEFs was elucidated. The telomere length was compared between MEFs 
established from litter mates proficient and deficient in PARP-1. Arsenite exposure for 24 
hours did not induce a significant decrease in telomere attrition (Figure 15A and B). 
However, the extent of telomere attrition was significantly (p < 0.05, two-way ANOVA) 
greater in PARP-1-/- cells (30-40 % loss) compared with the PARP-1+/+ cells (10-20 % 

















Figure 15 A, B: Telomere length measurements by flow-FISH in PARP-1+/+ and PARP-1-/- MEFs 
with arsenite treatment.  
PARP-1+/+ (Black columns) and PARP-1-/- MEFs (White columns) were treated with 1.5 µg/ml and 3.0 µg/ml 
sodium arsenite for (A) 24 hours (Block columns) and (B) 48 hours (Dotted columns). Error bars indicate standard 
deviation. Fifty metaphases were analysed per sample. MESF, molecules equivalent of soluble fluorochromes.  
*p < 0.05 as compared to PARP-1+/+ cells  
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3.1.4 PARP-1-/- MEFs are more sensitive to arsenite-induced cell death.  
Cell cycle analysis is useful for detecting early events of DNA damage/repair 
response, and cells deficient in DNA repair invariably exhibit abnormal cell cycle 
checkpoint regulation. Although no marked differences were observed between the two 
cell types at 24 hours after arsenic treatment (Figure 16A), PARP-1 null cells showed a 2-
fold increase over PARP-1 proficient cells in apoptotic death at 48 hours after arsenite 
treatment (p < 0.05, chi square test and Fisher’s exact test; Fig. 16B). There was also a 
corresponding decrease (p < 0.05) in G1 cell population in both PARP-1-proficient and 
PARP-1-deficient MEFs at 24 and 48 hours of treatment (Figure 16A and B). At 48 hours 
after treatment with arsenite, the percentage of G2-M phase cells had greatly reduced (p 
< 0.05) in PARP-1-/- MEFs compared with PARP-1+/+ MEFs. The increased cell death 
was verified by MTT assay (Figure 17 A, B). It is likely that mitotic catastrophe occurs 
increasingly in PARP-1-/- cells, leading to increased apoptotic death detected by an 














Figure 16 A, B: Cell cycle profile assessed by propidium iodide staining with flow cytometry in 
PARP-1+/+ and PARP-1-/- MEFs with arsenite treatment. 
PARP-1+/+ (first three columns) and PARP-1-/- (last three columns) MEFs after 1.5 and 3.0 µg/ml sodium arsenite 
treatment for (A) 24 hours and (B) 48 hours were analysed. Percentage of cells in each phase of cell cycle was 
compared with the respective phase in treated samples. Two sets of 10000 cells per sample were analysed. 
*p < 0.05 as compared to respective untreated controls  
 **p < 0.05 as compared to respective untreated control and As3+-treated PARP-1+/+ MEFs.  
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Figure 17 A, B: Cell viability assessed by MTT assay in arsenite-treated PARP-1+/+ and PARP-1-/- 
MEFs. 
PARP-1+/+ (Black columns) and PARP-1-/- MEFs (White columns) were treated with 1.5 µg/ml and 3.0 µg/ml 
sodium arsenite for (A) 24 hours (Block columns) and (B) 48 hours (Dotted columns). Percentage survival of cells 
in was compared with the untreated controls.  Error bars indicate standard error. Columns are means of 3 sets of 
experiments. 
*p < 0.05 as compared to respective untreated controls  
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3.1.5 Differential gene expression patterns in PARP-1+/+ and PARP-1-/- cells after 
arsenite treatment.  
 
PARP-1 has been demonstrated to function as a transcription factor 
(Krishnakumar et al., 2008). To evaluate the gene expression changes induced by PARP-
1 and arsenite treatment, we employed microarray on PARP-1+/+ and PARP-1-/- MEFs 
with or without arsenite treatment. Using this technology, the expression pattern of over 
34,000 genes was analysed and compared with untreated controls. PARP-1+/+ and PARP-
1-/- MEFs were treated with 1.5 µg/ml of arsenite for 24 hours and then subjected to gene 
expression studies. Microarray analysis was focused on genes that were altered with a 
more than 2-fold change with p < 0.05. One-way ANOVA test was applied to find 
distinct groups of genes that were significantly changed. Analysis has indicated that there 
are about 311 genes, which are differentially expressed among the different groups 
(control versus treated, PARP-1-/- versus PARP-1+/+). These genes belong to various 
biological processes and functions. The data are presented as hierarchical clustering in 
Figure 18 for the genes with differential expression in arsenic-treated samples. It is clear 
from the data that there are several genes, which are up-regulated in both PARP-1+/+ and 
PARP-1-/- following arsenic treatment. Differentially expressed genes were classified 










































































Figure 18: Genes with differential 
expression in arsenite treated 
samples between PARP-1+/+ and 
PARP-1-/- MEFs.  
PARP-1+/+ and PARP-1-/- MEFs 
were treated with 1.5 µg/ml of 
arsenite for 24 hours before mRNA 
was extracted. Control samples 
were prepared from PARP-1 +/+ and 
PARP-1-/- MEFs without arsenite 
treatment. Gene expression data 
were obtained using Affymetrix 
Mouse Genome 430 2.0 Gene Chip. 
Cluster diagram, 311 differentially 
expressed probes with p < 0.05 and 
fold change of >2.0 in one of the 
experimental conditions. Column, a 
single experiment condition; row, a 
single gene. Expression levels (red) 
for up-regulation and (blue) for 
down-regulation according to the 
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Figure 19: Classification of differentially expressed genes by Gene Ontology according to the 
biological process.  
PARP-1+/+ and PARP-1-/- MEFs treated with 1.5 µg/ml of arsenite for 24 hours were compared to their respective 
untreated control cell type. Differentially expressed genes identified with fold change of >2.0 in one of the 
experimental conditions were then classified according to their biological functions and grouped in the chart above. 
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3.1.6 DNA damage and oxidative stress pathway-specific analysis of gene expression 
profiles in PARP-1 deficient MEFs under conditions of arsenite-induced oxidative 
stress. 
 
Genes in the DNA damage signalling pathway as well as genes involved in 
oxidative stress and antioxidant defense pathways may affect the maintenance of 
genomic integrity.  From our microarray data, we identified genes involved in DNA 
damage signalling or oxidative stress and antioxidant defense to understand how PARP-1 
may affect the expression of these genes. We compiled the list of genes in the mentioned 
pathways from the listing used by SABiosciences in PCRarray for genes in the oxidative 
stress and antioxidant defense pathway (PAMM-065) and DNA damage signalling 
(PAMM-029). Figure 20 highlights the hierarchical clustering of genes differentially 
expressed in PARP-1+/+ and PARP-1-/- MEFs in the antioxidant defense pathway. The 
fold difference values obtained for specific genes as listed to be involved in oxidative 
stress and antioxidant defense (Table 3). Figure 21 illustrates the hierarchical clustering 
of genes in the DNA damage response pathway. Selected genes were found to be 
differentially expressed by at more than ± 2 with p <0.05. Table 4 highlights the fold 
difference values obtained for specific genes as listed to be involved in DNA damage 
signalling. Pathway studio 5.0 software was used to find enriched pathways using 
differentially expressed genes across PARP-1+/+ and PARP-1-/- MEFs. It was found that 
the pathways governing oxidative stress and antioxidant defense as well as DNA damage 
signalling were significantly affected (p <0.001) by PARP-1 deficiency upon arsenite-







Figure 20: Differentially expressed 
genes in PARP-1+/+ and PARP-1-/- 
MEFs from the oxidative stress and 
antioxidant defense pathway after 
arsenite treatment.  
PARP-1+/+ and PARP-1-/- MEFs were 
treated with 1.5 µg/ml of arsenite for 
24 hours and the gene expression 
analysed by microarray. Expression 
levels were compared to their 
respective untreated control cell type. 
Expression profile of selected genes, 
which were differentially expressed to 
a fold change of 2.0 or more in one of 
the treatment, is given. Data indicate 
the fold increase (positive values) or 
decrease (negative values) in treated 
samples compared to corresponding 






























































































glutathione peroxidase 6 AV001252 -1.39 7.71 -1.08 9.89 
kinesin family member 9 NM_010628 -4.62 4.33 -3.54 5.65 
interleukin 10-related T cell-derived 
inducible factor beta AJ249492 1.25 5.81 -1.00 4.64 
flavin containing monooxygenase 2 NM_018881 -1.92 3.31 -1.56 4.06 
glutathione peroxidase 2 NM_030677 2.22 4.97 1.78 4.00 
uncoupling protein 3 (mitochondrial, 
proton carrier) AF053352 -3.40 1.12 -1.05 3.64 
glutathione peroxidase 7 NM_024198 -2.01 -1.63 2.84 3.50 
aquarius AK016322 1.04 2.01 1.40 2.69 
excision repair cross-complementing 
rodent repair deficiency, 
complementation group 2 BB547876 -1.08 2.53 -1.05 2.60 
cardiomyopathy associated 1 NM_011724 -17.06 -1.53 -4.70 2.38 
eosinophil peroxidase NM_007946 4.14 1.43 5.91 2.04 
dynamin 2 BB762738 -1.35 1.30 1.14 2.00 
cytochrome b-245, alpha polypeptide AK018713 -1.90 1.69 -1.69 1.90 
recombination activating gene 2 NM_009020 -2.52 6.28 -9.20 1.72 
glutathione peroxidase 5 NM_010343 4.20 7.24 -1.03 1.67 
superoxide dismutase 3, extracellular NM_011435 1.43 4.62 -2.07 1.56 
thioredoxin interacting protein AF173681 3.67 1.26 4.44 1.53 
lactoperoxidase NM_080420 -1.40 2.23 -2.05 1.52 
RecQ protein-like 4 NM_058214 1.56 1.01 2.31 1.50 
nitric oxide synthase 2, inducible, 
macrophage AF065921 -1.67 3.51 -4.11 1.43 
zinc finger, MYND domain 
containing 17 AK014794 -13.16 -7.07 -1.36 1.37 
thioredoxin reductase 2 BE948556 1.07 2.68 -1.89 1.32 
apolipoprotein E AK019319 1.33 -1.65 2.73 1.25 
glutathione peroxidase 3 NM_008161 -1.69 1.00 -1.37 1.24 
thioredoxin reductase 2 NM_013711 1.59 -1.53 2.93 1.20 
solute carrier family 38, member 1 NM_134086 1.05 1.03 1.21 1.19 
glutathione reductase 1 AK019177 1.03 -1.55 1.86 1.17 
thyroid peroxidase NM_009417 1.40 8.56 -5.38 1.14 
peroxiredoxin 3 NM_007452 -1.86 1.09 -1.81 1.12 
Neuroglobin NM_022414 -1.17 1.66 -1.98 -1.03 
nudix (nucleoside diphosphate linked 
moiety X)-type motif 15 BB198496 -1.54 1.80 -2.87 -1.03 
thioredoxin reductase 3 AF349659 1.48 1.82 -1.36 -1.10 
Fanconi anemia, complementation 
group C BB116513 1.70 -1.01 1.55 -1.10 
myeloperoxidase NM_010824 1.66 -2.55 3.39 -1.25 
cytoglobin BM899392 2.71 -1.39 2.92 -1.29 
glutathione S-transferase kappa 1 AK002661 6.99 1.03 5.05 -1.34 
      
      
            
      
      
      
Table 3: Differentially expressed genes in the oxidative stress and antioxidant defense pathway from 
PARP-1+/+ and PARP-1-/- MEFs after arsenite treatment by microarray.  
PARP-1+/+ and PARP-1-/- MEFs were treated with 1.5 µg/ml of arsenite for 24 hours and the gene expression analysed 
by microarray. Expression levels were compared to their respective untreated control cell type. Genes, which were 
differentially expressed to a fold change of 2.0 or more in one of the treatment, are given. Data indicate the fold 
increase (positive values) or decrease (negative values) in treated samples compared to corresponding controls. (a) 
Gene expression compared with untreated PARP-1+/+ MEFs; (b) Gene expression compared with untreated PARP-1-/- 
MEFs; (c) Gene expression compared with untreated PARP-1+/+ MEFs; (d) Gene expression compared with treated 
PARP-1+/+ MEFs.  
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nucleoredoxin BB366804 -1.15 -1.64 -1.02 -1.45 
AV158882 Mus musculus head 
C57BL/6J 12-day embryo Mus 
musculus cDNA clone 3010020C13, 
mRNA sequence. AV158882 1.87 1.90 -1.54 -1.52 
thioredoxin reductase 1 NM_015762 -1.34 -2.96 1.38 -1.60 
EH-domain containing 2 BC027084 1.58 1.01 -1.12 -1.76 
sulfiredoxin 1 homolog (S. cerevisiae) BC011325 1.32 -1.43 1.05 -1.79 
membrane protein, palmitoylated 4 
(MAGUK p55 subfamily member 4) AB059357 1.39 -1.36 -1.05 -1.97 
Mus musculus protein kinase ATR 









intraflagellar transport 172 homolog 
(Chlamydomonas) AK006007 -1.39 -2.91 -1.06 -2.22 





tropomodulin 1 NM_021883 1.11 -2.44 1.20 -2.26 
superoxide dismutase 1, soluble BM240246 -1.35 -1.72 -1.92 -2.44 
protein phosphatase 1, regulatory 
(inhibitor) subunit 15b BC006897 1.19 -1.58 -1.38 -2.60 
prion protein BE630020 1.82 -1.27 -1.15 -2.66 
amyotrophic lateral sclerosis 2 
(juvenile) homolog (human) AB053307 1.32 -1.89 -1.08 -2.70 
neutrophil cytosolic factor 2 NM_010877 13.11 -2.92 13.56 -2.83 
prostaglandin-endoperoxide synthase 
2 M94967 -3.33 -1.81 -5.24 -2.85 
RIKEN cDNA 2310016C16 gene BC019664 2.14 1.17 -1.57 -2.86 
NADPH oxidase organizer 1 BC019525 -1.27 -1.48 -2.54 -2.98 
xeroderma pigmentosum, 
complementation group A BM117916 1.43 1.08 -2.51 -3.33 
aminoadipate-semialdehyde synthase BF687395 -1.26 1.64 -7.03 -3.39 
glutathione peroxidase 4 AF274027 9.29 1.72 1.50 -3.61 
serine (or cysteine) peptidase 
inhibitor, clade B, member 1b AF426025 2.78 16.55 -25.88 -4.34 
adenomatosis polyposis coli NM_007462 1.20 -3.01 -1.25 -4.53 
myoglobin NM_013593 1.22 1.87 -7.72 -5.01 
proteasome (prosome, macropain) 
subunit, beta type 5 NM_011186 2.17 -1.36 -1.91 -5.66 
AV147875 Mus musculus C57BL/6J 
10-11 day embryo Mus musculus 
cDNA clone 2810468P17, mRNA 
sequence. AV147875 -1.07 -7.93 1.25 -5.92 
      
      
      
      
      
      
      
      
Table 3 (Continued): Differentially expressed genes in the oxidative stress and antioxidant 
defense pathway from PARP-1+/+ and PARP-1-/- MEFs after arsenite treatment by microarray.  
PARP-1+/+ and PARP-1-/- MEFs were treated with 1.5 µg/ml of arsenite for 24 hours and the gene expression 
analysed by microarray. Expression levels were compared to their respective untreated control cell type. Genes, 
which were differentially expressed to a fold change of 2.0 or more in one of the treatment, are given. Data indicate 
the fold increase (positive values) or decrease (negative values) in treated samples compared to corresponding 
controls. (a) Gene expression compared with untreated PARP-1+/+ MEFs; (b) Gene expression compared with 
untreated PARP-1-/- MEFs; (c) Gene expression compared with untreated PARP-1+/+ MEFs; (d) Gene expression 















Parkinson disease (autosomal 
recessive, early onset) 7 BC002187 1.82 -1.60 -2.10 -6.11 
NADPH oxidase 4 AB041034 1.12 -8.23 1.33 -6.90 
growth factor receptor bound protein 
2-associated protein 1 NM_021356 1.11 -6.50 -1.02 -7.38 
isocitrate dehydrogenase 1 (NADP+), 
soluble AI788952 1.40 -1.57 -3.58 -7.82 
vimentin M24849 -1.79 -12.66 -1.19 -8.39 
xeroderma pigmentosum, 
complementation group A NM_011728 1.25 -5.43 -1.73 -11.77 
prostaglandin-endoperoxide synthase 
1 BB520073 -3.07 -21.74 -1.71 -12.16 
superoxide dismutase 2, 
mitochondrial NM_013671 1.45 -5.70 -1.84 -15.24 
peroxiredoxin 4 NM_016764 -1.59 -31.48 1.01 -19.55 
stearoyl-Coenzyme A desaturase 1 NM_009127 1.11 -13.53 -1.37 -20.53 
glutathione peroxidase 1 BI219063 1.47 -3.02 -5.30 -23.56 
peroxiredoxin 5 BC008174 1.53 -17.58 -1.81 -48.74 
isocitrate dehydrogenase 1 (NADP+), 
soluble NM_010497 1.22 -21.11 -1.91 -49.00 
peroxiredoxin 1 NM_011034 8.78 -1.53 -3.70 -49.71 
peroxiredoxin 2 NM_011563 2.69 -1.97 -11.59 -61.61 
cathepsin B M14222 2.69 -21.66 -1.44 -83.62 
Table 3 (Continued): Differentially expressed genes in the oxidative stress and antioxidant 
defense pathway from PARP-1+/+ and PARP-1-/- MEFs after arsenite treatment by microarray.  
PARP-1+/+ and PARP-1-/- MEFs were treated with 1.5 µg/ml of arsenite for 24 hours and the gene expression 
analysed by microarray. Expression levels were compared to their respective untreated control cell type. Genes, 
which were differentially expressed to a fold change of 2.0 or more in one of the treatment, are given. Data indicate 
the fold increase (positive values) or decrease (negative values) in treated samples compared to corresponding 
controls. (a) Gene expression compared with untreated PARP-1+/+ MEFs; (b) Gene expression compared with 
untreated PARP-1-/- MEFs; (c) Gene expression compared with untreated PARP-1+/+ MEFs; (d) Gene expression 















































































Figure 21: Differentially expressed 
genes in PARP-1+/+ and PARP-1-/- 
MEFs from the DNA damage 
signalling pathway after arsenite 
treatment.  
PARP-1+/+ and PARP-1-/- MEFs were 
treated with 1.5 µg/ml of arsenite for 
24 hours and the gene expression 
analysed by microarray. Expression 
levels were compared to their 
respective untreated control cell type. 
Expression profile of selected genes, 
which were differentially expressed to 
a fold change of 2.0 or more in one of 
the treatment, is given. Data indicate 
the fold increase (positive values) or 
decrease (negative values) in treated 
samples compared to corresponding 




















alpha thalassemia/mental retardation 
syndrome X-linked homolog (human) BB825830 -1.74 22.58 -2.90 13.51 
transformation related protein 53 BB828014 1.16 10.66 -1.47 6.24 
RAD52 homolog (S. cerevisiae) NM_011236 -3.73 1.46 1.14 6.22 
Rad51 homolog c (S. cerevisiae) NM_053269 -13.19 -2.98 -1.11 4.00 
mutS homolog 3 (E. coli) M24919 -2.30 39.03 -26.74 3.35 
poly (ADP-ribose) polymerase family, 
member 1 AF126717 1.06 1.48 2.17 3.02 
X-ray repair complementing defective 
repair in Chinese hamster cells 2 AK014963 -3.94 -1.33 1.00 2.95 
cryptochrome 2 (photolyase-like) BF303057 1.02 6.51 -2.35 2.73 
three prime repair exonuclease 1 NM_011637 -1.58 2.42 -1.46 2.61 
transient receptor potential cation channel, 
subfamily C, member 2 BC003841 -1.39 1.44 -1.15 1.74 
STE20-like kinase (yeast) NM_009289 -2.03 10.30 -13.05 1.60 
flap structure specific endonuclease 1 NM_007999 5.36 1.41 6.00 1.57 
RAD9 homolog B (S. cerevisiae) BC021784 -1.99 1.74 -2.35 1.47 
X-ray repair complementing defective 
repair in Chinese hamster cells 6 NM_010247 -1.52 -1.01 -1.04 1.44 
Fanconi anemia, complementation group G BG072083 2.74 2.85 1.34 1.39 
X-ray repair complementing defective 
repair in Chinese hamster cells 3 AW537713 1.02 1.07 1.23 1.30 
8-oxoguanine DNA-glycosylase 1 AK008192 2.08 2.11 1.23 1.24 
RAD1 homolog (S. pombe) NM_011232 2.90 1.83 1.82 1.15 
uracil DNA glycosylase BC004037 1.21 1.65 -1.20 1.14 
methyl-CpG binding domain protein 4 AF072249 -1.30 -1.10 -1.06 1.12 
meiotic recombination 11 homolog A (S. 
cerevisiae) NM_018736 -1.01 1.56 -1.41 1.11 
RNA binding motif protein 4 NM_009032 1.01 -1.08 1.13 1.03 
alpha globin regulatory element containing 
gene BB137740 -1.36 1.04 -1.41 1.01 
RAD18 homolog (S. cerevisiae) AK012795 -1.74 -1.59 -1.20 -1.10 
Fanconi anemia, complementation group C BB116513 1.70 -1.01 1.55 -1.10 
steroid 5 alpha-reductase 2 NM_053188 -5.33 -2.93 -2.06 -1.13 
mutL homolog 3 (E coli) BC003865 1.74 2.18 -1.47 -1.17 
Werner helicase interacting protein 1 AK019527 -3.95 -1.54 -3.28 -1.28 
REV1 homolog (S. cerevisiae) NM_019570 -1.33 -2.26 1.28 -1.33 
general transcription factor II H, 
polypeptide 1 BE688673 1.43 1.27 -1.35 -1.52 
nth (endonuclease III)-like 1 (E.coli) NM_008743 1.25 -1.04 -1.20 -1.56 
checkpoint kinase 1 homolog (S. pombe) BB298208 -1.57 -1.13 -2.23 -1.61 
RIKEN cDNA 2610028A01 gene NM_028228 2.07 1.27 -1.04 -1.70 
      
      
      
      
      
      
      
      
Table 4: Differentially expressed genes in the DNA damage signalling pathway from PARP-1+/+ 
and PARP-1-/- MEFs after arsenite treatment by microarray.  
PARP-1+/+ and PARP-1-/- MEFs were treated with 1.5 µg/ml of arsenite for 24 hours and the gene expression 
analysed by microarray. Expression levels were compared to their respective untreated control cell type. Genes, 
which were differentially expressed to a fold change of 2.0 or more in one of the treatment, are given. Data indicate 
the fold increase (positive values) or decrease (negative values) in treated samples compared to corresponding 
controls. (a) Gene expression compared with untreated PARP-1+/+ MEFs; (b) Gene expression compared with 
untreated PARP-1-/- MEFs; (c) Gene expression compared with untreated PARP-1+/+ MEFs; (d) Gene expression 














breast cancer 1 U31625 2.49 -1.05 1.51 -1.73 
Werner syndrome homolog (human) AF241636 -1.41 -2.62 1.06 -1.74 
RAD23a homolog (S. cerevisiae) NM_009010 -1.21 -1.07 -2.02 -1.78 
5'-3' exoribonuclease 2 NM_011917 1.60 -1.10 -1.01 -1.79 
C85740 Mouse fertilized one-cell-embryo 
cDNA Mus musculus cDNA clone 
J0213H11 3', mRNA sequence. C85740 -1.15 -1.69 -1.34 -1.96 
O-6-methylguanine-DNA 
methyltransferase NM_008598 1.20 -1.03 -1.71 -2.12 
excision repair cross-complementing rodent 
repair deficiency, complementation group 1 NM_007948 1.20 5.00 -9.22 -2.20 
mutS homolog 2 (E. coli) NM_008628 -1.63 -3.08 -1.18 -2.24 
transition protein 1 NM_009407 4.76 2.25 -1.07 -2.26 
protein kinase, DNA activated, catalytic 
polypeptide D87521 -1.18 1.17 -3.18 -2.31 
polymerase (DNA directed), eta (RAD 30 
related) NM_030715 1.29 -2.54 1.38 -2.37 
xeroderma pigmentosum, complementation 
group C NM_009531 1.51 -1.01 -1.75 -2.67 
telomeric repeat binding factor 1 NM_009352 1.19 -1.62 -1.41 -2.73 
DNA cross-link repair 1A, PSO2 homolog 
(S. cerevisiae) AF241240 1.96 -1.19 -1.19 -2.76 
polymerase (DNA directed), epsilon NM_011132 -1.28 -6.73 1.90 -2.76 
RAD51-like 1 (S. cerevisiae) NM_009014 -1.48 1.34 -5.52 -2.78 
general transcription factor II H, 
polypeptide 2 NM_022011 2.11 -2.35 1.70 -2.92 
breast cancer 2 NM_009765 -1.72 -2.52 -2.09 -3.05 
apurinic/apyrimidinic endonuclease 1 NM_009687 2.66 1.10 -1.34 -3.25 
H2A histone family, member X NM_010436 1.26 -1.28 -2.03 -3.26 
xeroderma pigmentosum, complementation 
group A BM117916 1.43 1.08 -2.51 -3.33 
exonuclease 1 BE986864 -1.78 -4.30 -1.50 -3.62 
postmeiotic segregation increased 1 (S. 
cerevisiae) BM200777 -1.03 -1.52 -2.52 -3.71 
C85740 Mouse fertilized one-cell-embryo 
cDNA Mus musculus cDNA clone 
J0213H11 3', mRNA sequence. C85740 2.95 1.27 -1.59 -3.71 
polymerase (DNA-directed), delta 3, 
accessory subunit AK010805 4.87 -5.13 6.05 -4.13 
RAD17 homolog (S. pombe) NM_011233 1.53 -2.65 -1.05 -4.28 
Hus1 homolog (S. pombe) NM_008316 1.49 -1.98 -1.50 -4.42 
tousled-like kinase 1 BB749708 1.94 -7.72 3.23 -4.64 
polymerase (DNA directed), iota NM_011972 1.25 -6.82 1.82 -4.67 
      
      
      
      
      
      
      
Table 4 (continued): Differentially expressed genes in the DNA damage signalling pathway from 
PARP-1+/+ and PARP-1-/- MEFs after arsenite treatment by microarray. PARP-1+/+ and PARP-1-/- MEFs 
were treated with 1.5 µg/ml of arsenite for 24 hours and the gene expression analysed by microarray. Expression 
levels were compared to their respective untreated control cell type. Genes, which were differentially expressed to a 
fold change of 2.0 or more in one of the treatment, are given. Data indicate the fold increase (positive values) or 
decrease (negative values) in treated samples compared to corresponding controls. (a) Gene expression compared 
with untreated PARP-1+/+ MEFs; (b) Gene expression compared with untreated PARP-1-/- MEFs; (c) Gene expression 















poly (ADP-ribose) polymerase family, 
member 2 AF072521 1.03 -4.58 -1.08 -5.07 
polymerase (DNA directed), delta 1, 
catalytic subunit BC009128 1.10 -1.20 -3.91 -5.13 
structural maintenance of chromosomes 3 AK005647 1.63 -3.82 1.09 -5.72 
growth arrest and DNA-damage-inducible 
45 alpha NM_007836 5.29 1.52 -1.67 -5.79 
X-ray repair complementing defective 
repair in Chinese hamster cells 1 NM_009532 -1.54 -7.13 -1.40 -6.46 
ligase I, DNA, ATP-dependent NM_010715 1.50 -3.64 -1.18 -6.48 
RAD51 homolog (S. cerevisiae) NM_011234 -1.38 -7.54 -1.20 -6.56 
mutL homolog 1 (E. coli) NM_026810 -1.98 -8.93 -1.46 -6.59 
N-methylpurine-DNA glycosylase BC014754 1.13 -2.41 -2.47 -6.74 
RAD50 homolog (S. cerevisiae) NM_009012 1.56 -3.72 -1.19 -6.95 
mutY homolog (E. coli) NM_133250 -1.24 -2.06 -4.38 -7.28 
ataxia telangiectasia mutated homolog 
(human) NM_007499 1.18 -11.17 1.75 -7.55 
postmeiotic segregation increased 2 (S. 
cerevisiae) BM239600 1.91 -4.78 1.15 -7.94 
RAD9 homolog (S. pombe) NM_011237 4.71 -15.88 7.11 -10.53 
RAD21 homolog (S. pombe) AF332085 1.06 -13.57 -1.19 -17.07 
macrophage migration inhibitory factor NM_010798 3.72 -2.62 -2.16 -21.10 
ubiquitin-conjugating enzyme E2A, RAD6 
homolog (S. cerevisiae) BG868960 -1.05 -65.26 -1.17 -72.81 
 
Table 4 (continued): Differentially expressed genes in the DNA damage signalling pathway from 
PARP-1+/+ and PARP-1-/- MEFs after arsenite treatment by microarray.  
PARP-1+/+ and PARP-1-/- MEFs were treated with 1.5 µg/ml of arsenite for 24 hours and the gene expression 
analysed by microarray. Expression levels were compared to their respective untreated control cell type. Genes, 
which were differentially expressed to a fold change of 2.0 or more in one of the treatment, are given. Data indicate 
the fold increase (positive values) or decrease (negative values) in treated samples compared to corresponding 
controls. (a) Gene expression compared with untreated PARP-1+/+ MEFs; (b) Gene expression compared with 
untreated PARP-1-/- MEFs; (c) Gene expression compared with untreated PARP-1+/+ MEFs; (d) Gene expression 





3.1.7 Copper containing genes were differentially expressed in PARP-1 deficient 
MEFs. 
 
Following the profiling of genome-wide gene expression in PARP-1 proficient 
and deficient MEFs with arsenite treatment by microarray, functional gene annotation 
was undertaken to classify differentially expressed genes into specific pathways based on 
their biological function using DAVID functional gene annotation software 2008 
(http://david.abcc.ncifcrf.gov/). This was followed up with Gene set enrichment analysis 
(GSEA) by Pathway studio 5.0 to determine if these pathways show statistically 
significant, concordant differences between two biological states i.e. the presence and 
absence of PARP-1 when subject to arsenite treatment. We identified that genes involved 
in copper metabolism and homeostasis were significantly affected when PARP-1 was 
absent.  Figure 22B indicates the hierarchical clustering of genes in this pathway. Genes 
involved in copper metabolism and copper binding pathway were significantly affected 
(p <0.001) when PARP-1 is absent and when treated with arsenite. Table 5 indicates the 
expression levels of the genes in this pathway as identified by microarray in the PARP-1 
proficient and deficient MEFs tested. Schwertle et al., had demonstrated that copper 
supplementation was able to inhibit the activity of isolated PARP-1 (Schwertle et al., 
2007). We identified that when PARP-1+/+ MEFs were subjected to copper chelator 
treatment, the levels of Parp-1 mRNA were reduced about 1.4 fold (Figure 22A). 
Additionally, we investigated if expression of genes in the copper metabolism pathway 














Figure 22A: Real time rtPCR expression of Parp-1 mRNA in PARP-1+/+ and PARP-1-/- MEFs. 
Parp-1 mRNA expression was investigated by rtPCR in PARP-1+/+ and PARP-1-/- MEFs with and without 24 hour 
treatment of 200µM of copper chelator, BCS. The Parp-1 mRNA expression was in PARP-1 deficient MEFs was 
included as a negative control. The figure indicates Parp1 mRNA expression as a fold difference relative to 
expression in PARP-1+/+ MEFs. Expression values were normalised to Gapdh housekeeping gene. Error bars 
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Figure 22B: Differentially expressed 
genes coding for copper containing 
proteins in PARP-1+/+ and PARP-1-/- 
MEFs after arsenite treatment.  
PARP-1+/+ and PARP-1-/- MEFs were 
treated with 1.5 µg/ml of arsenite for 
24 hours and the gene expression 
analysed by microarray. Expression 
levels were compared to their 
respective untreated control cell type. 
Expression profile of selected genes, 
which were differentially expressed to 
a fold change of 2.0 or more in one of 
the treatments are given. Data indicate 
the fold increase (positive values) or 
decrease (negative values) in treated 
samples compared to corresponding 
controls. acompared with untreated 
PARP-1+/+ MEFs;  bcompared with 
untreated PARP-1-/- MEFs; ccompared 
with untreated PARP-1+/+ MEFs; 
dcompared with treated PARP-1+/+ 



















































Gene Symbol PARP-1-/- untreateda PARP-1-/- arsenite 
treatedb 
ATX1 (antioxidant protein 1) homolog 1 (yeast) Atox1 -13.20 -2.93 
peptidylprolyl isomerase C-associated protein Ppicap -5.13  -  
ATPase, Cu2+ transporting, alpha polypeptide Atp7a -4.06  - 
six transmembrane epithelial antigen of the prostate Steap -3.16  -  
ceruloplasmin Cp -2.96  - 
six transmembrane epithelial antigen of the prostate Steap -2.42 -5.12 
lysyl oxidase-like 3 Loxl3 -2.16 -2.42 
ATP-binding cassette, sub-family B (MDR/TAP), member 1A Abcb1a 2.05  - 
Metallothionein 1 Mt1 2.17  - 
superoxide dismutase 1, soluble Sod1  - -2.44 
solute carrier family 40 (iron-regulated transporter), member 1 Slc40a1  - -2.58 
S-adenosylhomocysteine hydrolase Ahcy  - -2.58 
prion protein Prnp  - -2.66 
prostaglandin-endoperoxide synthase 2 Ptgs2  - -2.85 
vascular endothelial growth factor A Vegfa  - -3.03 
cytosolic ovarian carcinoma antigen 1 Cova1  - -3.30 
metallothionein 2 Mt2  - -3.53 
U2af1-rs1 region 1 Murr1  - -6.97 
nuclear factor of kappa light chain gene enhancer in B-cells 1, p105 Nfkb1  - -7.53 
superoxide dismutase 2, mitochondrial Sod2  - -15.24 
glutathione peroxidase 1 Gpx1  - -23.56 
    
Table 5: Expression of genes in the copper metabolism pathway in PARP-1+/+ and PARP-1-/- MEFs by microarray.   
PARP-1+/+ and PARP-1-/- MEFs were treated with 1.5 µg/ml of arsenite for 24 hours and the gene expression analysed by microarray. Expression levels were compared to their 
respective untreated control cell type. Genes involved in copper binding or metabolism was identified using DAVID gene annotation software. Genes, which were differentially 
expressed to a fold change of 2.0 or more in one of the treatment, are given. Data indicate the fold increase (positive values) or decrease (negative values) in treated samples 
compared to corresponding controls. (a) Gene expression compared with untreated PARP-1+/+ MEFs; (b) Gene expression compared with arsenite treated PARP-1+/+ MEFs. Dashes 




3.2  Role of copper metabolism in DNA damage response 
3.2.1 Copper supplementation reduced levels of double strand breaks following 
genotoxic damage in normal MEFs. 
 
We identified that arsenite-induced DNA damage caused differential gene 
expression patterns in genes coding for protein involved in copper metabolism and 
copper binding. Furthermore, since PARP-1 is an important factor governing response to 
DNA damage, and changes in copper metabolism genes were evident in these cells, we 
sought to investigate if copper metabolism may have a direct role in the levels of DNA 
damage in cells. We looked at the levels of double strand breaks (DSB) in cells subjected 
to genotoxicants with or without pre-treatment with copper. This was carried out by 
quantitating the γH2AX foci formation in cells using immunostaining techniques (Figure 
23 A and B). We thus investigated the effect of copper supplementation and chelation on 
DNA damage in normal MEFs following arsenite, H2O2 and radiation treatment. Cells 
were treated with arsenite and H2O2 for 2 hours or exposed to radiation and assayed after 
30 minutes. In normal MEFs, the pre-treatment of between 0 to 100 µM of copper prior 
to 2.5 µg/ml arsenite treatment for 2 hours was sufficient to induce a decrease in double 
strand breaks (DSB) that were significantly lower than (p <0.001, Student’s t-test) the 
MEFs treated with arsenite alone (Figure 24A). Based on the dose response results and 
the dose of copper used in an earlier study (Hamza et al., 2003), 10 µM of copper was 
used for all subsequent copper supplementation experiments. This dose of copper was 
able to induce significant reduction in the levels of DSBs following arsenite (Figure 





Figure 23 A, B: γH2AX foci staining in MEFs. 
Cell nuclei were stained were stained with DAPI (Blue) and γH2AX foci (green) were detected by 
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Figure 24 A, B: γH2AX foci staining in normal MEFs. 
(A) Normal MEFs were subjected 2.5 µg/ml sodium arsenite treatment for 2 hours. Cells were pre-treated with 0 to 
100 µM of copper chloride for 24 hours prior to addition of arsenite. As a control, a set with no arsenite and copper 
supplementation was included. γH2AX foci formation is a direct indicator of the levels of DSB induced by arsenite. 
We identified 10 µM of copper for use in pre-treatment for all subsequent experiments.  (B) Normal MEFs were then 
subjected to 0, 1.5, 2.0 and 2.5 µg/ml sodium arsenite treatment for 2 hours (white bars). Another set of cells were 
pre-treated with 10 µM of copper (black bars) for 24 hours prior to arsenite addition. Error bars indicate standard 
error. Fifty nuclei were analysed per sample. Columns are means of 2 experiments. 
 ## p <0.001 as compared to untreated sample 
** p <0.001 as compared to respective 0 arsenite controls 
* p <0.05 as compared to respective 0 arsenite controls 
^^ p <0.001 as compared to arsenite only sample of that dose 
 (Student’s t-test) 
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Figure 24 C, D: γH2AX foci staining in normal mouse embryonic fibroblasts. 
(C) Normal MEFs were subjected to 0 to 100 µM hydrogen peroxide for 2 hours (black bars) and compared with 
normal MEFs with 10 µM of copper pre-treatment for 24 hours prior to hydrogen peroxide exposure (white bars). 
(D) Normal MEFs were subjected 0 to 2 Gy radiation (black bars) and compared with normal MEFs with 10 µM of 
copper pre-treatment for 24 hours prior to radiation exposure (white bars). γH2AX foci formation is a direct 
indicator of the levels of DSB. Error bars indicate standard error. Columns are means of 2 experiments. Fifty nuclei 
were analysed per sample. 
** p <0.001 as compared to respective 0 arsenite controls 
* p <0.05 as compared to respective 0 arsenite controls 
 ^^ p <0.001 as compared to arsenite only sample of that dose 
 ^p <0.05 as compared to arsenite only sample of that dose (Student’s t-test) 
 
 
 Normal MEFs w/o copper pre-treatment 
 Normal MEFs with 10 µM copper pre-treatment 
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3.2.2 Copper metabolism diseases display increased susceptibility to DNA double 
strand breaks. 
To further evaluate the effects of copper levels on DNA damage, we took copper 
metabolism disease patient cells as a model to investigate the effects of various DNA 
damaging agents. Menkes and Wilson’s disease patients suffer from a pathological 
intracellular accumulation of copper due to aberrant copper transport. Menkes and 
Wilson’s disease patient lymphoblastoid cells were subjected to arsenite, H2O2 and 
radiation exposure and the levels of γH2AX foci investigated. The addition of sodium 
arsenite induced a significant increase in the levels of DSBs at all doses of arsenite as 
compared to the respective untreated controls (Figure 25A; p <0.001, Student’s t-test). In 
both treated and untreated cells, Menkes disease cells displayed more than 2 fold higher 
DSB formation as compared to normal lymphoblastoid cells (p <0.001; Student’s t-test). 
This level of damage in Menkes disease cells was also higher at all doses of arsenite than 
the Wilson’s disease lymphoblastoid cells (p <0.001; Student’s t-test).  
With hydrogen peroxide treatment, the Menkes disease cells again displayed 
augmented γH2AX foci in both untreated and treated cells as compared to normal 
lymphoblastoid cells (Figure 25B). However, Wilson’s disease cells displayed reduced 
damage than the normal cells with hydrogen peroxide treatment (p <0.05; Student’s t-
test). Radiation exposure induced DSB in all cell types tested and the levels of DSB 
increased with the dose used (Figure 25C). At 0, 0.5 and 1Gy radiation, Menkes and 
Wilson’s disease cells displayed higher numbers of γH2AX foci as compared to the 
normal cells. At the 2 Gy dose, however, no significant difference was observed between 
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Figure 25 A, B: γH2AX foci staining in copper metabolism disease cells. 
Normal (White bars), Menkes disease (Horizontal striped bars) and Wilson’s disease human lymphoblastoid cells 
(Diagonally striped bars) were treated with (A) 0 to 2.5 µg/ml sodium arsenite for 2 hours and (B) 0 to 100 µM 
hydrogen peroxide for 2 hours. γH2AX foci formation is a direct indicator of the levels of DSB. Error bars indicate 
standard error. Columns are means of 2 experiments. Fifty nuclei per sample were analysed. 
+ p <0.05 as compared to normal human lymphoblastoid cells of that dose 
++ p <0.001 as compared to normal human lymphoblastoid cells of that dose 
** p <0.001 as compared to respective 0 controls 
* p <0.05 as compared to respective 0 controls 
@@ p <0.001 as compared to Menkes of the same dose 
@ p <0.05 as compared to Menkes of the same dose                                                                                                                      
(Student’s t-test) 
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Figure 25 C: γH2AX foci staining in copper metabolism disease cells. 
(C) Normal (White bars), Menkes disease (Horizontal striped bars) and Wilson’s disease human lymphoblastoid 
cells (Diagonally striped bars) were treated with 0 to 2 Gy radiation. γH2AX foci formation is a direct indicator of 
the levels of DSB. Error bars indicate standard error. Columns are means of 2 experiments. Fifty nuclei per sample 
were analysed. 
+ p <0.05 as compared to normal human lymphoblastoid cells of that dose 
++ p <0.001 as compared to normal human lymphoblastoid cells of that dose 
** p <0.001 as compared to respective 0 controls 
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3.2.3 Copper supplementation and chelation affected susceptibility of cells with 
copper metabolism defects to DNA damage. 
Since the copper metabolism disease lymphoblastoid cells displayed differential 
response to DNA damaging agents as compared to the normal cell type, the effects of 
copper supplementation and chelation on the levels of DSBs incurred in the different cell 
types were investigated. In normal cell types with arsenite treatment (Figure 26A), a 
significant increase in DSBs were observed. This was further augmented when copper 
chelator was added prior to arsenite exposure. However, when cells were pre-treated with 
copper, there was no significant increase in the levels of DSBs when exposed to 1.5 
µg/ml and 2.0 µg/ml of arsenite (Figure 26A) compared to arsenite-treated cells without 
copper pre-treatment. Heightened DSB formation was observed only at the highest dose 
of 2.5 µg/ml of arsenite when copper was pre-added. However, in Menkes disease 
lymphoblastoid cells, copper pre-treatment with 2.5 µg/ml arsenite induced 1.5 times 
greater γH2AX foci formation than with arsenite alone (Figure 26B). Wilson’s disease 
cells displayed 1.8 and 1.5 times lower γH2AX foci formation at 2 µg/ml and 2.5 µg/ml 
arsenite respectively following copper supplementation (Figure 26C). In comparison 
between all the doses of arsenite, the highest DSBs were observed in cells with copper 
chelator. This was evident in all three cell types. 
Hydrogen peroxide is a known inducer of DSBs (Ward et al., 1985). Upon 
hydrogen peroxide treatment (Figure 27A) increased DSBs were observed in all three cell 
types. A significant decrease in DSBs was evident in the copper supplemented normal 
cells with 25 µM and 100 µM hydrogen peroxide (Figure 27A). With Menkes disease 
cells, as observed with arsenite, copper supplementation induced greater frequency of 
foci upon hydrogen peroxide exposure (Figure 27B). At 100 µM of hydrogen peroxide, 
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copper chelation was able to significantly reduce the damage in Menkes disease cells. 
Conversely, with both normal cells and Wilson’s disease cells, copper chelation increased 
the DSB levels (Figure 27C). Copper supplementation did not induce any significant 
changes in the levels of foci formation in Wilson’s disease cells.  
As expected, increased DSBs were evident from the high levels of foci detected 
following radiation (Figure 28). Uniquely, copper supplementation was not able to induce 
significant reduction in damage following radiation unlike arsenite and H2O2 in normal 
human cell types. Copper chelation caused an increase in DSBs in normal (Figure 28A), 
Menkes (Figure 28B) and Wilson’s disease cells (Figure 28C) at the lower doses of 
radiation. Yet at higher doses, no apparent difference was discernable between cells with 
and without copper supplementation or chelation.  
For better comparison of the differences between the normal and copper 
metabolism disease cell types, the data was re-tabulated to compare between normal, 
Menkes and Wilson’s disease cells with copper pre-treatment (Figure 29) and copper 
chelator pre-treatment (Figure 30). With both arsenite (Figure 29A) and hydrogen 
peroxide (Figure 29B), Menkes disease cells sustained the highest levels of DSBs as 
compared to the other cell types upon copper supplementation. Wilson’s disease cells, on 
the other hand displayed significantly lower foci formation as compared to Menkes cells 
upon copper supplementation (Figure 29A, B). With radiation exposure however, 
Menkes and Wilson’s disease cells were not significantly different in DSB formation 
following copper pre-treatment at all doses tested (Figure 29C). 
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Menkes disease cells had the greatest DSB formation with copper chelator, BCS, 
prior to arsenite exposure (Figure 30A). Normal and Wilson’s disease cells had similar 
response to arsenite treatment upon following BCS pre-treatment except at the highest 
dose of 2.5 µg/ml of arsenite where Wilson’s disease cells had 1.7 fold increases in foci 
detected compared to the normal cells (Figure 30A). With hydrogen peroxide, Menkes 
cells sustained greater damage than normal and Wilson’s disease cells at the higher doses 
of 50 and 100 µM (Figure 30B). DSB formation was at reduced levels in the Wilson’s 
disease cells relative to the normal cells (Figure 30B). With radiation, Wilson’s disease 
cells formed significantly higher numbers of foci than the normal cells (Figure 30C). No 
significant differences were observed between Menkes and Wilson Disease cell types 
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Figure 26 A, B: γH2AX foci staining with sodium arsenite treatment following copper 
supplementation or chelation. 
(A) Normal human lymphoblastoid cells were treated with 0 to 2.5 µg/ml sodium arsenite for 2 hours (White bars) 
and compared to normal cells with either 10 µM copper chloride pre-treatment for 24 hours (Black bars) or 200 µM 
copper chelator, BCS, pre-treatment for 24 hours (Gray bars) (B) Menkes disease lymphoblastoid cells were treated 
with 0 to 2.5 µg/ml sodium arsenite for 2 hours (Horizontal striped bars), and compared to Menkes disease cells with 
either 10 µM copper chloride pre-treatment for 24 hours (Bars with vertical dashes) or 200 µM copper chelators, 
BCS, pre-treatment for 24 hours (Bars with bubbles).  γH2AX foci formation is a direct indicator of the levels of 
DSB. Error bars indicate standard error. Columns are means of 2 experiments. Fifty nuclei were analysed per sample. 
+ p <0.05 as compared to cells without copper supplementation or copper chelation for that dose 
++ p <0.001 as compared to cells without copper supplementation or copper chelation for that dose 
** p <0.001 as compared to respective 0 controls 
* p <0.05 as compared to respective 0 controls 
@@ p <0.001 as compared to copper supplemented sample of the same dose 
 @ p<0.05 as compared to copper supplemented sample of the same dose (Student’s t-test) 
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Figure 26 C: γH2AX foci staining with sodium arsenite treatment following copper 
supplementation or chelation. 
(C) Wilson’s disease lymphoblastoid cells were treated with 0 to 2.5 µg/ml sodium arsenite for 2 hours (Diagonally 
striped bars), and compared to Wilson’s disease cells with either 10 µM copper chloride pre-treatment for 24 hours 
(Checked bars) or 200 µM copper chelator, BCS, pre-treatment for 24 hours (Dotted bars). γH2AX foci formation 
is a direct indicator of the levels of DSB. Error bars indicate standard error. Columns are means of 2 experiments. 
Fifty nuclei were analysed per sample. 
+ p <0.05 as compared to cells without copper supplementation or copper chelation for that dose 
++ p <0.001 as compared to cells without copper supplementation or copper chelation for that dose 
** p <0.001 as compared to respective 0 controls 
* p <0.05 as compared to respective 0 controls 
@@ p <0.001 as compared to copper supplemented sample of the same dose 
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Figure 27 A, B: γH2AX foci staining with hydrogen peroxide treatment following copper 
supplementation or chelation. 
 (A) Normal human lymphoblastoid cells were treated with 0 to 100 µM hydrogen peroxide for 2 hours (White bars) 
and compared to normal cells with either 10 µM copper chloride pre-treatment for 24 hours (Black bars) or 200 µM 
copper chelator, BCS, pre-treatment for 24 hours (Gray bars) (B) Menkes disease lymphoblastoid cells were treated 
with 0 to 2.5 µg/ml sodium arsenite for 2 hours (Horizontal striped bars), and compared to Menkes disease cells with 
either 10 µM copper chloride pre-treatment for 24 hours (Bars with vertical dashes) or 200 µM copper chelators, BCS, 
pre-treatment for 24 hours (Bars with bubbles). Error bars indicate standard error. Columns are means of 2 
experiments. Fifty nuclei were analysed per sample.  
+ p <0.05 as compared to cells without copper supplementation or copper chelation for that dose 
++ p <0.001 as compared to cells without copper supplementation or copper chelation for that dose 
** p <0.001 as compared to respective 0 controls 
* p <0.05 as compared to respective 0 controls 
@@ p <0.001 as compared to copper supplemented sample of the same dose 
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Figure 27C: γH2AX foci staining with hydrogen peroxide treatment following copper 
supplementation or chelation. 
(C) Wilson’s disease lymphoblastoid cells were treated with 0 to 100 µM hydrogen peroxide for 2 hours 
(Diagonally striped bars), and compared to Wilson’s disease cells with either 10 µM copper chloride pre-treatment 
for 24 hours (Checked bars) or 200 µM copper chelator, BCS, pre-treatment for 24 hours (Dotted bars). γH2AX 
foci formation is a direct indicator of the levels of DSB. Error bars indicate standard error. Columns are means of 2 
experiments. Fifty nuclei were analysed per sample. 
+ p <0.05 as compared to cells without copper supplementation or copper chelation for that dose 
++ p <0.001 as compared to cells without copper supplementation or copper chelation for that dose 
** p <0.001 as compared to respective 0 controls 
* p <0.05 as compared to respective 0 controls 
(Student’s t-test) 
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Figure 28 A, B: γH2AX foci staining with radiation exposure following copper supplementation 
or chelation. 
(A) Normal human lymphoblastoid cells were treated with 0 to 2 Gy radiation (White bars) and compared to 
normal cells with either 10 µM copper chloride pre-treatment for 24 hours (Black bars) or 200 µM copper chelator, 
BCS, pre-treatment for 24 hours (Gray bars) (B) Menkes disease lymphoblastoid cells were treated with 0 to 2.5 
µg/ml sodium arsenite for 2 hours (Horizontal striped bars), and compared to Menkes disease cells with either 10 
µM copper chloride pre-treatment for 24 hours (Bars with vertical dashes) or 200 µM copper chelators, BCS, pre-
treatment for 24 hours (Bars with bubbles). Error bars indicate standard error. Columns are means of 2 
experiments. Fifty nuclei were analysed per sample.  
+ p <0.05 as compared to cells without copper supplementation or copper chelation for that dose 
++ p <0.001 as compared to cells without copper supplementation or copper chelation for that dose 
** p<0.001 as compared to respective 0 controls 
* p<0.05 as compared to respective 0 controls (Student’s t- test) 
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Figure 28 C: γH2AX foci staining with radiation exposure following copper supplementation or 
chelation. 
(C) Wilson’s disease lymphoblastoid cells were treated with 0 to 2 Gy radiation (Diagonally striped bars), and 
compared to Wilson’s disease cells with either 10 µM copper chloride pre-treatment for 24 hours (Checked bars) or 
200 µM copper chelator, BCS, pre-treatment for 24 hours (Dotted bars). γH2AX foci formation is a direct indicator 
of the levels of DSB. Error bars indicate standard error. Columns are means of 2 experiments. Fifty nuclei were 
analysed per sample. 
 
+ p <0.05 as compared to cells without copper supplementation or copper chelation for that dose 
++ p <0.001 as compared to cells without copper supplementation or copper chelation for that dose 
** p <0.001 as compared to respective 0 controls 
(Student’s t-test) 
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Figure 29 A, B: γH2AX foci staining with copper supplementation in copper metabolism disease 
cells. 
Normal (Black bars), Menkes disease (Bars with vertical dashes) and Wilson’s disease human lymphoblastoid cells 
(Checked bars) were pre treated with 10 µM of copper chloride for 24 hours. The cells were then treated with (A) 0 
to 2.5 µg/ml sodium arsenite for 2 hours or (B) 0 to 100 µM hydrogen peroxide for 2 hours.  γH2AX foci formation 
is a direct indicator of the levels of DSB. Error bars indicate standard error. Columns are means of 2 experiments. 
Fifty nuclei were analysed per sample. 
 + p <0.05  
++ p <0.001 
** p <0.001 as compared to respective 0 controls 
* p <0.05 as compared to respective 0 controls 
@@ p <0.001 as compared to copper supplemented sample of the same dose 
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Figure 29 C: γH2AX foci staining with copper supplementation in copper metabolism disease 
cells. 
Normal (Black bars), Menkes disease (Bars with vertical dashes) and Wilson’s disease human lymphoblastoid cells 
(Checked bars) were pre-treated with 10 µM of copper chloride for 24 hours. The cells were then treated with (C) 0 
to 2 Gy radiation. γH2AX foci formation is a direct indicator of the levels of DSB. Error bars indicate standard 
error. Columns are means of 2 experiments. Fifty nuclei were analysed per sample. 
 
+ p <0.05  
++ p <0.001 
** p <0.001 as compared to respective 0 controls 
(Student’s t-test) 
 
Wilson’s disease lymphoblastoid cells with 10 µM copper pre-treatment 
 
Normal human lymphoblastoid cells with 10 µM copper pre-
 
 

















0 25 50 100 




















Figure 30 A, B: γH2AX foci staining with copper chelator supplementation in copper metabolism 
disease cells. 
Normal (Gray bars), Menkes disease (Bars with bubbles) and Wilson’s disease human lymphoblastoid cells (Dotted 
bars) were pre-treated with 200 µM of copper chelator, BCS for 24 hours. The cells were then treated with (A) 0 to 
2.5 µg/ml sodium arsenite for 2 hours or (B) 0 to 100 µM hydrogen peroxide for 2 hours. γH2AX foci formation is 
a direct indicator of the levels of DSB. Error bars indicate standard error. Columns are means of 2 experiments. 
Fifty nuclei were analysed per sample. 
+ p <0.05 as compared to normal human lymphoblastoid cells of that dose 
++ p <0.001 as compared to normal human lymphoblastoid cells of that dose 
** p <0.001 as compared to respective 0 controls 
* p <0.05 as compared to respective 0 controls 
@@ p <0.001 as compared to Menkes of the same dose 
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Figure 30 C: γH2AX foci staining with copper chelator supplementation in copper metabolism 
disease cells. 
Normal (Gray bars), Menkes disease (Bars with bubbles) and Wilson’s disease human lymphoblastoid cells (Dotted 
bars) were pre-treated with 200 µM of copper chelator, BCS for 24 hours. The cells were then treated exposed to 
(C) 0 to 2 Gy radiation. γH2AX foci formation is a direct indicator of the levels of DSB. Error bars indicate 
standard error. Columns are means of 2 experiments. Fifty nuclei were analysed per sample. 
 
+ p <0.05 as compared to normal human lymphoblastoid cells of that dose 
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** p <0.001 as compared to respective 0 controls 
* p <0.05 as compared to respective 0 controls 
(Student’s t-test) 
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3.2.4 Menkes disease lymphoblastoid cells displayed increased genomic instability. 
DSBs underlie the onset of genomic instability within cells. Micronuclei 
formation is a good indicator of genomic instability in cells. Normal, Menkes and 
Wilson’s disease cells were subjected to micronuclei analysis following 24 hours of 
arsenite and radiation treatment. As compared to normal cells, Menkes and Wilson’s 
disease cells had significantly increased levels of micronuclei formation (Figure 31A; p 
<0.05; Student’s t-test). With 3.0 µg/ml arsenite, Menkes disease cells had more than 2 
fold higher micronuclei formation than normal cells. However, we did not observe any 
binucleated cells in Wilson’s disease cells at this dose. Radiation induced an increase in 
micronuclei formation in all cell types compared to its respective untreated controls 
(Figure 31B; p <0.001; Student’s t-test). Menkes disease cells, at all doses of radiation, 
displayed increased micronuclei levels compared to the normal cells. Wilson’s disease 
cells displayed 1.7 times higher micronuclei formation at 2 Gy dose of radiation than 
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Figure 31 A, B: Micronuclei induction measured by the cytokinesis-blocked micronucleus assay in 
copper metabolism disease human lymphoblastoid cells following genotoxic damage.  
Normal (White bars), Menkes disease (Horizontal striped bars) and Wilson’s disease human lymphoblastoid cells 
(Diagonally striped bars) were treated with (A) 0 to 3.0 µg/ml sodium arsenite for 2 hours and (B) 0 to 2 Gy 
radiation. Percentage micronuclei are an indicator of the levels of genomic instability. Error bars indicate standard 
error. Columns are means of 2 experiments. Thousand binucleated cells were analysed per sample. 
+ p <0.05 as compared to normal human lymphoblastoid cells of that dose 
++ p <0.001 as compared to normal human lymphoblastoid cells of that dose 
** p <0.001 as compared to respective 0 controls 
* p <0.05 as compared to respective 0 controls 
@@ p <0.001 as compared to Menkes of the same dose 
 @ p <0.05 as compared to Menkes of the same dose (student’s t-test) 
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3.3 Role of copper chaperone Antioxidant protein 1 (ATOX1) in DNA 
damage response. 
 
3.3.1 Atox1 levels are reduced in PARP-1 deficient MEFs. 
ATOX1 is a copper chaperone whose role in DNA damage has not yet been 
elucidated. However, it has been shown to have important roles as an antioxidant protein 
in yeast (Lin and Culotta, 1995). ATOX1 was down regulated upon DNA damage in 
PARP-1 deficient MEFs in our microarray (Figure 32). We confirmed reduced Atox1 
expression in PARP-1-/- MEFs by PCR (Figure 33A). Parp-1 mRNA expression was 
conversely higher in Atox1-/- MEFs (Figure 33B). To identify the effect of DNA 
damaging agents on Atox1 mRNA expression, we challenged Atox1 proficient and 
deficient MEFs with 100 µM of H2O2 and 1.0 µg/ml sodium arsenite.  Atox1 expression 
increased in the Atox1+/+ MEFs treated with H2O2 and arsenite (Figure 34). Expectedly, 
this increase was not observed in Atox1-/- MEFs (Figure 34). Additionally, we checked 
for the effect of radiation on Atox1 expression in human peripheral blood derived 
lymphocytes exposed to radiation doses between 0 to 0.5 Gy (Figure 35).  Normal human 
lymphocytes showed a decrease in Atox1 mRNA expression in the irradiated cells when 
assayed at 2 hours after exposure by microarray. However, when kept in culture for an 
additional 22 hours (24 hour time point) at atmospheric oxygen, the levels of Atox1 












Figure 32: Microarray expression of Atox1 in PARP-1+/+ and PARP-1-/- MEFs with arsenite 
treatment.  
PARP-1+/+ and PARP-1-/- MEFs were treated with 1.5 µg/ml of arsenite for 24 hours and the gene expression 
analysed by microarray. Expression levels were compared to their respective untreated control cell type. Graph 
indicates the expression of ATOX1 as analysed by Gene spring 7.2. First bar indicates Atox1 mRNA expression in 
PARP-1+/+ arsenite–treated cells as compared to the PARP-1+/+ untreated controls. The second bar indicates the 
expression of Atox1 mRNA in PARP-1-/- arsenite-treated cells as compared to PARP-1-/- untreated. The third bar 
displays the expression of Atox1 mRNA in PARP-1-/- untreated compared to PARP-1+/+ untreated controls. The 
fourth bar is indicative of the expression of Atox1 mRNA PARP-1-/- arsenite–treated cells as compared to PARP-
1+/+ arsenite-treated cells. 
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Figure 33: Real time rtPCR expression of Atox1 and Parp-1 mRNA in PARP-1+/+, PARP-1-/- , 
Atox1+/+, Atox1-/- MEFs following genotoxic damage. 
Parp-1 and Atox1 mRNA expression was investigated in PARP-1+/+, PARP-1-/- , Atox1+/+ and Atox1-/- MEFs by 
rtPCR. (A) Atox1 mRNA expression in Atox1-/- MEFs relative to Atox1+/+ MEFs and in PARP-1-/- MEFs relative to 
PARP-1+/+ MEFs. (B) Parp1 mRNA expression in Atox1-/- MEFs relative to Atox1+/+ MEFs and in PARP-1-/- MEFs 
relative to PARP-1+/+ MEFs. Dotted lines indicate fold change of ±1. 
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Figure 34: Atox1 mRNA expression upon arsenite and hydrogen peroxide treatment.  
Atox1+/+ and Atox1-/- MEFs were exposed to 100 µM of hydrogen peroxide for 2 hours or 1 µg/ml sodium arsenite 
for 24 hours and the levels of Atox1 mRNA was measured by rt-PCR and normalised to Gapdh mRNA expression. 
Dotted lines indicate fold change of 1.  
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Figure 35: Atox1 mRNA expression in primary lymphocytes with radiation exposure. 
Peripheral blood derived lymphocytes from 4 healthy donors was exposed to low doses of radiation between 0 to 
0.5 Gy and mRNA was extracted 2 hours and 24 hours following exposure.  The mRNA was then subjected to 









3.3.2 Atox1 deficient MEFs display increased sensitivity to arsenite-induced DNA 
damage. 
 
Hence, to investigate if ATOX1 have effects on DNA damage response, Atox1 
deficient MEFs were subjected to DNA damaging agents. The extent of arsenic induced 
DNA damage and repair was estimated by alkaline single cell gel electrophoresis (Comet 
assay) (Figure 36). Comet assay reflected a significantly increased level of damage in 
Atox1 deficient MEFs following 3.0 µg/ml arsenite treatment for 24 hours as compared to 
the Atox1 proficient MEFs (Figure 36; p <0.001; Student’s t-test). Without arsenite 
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Figure 36: DNA damage as measured by the comet assay in Atox1+/+ and Atox1-/- MEFs following 
arsenite exposure. 
Atox1+/+ (Black bars) and Atox1-/- MEFs (White bars) were treated with 1.5 µg/ml and 3.0 µg/ml of sodium arsenite 
for 24 hours. The extent of DNA damage is expressed as a fold difference between the tail moment (product of tail 
length and fraction of DNA) of the respective untreated controls against the arsenite treated samples. Error bars are 
indicative of standard error. Fifty nuclei were analysed. Columns are means of 2 experiments. 
 ++ p <0.001 as compared to Atox1+/+ MEFs of that dose 
** p <0.001 as compared to respective 0 controls 









3.3.3 Atox1 deficient MEFs displayed increased MN formation upon As3+ and 
radiation exposure. 
 
Micronuclei analysis was employed to further investigate if Atox1 deficiency 
predisposed the cells to increased chromosomal damage and genomic instability. To 
further understand the response to different types of genotoxicants, Atox1 proficient and 
deficient MEFs were subjected to both radiation and arsenite treatment. Sodium arsenite 
induced significant increase in micronuclei formation in both the cell types used (p 
<0.001; Student’s t-test). Atox1 deficient cell types reflected increased percent 
micronuclei at both 24 hours and 48 hours arsenite treatment (Figure 37A and B) as 
compared to the proficient cells. However, at the 3.0 µg/ml dose of As3+ for 48 hours, no 
binucleated cells were observed possibly due to the damage sustained being too high for 
cell division (Figure 37B). Radiation exposure produced significant increase in MN 
frequency with increasing radiation dose in both Atox1 proficient and deficient MEFs 
(Figure 38; p <0.001; Student’s t-test). As with the effects observed with sodium arsenite 
treatment, Atox1 deficient MEFs sustained more damage upon radiation exposure than 
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Figure 37 A, B: Micronuclei induction measured by the cytokinesis-blocked micronucleus assay in 
Atox1+/+ MEFs and Atox1-/- MEFs following arsenite treatment. 
 Atox1+/+ (Black bars) and Atox1-/- MEFs (White bars) were treated with 1.5 µg/ml and 3.0 µg/ml of sodium 
arsenite for (A) 24 hours (Solid bars) and (B) 48 hours (Dotted bars). 1000 binucleated cells were analysed per 
sample. Columns are the means of 2 experiments. 
++ p <0.001 as compared to Atox1+/+ MEFs of that dose 
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Figure 38: Micronuclei induction measured by the cytokinesis-blocked micronucleus assay in 
Atox1+/+ MEFs and Atox1-/- MEFs following radiation exposure.  
Atox1+/+ (Black bars) and Atox1-/- MEFs (White bars) were treated with 0 to 2 Gy of radiation. 1000 binucleated 
cells were analysed per sample. Columns are means of 2 experiments. 
++ p <0.001 as compared to Atox1+/+ MEFs of that dose 









3.3.4 Atox1 deficient MEFs display increased levels of chromosomal aberrations 
following As3+ treatment and radiation exposure.  
 
Impairment in genome stability mechanisms can result in gross chromosomal 
rearrangements. Hence, to investigate if ATOX1 may play a role in the maintenance of 
genomic instability, chromosomal analysis by FISH was carried out on Atox1 proficient 
and deficient MEFs following arsenite and radiation exposure. In agreement with the 
CBMN studies, increased chromosomal aberrations were observed upon As3+ treatment 
(Figure 39; Table 6) and radiation exposure (Figure 40; Table 7) in both normal and 
Atox1 deficient cells.  Atox1-/- MEFs displayed higher levels of chromosomal aberrations 
than the Atox1 proficient MEFs upon arsenite treatment at 24 hours (Figure 39A). This 
was also observed at 48 hours (Figure 39B). No metaphase spreads were observed at the 
3.0 µg/ml dose of 48 hours arsenite treatment. Similarly, at all doses of radiation 
exposure, Atox1-/- cells showed more aberrations (Figure 40; p <0.001). Atox1 deficient 
MEFs sustained increased levels of breaks and fragments than the normal MEFs upon 
radiation exposure (Table 7). With 2 Gy radiation, Atox1-/- cells had almost twice the total 
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Figure 39 A, B: Chromosome aberrations detected by telomere PNA-FISH analysis in Atox1+/+ 
MEFs and Atox1-/- MEFs following arsenite treatment. 
Atox1+/+ (Black bars) and Atox1-/- MEFs (White bars) were treated with 1.5 µg/ml and 3.0 µg/ml of sodium arsenite 
for (A) 24 hours (Block columns) and (B) 48 hours (Dotted columns). 100 metaphase spreads were analysed per 
sample. Frequency of chromosome aberrations per cell is given.  Chromosome alterations detected include 
fragments, breaks, and end-to-end fusions.  
 + p <0.05 as compared to Atox1+/+ MEFs of that dose 
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Atox1+/+ Treatment time 
No. of metaphases 
Fusions Breaks Fragments Total aberrations analysed 
ctrl  - 94 1 0 2 3 (0.03) 
1.5 24 hours 100 6 4 33 43 (0.43) 
3 24 hours 25 1 3 10 14 (0.56) 
ctrl  48 hours 50 1 1 0 2 (0.04) 
1.5 48 hours 50 5 6 11 22 (0.44) 
3 48 hours No metaphases  -  -  - -  
Concentration of 
arsenite in Atox1-
/- Treatment time 
No. of metaphases 
Fusions Breaks Fragments Total aberrations analysed 
ctrl  - 97 0 1 7 8 (0.08) 
1.5 24 hours 97 16 15 21 52 (0.5) 
3 24 hours 44 20 10 11 41 (0.9) 
ctrl  48 hours 100 1 5 2 8 (0.08) 
1.5 48 hours 100 7 25 35 67 (0.67) 





Table 6: Chromosomal aberrations observed in Atox1+/+ and Atox1-/- MEFs following sodium arsenite treatment.  
Atox1+/+ and Atox1-/- MEFs were treated with 1.5 and 3.0 µg/ml of arsenite for periods of 24 hours and 48 hours and analysed for chromosomal aberrations. 
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Figure 40: Chromosome aberrations detected by telomere PNA-FISH analysis in Atox1+/+ MEFs 
and Atox1-/- MEFs following radiation exposure. 
Atox1+/+ (Black bars) and Atox1-/- MEFs (White bars) were treated with 0 to 2 Gy radiation. 100 metaphase spreads 
were analysed per sample. Frequency of chromosome aberrations per cell is given.  Chromosome alterations 
detected include fragments, breaks, and end-to-end fusions.  
+ p <0.05 as compared to Atox1+/+ MEFs of that dose 
++ p <0.001 as compared to Atox1+/+ MEFs of that dose 







Dose of radiation in 
Atox1+/+ 
No. metaphases 
Fusions Breaks Fragments Total aberrations analysed 
0 100 2 0 5 7 (0.07) 
0.5 100 16 6 1 23 (0.23) 
1 96 17 3 11 31 (0.32) 
2 74 16 8 12 36 (0.49) 
Dose of radiation in 
Atox1-/- 
No. metaphases 
analysed Fusions Breaks Fragments Total aberrations 
0 100 4 4 0 8 (0.08) 
0.5 99 12 20 16 48 (0.48) 
1 100 8 19 39 66 (0.66) 




















Table 7: Chromosomal aberrations observed in Atox1+/+ and Atox1-/- MEFs following radiation.  





3.3.5 Atox1 deficient MEFs sustained increased levels of double strand breaks as 
evidenced by increased γH2AX foci formation in response to DNA damaging agents. 
 
Arsenite exposure induced a significant increase in DSB in both MEFs as 
compared to their respective untreated controls. Arsenite exposure for 2 hours did not 
cause a significant difference between Atox1+/+ and Atox1-/- cell types (Figure 41A). 
However, copper pre-treatment was able to induce a significant decrease in DSB as 
compared to As3+ treated samples without copper supplementation. At 2.5 µg/ml of 
arsenic, copper induced about 2 fold reduction in DNA damage (Figure 41A). The 
resulting levels of damage in the arsenite-treated samples were similar to that of the 
samples without arsenite treatment. A significant difference was observed upon H2O2 
treatment, with Atox1 deficiency conferring increased levels of DSBs at all the doses 
tested (Figure 41B). Atox1 deficiency was overcome when cells were supplemented with 
copper prior to H2O2 treatment (Figure 41B). 
Similarly, radiation-induced damage was significantly different in Atox1-/- MEFs 
compared to Atox1+/+ MEFs at all the doses tested (Figure 41C). While radiation induced 
a significant increase in DSB in both Atox1+/+ and Atox1-/- MEFs compared to the 
respective untreated controls, pre-treatment with 100 µM of copper induced a reduction 
in the levels of foci detected (Figure 41C). At this dose, in both normal and Atox1 
deficient MEFs, the decrease in damage was more than 4 fold. With all the genotoxicants 
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Figure 41 A, B: γH2AX foci staining in Atox1+/+ MEFs and Atox1-/- MEFs following genotoxic 
damage with copper supplementation. 
Atox1+/+ MEFs (Black bars) and Atox1-/- MEFs (White bars) were subjected to (A) 0 to 2.5 µg/ml sodium arsenite 
for 2 hours (Solid bars) and compared to Atox1+/+ MEFs and Atox1-/- MEFs with 10 µM copper chloride pre-
treatment for 24 hours prior to arsenite exposure (Dotted bars) (B) 0 to 100 µM hydrogen peroxide for 2 hours 
(Solid bars) and compared to Atox1+/+ MEFs and Atox1-/- MEFs with 10 µM copper chloride pre-treatment for 24 
hours prior to H2O2 exposure (Dotted bars). γH2AX foci formation is a direct indicator of the levels of DSB. Error 
bars indicate standard error. Columns are means of 2 experiments. Fifty nuclei were analysed per sample. 
** p <0.001 as compared to respective 0 controls 
* p <0.05 as compared to respective 0 controls 
@@ p <0.001 as compared to Atox1+/+ MEFs 
 @ p <0.05 as compared to Atox1+/+ MEFs 
^^ p <0.001 as compared to arsenite only sample of that dose 
^ p <0.05 as compared to arsenite only sample of that dose (Student’s t-test) 
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Figure 41 C: γH2AX foci staining in Atox1+/+ MEFs and Atox1-/- MEFs following genotoxic 
damage with copper supplementation. 
Atox1+/+ MEFs (Black bars) and Atox1-/- MEFs (White bars) subjected to (C) 0 to 2 Gy radiation (solid bars) or with 
10µM of copper pre-treatment (Dotted bars) prior to radiation exposure.  
** p <0.001 as compared to respective 0 arsenite controls 
* p <0.05 as compared to respective 0 arsenite controls 
@@ p <0.001 as compared to Atox1+/+ MEFs 
 @ p <0.05 as compared to Atox1+/+ MEFs 
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3.3.6 Atox1 deficiency is associated with increased superoxide formation. 
Oxygen metabolism itself has been demonstrated to contribute to increased levels 
of double strand breaks (Karanjawala et al., 2002). To evaluate whether the increased 
levels of double stranded breaks observed in Atox1 deficient MEFs were a product of 
increased ROS, the levels of superoxide were investigated by HE staining. Atox1 
deficient MEFs displayed increased levels of superoxide as seen in the shift of the peak 
towards the right (Figure 42B). When challenged with 100 µM of H2O2, Atox1+/+ MEFs 
displayed a further rise in superoxide levels (Figure 42C). Conversely, in the Atox1-/- 
MEFs a reduction in superoxide production was evident when challenged with H2O2 
relative to the untreated Atox1 deficient MEFs (Figure 42D). When the H2O2 treated 
Atox1+/+ and Atox1-/- cells were compared, superoxide levels were slightly lower in Atox1 
deficient MEFs (Figure 42E).  Copper supplementation produced evident O2- production 
in normal cells (Figure 42F) which was not observed in Atox1 deficient MEFs (Figure 
42G). Similar trends were observed when copper chelator, BCS was added (Figure 42H 
and I). In copper supplemented or chelated cells, no significant difference in superoxide 
levels was observed between Atox1 proficient and deficient cells (Figure 42L and N). 
Yet, when challenged with hydrogen peroxide, Atox1 deficient MEFs with copper 
chelator produced the greatest increase in superoxide levels as compared to the Atox1 









Figure 42: Superoxide formation observed in Atox1+/+ and Atox1-/- MEFs following radiation.  
Atox1+/+ and Atox1-/- MEFs were treated with 100 µM hydrogen peroxide for 30 minutes. They were analysed for superoxide formation by HE staining with flow cytometry. 
(A) Atox1+/+ MEFs unstained with HE (red) and Atox1+/+ MEFs stained with HE as a control. (B) Atox1+/+ MEFs with no H2O2 (red) and Atox1-/- MEFs with no H2O2 added 
(Black). (C) Atox1+/+ MEFs with no H2O2 (red) and Atox1+/+ MEFs with 100µM H2O2 (Black). (D) Atox1-/- MEFs with no H2O2 (red) and Atox1-/- MEFs with 100 µM H2O2 
(Black). (E) Atox1+/+ MEFs with 100 µM H2O2 (red) and Atox1-/- MEFs with 100 µM H2O2 (Black). (F) Atox1+/+ MEFs with no H2O2 (red) and Atox1+/+ MEFs with no H2O2 







Atox1+/+ 0 µM H2O2 (red) vs. Atox1-/- 0 µM 
H2O2 (Black) 
Atox1+/+ untreated (red) vs. Atox1+/+ HE 
stained control (Black) 
Atox1+/+ 0 µM H2O2 (red) vs. Atox1+/+ 100µM 
H2O2 (Black) 
Atox1-/- 0 µM H2O2 (red) vs. Atox1-/- 100 µM 
H2O2 (Black) 
Atox1+/+ 100 µM H2O2 (red) vs. Atox1-/- 100 
µM H2O2 (Black) 
Atox1+/+ 0 µM H2O2 (red) vs. Atox1+/+ 0 µM 
H2O2 with 10µM copper (Black) 
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Atox1-/- 0µM H2O2 (red) vs. Atox1-/- 0µM 
H2O2 with 10µM copper (Black) 
Atox1+/+ 0µM H2O2 (red) vs. Atox1+/+ 0µM 
H2O2 with 200µM BCS (Black) 
Atox1+/+ 0µM H2O2 (red) vs. Atox1+/+ 0µM H2O2 with 
10µM copper (Black) vs. Atox1+/+ 0µM H2O2 with 
200µM BCS (Blue) 
 
Atox1-/- 0µM H2O2 (red) vs. Atox1-/- 0µM H2O2 with 
10µM copper (Black) vs. Atox1-/-  0µM H2O2 with 
200µM BCS (Blue) 
 
Atox1-/- 0µM H2O2 (red) vs. Atox1-/- 0µM 
H2O2 with 200µM BCS (Black) 
Atox1+/+ 0µM H2O2 10µM copper (red) vs. 
Atox1-/- 0µM H2O2 with 10µM copper 
(Black) 
Figure 42: Superoxide formation observed in Atox1+/+ and Atox1-/- MEFs following radiation.  
Atox1+/+ and Atox1-/- MEFs were treated with hydrogen peroxide for 30minutes. They were analysed for superoxide formation by HE staining followed by flow cytometry. (G) 
Atox1-/- MEFs with no H2O2 (red) and Atox1-/- MEFs with no H2O2 supplemented with 10µM copper (Black). (H) Atox1+/+ MEFs with no H2O2 (red) and Atox1+/+ MEFs with 
no H2O2 supplemented with 200µM BCS (Black)  (I) Atox1-/- MEFs with no H2O2 (red) and Atox1-/- MEFs with no H2O2 supplemented with 200µM BCS (Black).  (J) Atox1+/+ 
MEFs with no H2O2 (red) and Atox1+/+ MEFs with no H2O2 supplemented with 10µM copper (Black) and Atox1+/+ MEFs with no H2O2 supplemented with 200µM BCS 
(Blue). (K) Atox1-/- MEFs with no H2O2 (red) and Atox1-/-MEFs with no H2O2 supplemented with 10µM copper (Black) and Atox1-/- MEFs with no H2O2 supplemented with 
200µM BCS (Blue).  (L) Atox1+/+ MEFs with no H2O2 supplemented with 10µM copper (red) and Atox1-/- MEFs with no H2O2 supplemented with 10µM copper (Black). 
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Atox1+/+ 100µM H2O2 with 10µM copper 
(red) vs. Atox1-/- 100µM H2O2 with 10µM 
copper (Black) 
Atox1+/+ 0µM H2O2 200µM BCS (red) vs. 
Atox1-/- 0µM H2O2 with 200µM BCS (Black) 
Atox1+/+ 100µM H2O2 200µM BCS (red) vs. 
Atox1-/- 100 µM H2O2 with 200µM BCS 
(Black) 
M N O 
Figure 42: Superoxide formation observed in Atox1+/+ and Atox1-/- MEFs following radiation.  
Atox1+/+ and Atox1-/- MEFs were treated with hydrogen peroxide for 30minutes. They were analysed for superoxide formation by HE staining followed by flow cytometry. 
(M) Atox1+/+ MEFs with 100µM H2O2 supplemented with 10µM copper (red) and Atox1-/- MEFs with 100µM H2O2 supplemented with 10µM copper (Black). (N) Atox1+/+ 
MEFs with no H2O2 supplemented with 200µM BCS (red) and Atox1-/- MEFs with no H2O2 supplemented with 200µM BCS (Black)  (O) Atox1+/+ MEFs with 100µM H2O2 










 3.3.7 Atox1 deficiency causes differences in survival upon DNA damage in MEFs. 
 
To investigate if Atox1 deficiency may affect the proliferation of cells in response 
to damage, Atox1+/+ and Atox1-/- MEFs were subjected to arsenite treatment for 2, 24 and 
48 hours. Cells were supplemented with either copper or copper chelator, BCS. With 2 
hours of arsenite treatment, Atox1 deficient MEFs displayed reduced proliferation with 
and without copper supplementation (Figure 43A). Arsenite treatment did not induce 
significant cell death at the 2 hour time point in all the doses tested. However, arsenite 
treatment for 24 hours and 48 hours induced significant cell death in all the samples. 
Interestingly, at 24 hours of arsenite exposure, Atox1 deficient MEFs indicated 30 % 
higher survival than Atox1 proficient MEFs (Figure 43B). Copper supplementation was 
able to bring survival values of Atox1 proficient and deficient MEFs to similar ranges. 
BCS-treated Atox1 deficient MEFs tolerated arsenite treatment better than Atox1 
proficient MEFs pre-treated with BCS. In cells exposed to arsenite for 48 hours, the BCS 
pre-treated Atox1 proficient and deficient MEFs had survival levels similar to that of the 
copper pre-treated Atox1-/- cells. Forty eight hours of arsenite treatment induced high 
levels of cell death in all the cell types (Figure 43C). The levels of cells surviving 48 
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Figure 43 A, B: Cell survival by Crystal violet assay in Atox1+/+ MEFs and Atox1-/- MEFs 
following arsenite damage with copper supplementation or chelation. 
Atox1+/+ MEFs (Black bars) and Atox1-/- MEFs (White bars) were subjected to 0 to 2.5 µg/ml sodium arsenite 
treatment for (A) 2 hours, (B) 24 hours and compared with Atox1+/+ MEFs (vertical striped bars) and Atox1-/- MEFs 
(horizontal striped bars)  pre-treated with 10 µM of copper chloride or 200 µM  copper chelator, BCS, prior to 
arsenite addition (Atox1+/+ MEFs with diagonal striped bars and Atox1-/- MEFs with checked bars). Error bars 
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Figure 43 C: Cell survival by Crystal violet assay in Atox1+/+ MEFs and Atox1-/- MEFs following 
arsenite damage with copper supplementation or chelation. 
 Atox1+/+ MEFs (Black bars) and Atox1-/- MEFs (White bars) were subjected to 0 to 2.5 µg/ml sodium arsenite 
treatment for (C) 48 hours and compared with Atox1+/+ MEFs (vertical striped bars) and Atox1-/- MEFs (horizontal 
striped bars) pre-treated with 10 µM of copper chloride or 200 µM  copper chelator, BCS, prior to arsenite addition 
(Atox1+/+ MEFs with diagonal striped bars and Atox1-/- MEFs with checked bars). Error bars indicate standard error. 
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3.3.8 Absence of Atox1 causes changes in gene expression for genes in the DNA 
damage and oxidative stress pathways. 
 
ATOX1 has been established as a copper dependent transcription factor (Itoh et 
al., 2008). To understand the differences in gene expression profile induced by arsenite 
and radiation damage in Atox1 proficient and deficient MEFs, PCRarray (SABiosciences, 
USA) was utilised to profile mRNA expression of genes in the DNA damage response 
and oxidative stress and antioxidant defense pathways.   
3.3.8.1 Genes in the antioxidant defense pathway were differentially expressed between 
Atox1 proficient and deficient cells following radiation exposure. 
 
 ATOX1 has been suggested to have an important role in antioxidant defence. 
Expectedly, a significant number of genes in this pathway were differentially expressed 
upon DNA damage when Atox1 was absent. Majority of the genes were up-regulated 
both with and without arsenite and radiation exposure in the absence of ATOX1. These 
included glutathione peroxidases, peroxiredoxins, peroxidases, other antioxidants, other 
genes involved in superoxide metabolism, oxidative stress responsive genes and oxygen 
transporters. A gene that was significantly down-regulated in both untreated and arsenite 
and radiation exposed Atox1 deficient MEFs was solute carrier family 38, member 1 
(Slc38a1), an oxygen transporter.  Another subset of genes, which includes EH-domain 
containing protein 2 (Ehd2), prostaglandin-endoperoxide synthase 2 (Ptgs2), 
peroxiredoxin 6, related sequence 1 (Prdx6-rs1), glutathione reductase (Gsr), sulfiredoxin 
1 homolog (Srxn1), excision repair cross-complementing rodent repair deficiency, 
complementation group 2 (Ercc2) and thioredoxin reductases (Txrnd2) were observed to 
down-regulated in Atox1 deficient MEFs. However, upon arsenite treatment, all of these 
132 
 
genes were significantly up-regulated as compared to the Atox1 proficient cell types 
(Table 8).  
3.3.8.2 Genes involved in DSB repair were significantly up-regulated upon DNA damage 
in Atox1 deficient cells. 
 
Eighty four genes involved in the DNA damage signalling pathway were analysed 
for gene expression changes following 2 Gy radiation exposure and 1.5 µg/ml arsenite 
exposure (Table 9). Several genes involved in DNA double strand break processing were 
significantly up-regulated in Atox1 deficient MEFs. Protein kinase, DNA-activated, 
catalytic polypeptide (Prkdc), meiotic recombination 11 homolog A (Mre11a), X-ray 
repair complementing defective repair in Chinese hamster cells (Xrcc3), Transformation 
related protein 53 (Trp53), ataxia telangiectasia mutated (Atm), breast cancer 1 (Brca1), 
breast cancer 2 (Brca2), RAD51, DNA repair protein RAD51 homologue C (Rad51c) and 
RAD52 that play a role in processing DSBs were up-regulated upon arsenite treatment in 
Atox1 deficient MEFs (Table 9) as compared to the Atox1 proficient cell types. Similarly, 
Prkdc, Xrcc3 and Mre11a were significantly up-regulated upon radiation exposure. 
 O6-methylguanine–DNA methyltransferase (Mgmt) is involved in repairing 
alkylated DNA adducts and have been implicated in cancer types such as brain and breast 
cancer (Preuss et al., 1995). It was interesting to note that Mgmt was consistently down-
regulated in the Atox1 deficient cell types with and without arsenite and radiation induced 
damage as compared to the Atox1 proficient cell types.  Cryptochrome 2 (Cry2) and 
polymerase (DNA directed) kappa (Polk) were two other genes which were significantly 




3.3.9 Atox1 consensus sequences present in some genes involved in DNA damage 
response and antioxidant defense. 
 
Recent publications have demonstrated the unique function of Atox1 as a copper-
dependent transcription factor (Itoh et al., 2008). To understand whether some of the 
differentially expressed genes in DNA damage and antioxidant defense pathways could 
be transcriptional targets of Atox1, we analysed the promoter sequences of the pathways 
to see if known Atox1 binding sequences, GAAAGA (Itoh et al., 2008) and 
TGAAACTAA (Muller and Klomp, 2009) could be found. We searched for both 
GAAAGA and TGAAACTAA sequences in the promoter sequences upstream of the 
transcription start site by bioinformatics approaches. Indeed some of the genes were 
found to have the Atox1 consensus sequences. Of particular interest are genes such as 
SOD3 and Slc38a1 which were significantly down regulated in the PCRarray analysis in 
Atox1 deficient cells (Table 10). These genes also have Atox1 consensus sequences thus 
supplying evidence for further investigation for possible transcriptional regulation by 


















treatment c Function 
Gpx8 2.40 3.01 - Glutathione Peroxidases 
Gpx1 - 2.21 2.18 Glutathione Peroxidases 
Prdx1 2.46 2.33 - Peroxiredoxins  
Apc 2.15 2.17 2.15 Other Peroxidases 
Ctsb 5.87 3.17 3.61 Other Peroxidases 
Serpinb1b 9.60 3.29 - Other Peroxidases 
Kif9 10.83 5.03 - Other Peroxidases 
Nxn 4.72 2.74 2.31 Other Antioxidants 
Cygb - 2.86 2.22 Other Genes Involved in Superoxide Metabolism 
Nox4 10.36 9.42 2.69 Other Genes Involved in Superoxide Metabolism 
Scd1 5.67 3.93 - Other Genes Involved in Superoxide Metabolism 
Ctsb 5.87 3.17 3.61 Oxidative Stress Responsive Genes 
Ercc6 2.16 3.58 - Oxidative Stress Responsive Genes 
Idh1 4.70 8.88 - Oxidative Stress Responsive Genes 
Prdx1 2.46 2.33 - Oxidative Stress Responsive Genes 
Cygb - 2.86 2.22 Oxygen transporters 
Dnm2 4.51 5.31 - Oxygen transporters 
Vim 3.88 3.78 2.67 Oxygen transporters 
Slc38a1 -106.71 -8.43 -20.53 Oxygen transporters 
Sod3 -30.54 20.46 -7.44 Superoxide dismutase 
Ptgs2 -23.47 11.24 - Other Peroxidases 
Ercc2 -4.75 11.63 - Oxidative Stress Responsive Genes 
Txnrd2 -5.07 7.73 - Oxidative Stress Responsive Genes 
Txnip 12.10 -1.22 -1.06 Oxidative Stress Responsive Genes, Thioredoxin pathway 
Txnrd1 4.28 13.09 3.69 Oxidative Stress Responsive Genes, Thioredoxin pathway 
Txnrd2 -5.07 7.73 1.56 Oxidative Stress Responsive Genes, Thioredoxin pathway 
     Table 8: Differentially expressed genes in the oxidative stress and antioxidant defense pathway from Atox1+/+ and Atox1-/- MEFs after arsenite and 
radiation treatment by PCRarray. 
Atox1+/+ and Atox1-/- MEFs were treated with 1.5 µg/ml of arsenite for 24 hours and the gene expression analysed by PCRarray. Genes, which were differentially expressed to a 
fold change of 1.5 or more in one of the treatment, is given. Data indicate the fold increase (positive values) or decrease (negative values) in treated samples compared to 
corresponding controls. (a) untreated Atox1-/- relative to untreated Atox1+/+ MEFs; (b) arsenite treated Atox1-/- MEFs relative to arsenite treated Atox1+/+ MEFs; (c) radiation treated 










treatment c Function 
Trp53 2.08 7.92 - Apoptosis 
Xrcc3 2.33 16.51 2.80 Damaged DNA Binding, Double-strand Break Repair 
Mre11a - 20.68 2.11 Double-strand Break Repair 
Atm - 4.99 - Apoptosis and Other Genes Related to DNA Repair 
Brca2 - 7.70 - Double-strand Break Repair 
Prkdc -2.01 6.04 2.31 Double-strand Break Repair 
Rad51 - 2.81 - Damaged DNA Binding, Double-strand Break signalling 
Rad51c - 5.05 - Damaged DNA Binding, Double-strand Break signalling 
Brca1 -2.08 4.47 - Damaged DNA Binding, Double-strand Break signalling 
H2afx 3.62 4.94 - Damaged DNA Binding, Double-strand Break signalling 
Rad52 - 8.31 - Double-strand Break Repair 
Mlh1 2.12 4.23 - Mismatch Repair 
Pms1 2.11 4.87 - Mismatch Repair 
Mlh3 -2.70 2.95 - Mismatch Repair 
Msh3 -2.10 5.46 - Mismatch Repair 
Pms2 -2.15 3.23 - Mismatch Repair 
Mgmt -7.25 -5.50 -10.74 Apoptosis, Methyltransferase 
Table 9: Differentially expressed genes in the DNA damage signalling pathway from Atox1+/+ and Atox1-/- MEFs after arsenite and radiation 
treatment by PCRarray. 
Atox1+/+ and Atox1-/- MEFs were treated with 1.5 µg/ml of arsenite for 24 hours and the gene expression analysed by PCRarray. Genes, which were differentially expressed to a 
fold change of 1.5 or more in one of the treatment, is given. Data indicate the fold increase (positive values) or decrease (negative values) in treated samples compared to 
corresponding controls. (a) untreated Atox1-/- relative to untreated Atox1+/+ MEFs; (b) arsenite treated Atox1-/- MEFs relative to arsenite treated Atox1+/+ MEFs; (c) radiation 








Gene Function Distance from transcription start site (bp) Consensus Sequence 
Xrcc3 DNA damage  2537 GAAAGA 
Atm DNA damage 1941 GAAAGA 
  2254 GAAAGA 
  2276 GAAAGA 
  2300 GAAAGA 
Rad51 DNA damage 1559 GAAAGA 
Rad51c DNA damage 2532 GAAAGA 
  2755 GAAAGA 
  3628 GAAAGA 
Pms2 DNA damage 2673 GAAAGA 
  2677 GAAAGA 
Mgmt DNA damage 3719 GAAAGA 
Slc38a1 Antioxidant defense 1894 GAAAGA 
  2303 TGAAACTCAAA 
Sod3 Antioxidant defense 2038 GAAAGA 
  2457 GAAAGA 
  2982 GAAAGA 
  3692 GAAAGA 
  3801 GAAAGA 
Nox4 Antioxidant defense 1701 GAAAGA 
    
Table 10: Bioinformatics search of Atox1 consensus sequences and response elements in the promoter of genes involved in DNA damage response 
and antioxidant defense. 
Atox1+/+ and Atox1-/- MEFs were treated with 1.5 µg/ml of arsenite for 24 hours and the gene expression analysed by PCRarray. Genes, which were differentially expressed to a 
fold change of 1.5 or more in one of the treatment were selected and the DNA sequence up to 5000bp upstream of the promoter were downloaded from NCBI database using 







4.1 PARP-1 is important for regulation of telomere-mediated 
genomic stability following arsenite-induced damage.  
 
 
Poly (ADP-Ribose) polymerase 1 (PARP-1) is an important player in the base 
excision repair pathway. The increased DNA damage observed in this study corroborates 
many earlier studies that emphasise the important role of PARP-1 in DNA repair. In view 
of the interactions of PARP-1 with the participants of the BER pathway (Dantzer et al., 
2000; Sanderson and Lindahl, 2002), it is likely that PARP-1 deficiency may be a 
contributing factor to the rapid telomere shortening due to perturbations in the cellular 
processes of DNA damage recognition and repair. Consistent with this, deficiencies in 
both short long- and long-patch BER pathways have been reported in PARP-1-deficient 
cells (Dantzer et al., 2000). This study (Dantzer et al., 2000) showed that both uracil and 
8-oxoguanine are poorly repaired in PARP-1- deficient cells compared with wild-type 
cells. Arsenite induces a wide variety of oxidised base lesions, including 8-
hydroxyguanine (Mei et al., 2002). Furthermore, acute arsenic treatment inhibits the 
activity of human 8-hydroxyguanine glycosylase (OGG1) enzyme (Mei et al., 2002). 
Hence, a fundamental BER deficiency in the absence of PARP-1 is presumably 
responsible for the enhanced sensitivity of PARP-1 null cells to arsenite treatment.  
Arsenic mutagenicity has been shown to involve mitochondrial DNA damage (Liu et al., 
2005), and it is presently unclear whether PARP-1 is also involved in BER process in 
mitochondrial DNA. Lower levels of chromosomal aberrations were observable in 
PARP-1-/- MEFs when treated with 3.0µg/ml arsenite for 24 hours. However, this could 
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be attributed to cells undergoing cell death having received augmented levels of DNA 
damage. This is evidenced by the higher levels of apoptotic cells observed by cell cycle 
analysis.  
PARP-1 was shown to be a regulator of telomere length and telomeric end-
capping function (d'Adda di Fagagna et al., 1999). PARP-1 also has a synergistic role 
together with other repair proteins for the maintenance of telomere-chromosomal 
integrity (Tong et al., 2002; Tong et al., 2001). In this study, we investigated the role of 
PARP-1 at the telomeres under conditions of arsenite-induced DNA damage. PARP-1 
deficient cells showed greater telomere attrition than PARP-1 proficient cell lines at doses 
of 11.5 and 23 µM. Use of low concentrations (<1.0 µM) of arsenite has been shown to 
promote telomerase activity with or without an increment in telomere length (Zhang et 
al., 2003). High concentrations of arsenite (>1.0 µM) used in this study displayed rapid 
and dramatic loss of telomeric DNA and apoptotic cell death. Although the inhibition of 
telomerase by arsenite may cause telomere shortening over numerous population 
doublings, rapid telomere loss was observed in PARP-1-/- cells within 24 to 48 hours of 
sodium arsenite treatment. This rapid telomere loss may be due to the susceptibility of the 
hexametric repeat structure of telomeric DNA (triple-G-containing structures) to 
oxidative damage (Le Page et al., 2003; Petersen et al., 1998). Available evidences 
indicate that oxidative stress has the potency to break polyguanosine sequences in 
telomeric repeats, leading to telomere loss (Evans, 2004; von Zglinicki, 2002). Arsenite, 
being one of the efficient inducers of oxidative stress (Hei et al., 1998; Kessel et al., 
2002; Liu et al., 2001), can also break polyguanosine sequences in telomeric repeats, 
resulting in rapid telomere loss (Liu et al., 2003). Additionally, DNA repair in the 
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telomeric DNA was less efficient than in the rest of the genome (Evans, 2004), further 
exacerbating telomere attrition in the absence of the PARP-1.  
Earlier studies have implicated telomere shortening as an important checkpoint to 
limit the potential of human cells to proliferate (Maser and DePinho, 2002). Telomeres 
shortening caused by oxidative stress triggers an apoptotic response in a p53-dependent 
manner (Saretzki et al., 1999). Telomere dysfunction coupled with chromosome 
instability due to inefficient DNA repair may be responsible for increased cell death in 
PARP-1-deficient cells. The cellular hypersensitivity of PARP-1 null cells therefore 
unequivocally projects the role of PARP-1 as a survival factor against arsenic exposure.  
One of the earliest responses to ionising radiation and alkylating agent–induced 
DNA damage is the poly(ADP) ribosylation of many nuclear proteins, which is mediated 
chiefly by PARP-1 and to a lesser extent by the PARP family of proteins (Bürkle, 2001; 
Shall and de Murcia, 2000). Arsenite was shown to inhibit poly(ADP) ribosylation of 
proteins (Hartwig, 2003) in mammalian cells. As PARP-1 is implicated in diverse repair 
pathways, particularly BER, it is reasonable to assume that the increased cell death, 
telomere attrition, and genomic instability observed in PARP-1 null cells is due to 
inefficient repair of oxidised base lesions. The inhibition of PARP-1 activity by low 
doses of arsenite has also been demonstrated to increase the levels of oxidative damage 
(Ding et al., 2009). Additionally, telomere length maintenance has been implicated in 
cancer development due to reactivation of telomerase in tumour cells. Telomerase 
inhibition is therefore emerging as a promising approach in cancer chemotherapy (Shay 
and Wright, 2002, 2005). Treatment of cancer cell with telomerase inhibitors induced 
telomere shortening and halted cellular proliferation (Shay and Wright, 2002). The 
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importance of PARP-1 in telomere integrity suggests that PARP-1 inhibitors may present 
a myriad of potential therapeutic applications, especially in cancer treatment (Seimiya et 
al., 2005; Tentori et al., 2002). Seimiya et al. (Seimiya et al., 2005) showed that the 
combination of inhibitors to the PARP family protein found at the telomeres, tankyrase, 
might serve as an effective anticancer therapy approach (Seimiya et al., 2005; Shay and 
Wright, 2005). Additionally, the inhibition of PARP-1 reduced hepatocellular carcinoma 
growth in xenograft mice models by modulating the expression of tumour related genes 
(Quiles-Perez et al., 2010). As PARP-1 deficiency increases the cytotoxicity of arsenite 
treatment, PARP-1 inhibitors could also be used in combination with other DNA-
damaging agents to increase the killing of cancer cells with some such inhibitors used in 
clinical trials (Calabrese et al., 2004; Miknyoczki et al., 2003).  
Gene expression studies have revealed differential expression of more than 300 
genes following arsenic treatment in PARP-1+/+ and PARP-1-/- MEFs. PARP-1 has been 
established as a transcription factor [reviewed in (Kraus, 2008)]. Recent studies show that 
PARP-1 inhibition down regulated Rad51 and Brca1 expression (Hegan et al., 2010). In 
agreement with this, gene expression data obtained in the present study also reveals a 
similar decrease in the above factors. This inhibition of Brca1 and Rad51 when PARP-1 
is absent may be an additional cause of the increased sensitivity to oxidative stress 
(Hegan et al., 2010). Hence, further exploration of genes involved in DNA damage 
processing and oxidative stress response that were variably expressed when PARP-1 was 
absent may allow for identification of other novel factor regulated by PARP-1 that assist 
PARP-1 function in ensuring genomic integrity. Genes that are up-regulated or down-
regulated following treatment with arsenite in both cell types include genes that 
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participate in diverse biological processes, such as cell death, signal transduction, 
response to stress/external stimulus, and cell growth and/or maintenance. This clearly 
indicates that PARP-1 has a role in the above cellular processes, which warrants further 
validation and investigation. Arsenite was recently shown to affect the posttranslational 
poly(ADP-ribosyl)ation of p53 at non-toxic doses (Komissarova and Rossman, 2010). 
This was proposed to be a possible mechanism for arsenic-induced carcinogenesis in 
keratinocytes (Komissarova and Rossman, 2010). Thus, further enquiry into the 
expression patterns identified by our microarray results may provide biomarkers for 
gaining insights into mode of arsenic toxicity. Taken together, our study identifies PARP-
1 as one of the important genetic factors responsible for mediating the toxic effects of 
arsenite.  
4.2 Copper homeostasis may affect the response to DNA damaging 
agents. 
 
Gene set enrichment analysis revealed that copper metabolism and homeostasis 
genes were significantly affected in the absence of PARP-1 when subjected to arsenite 
treatment. Additionally, Parp-1 mRNA was down regulated when copper chelators were 
applied. Although the level of decrease in Parp-1 was small (< 1.5 fold), we are currently 
unsure of the biological relevance of this change and how this level of change may vary 
at other concentrations of copper chelators. Still, another group demonstrated that at 
doses of copper supplementation higher than those used in this study, PARP-1 activity 
was inhibited (Schwerdtle et al., 2007). Hence, while these evidences point to a link 
between Parp-1 gene expression and intracellular copper levels, the mechanism behind 
this is not fully understood and needs to be further investigated.  
142 
 
Copper is an essential trace element in all living systems. Paradoxically, it is both 
a key component of enzymatic anti oxidative defence systems and an inducer of ROS. 
Oxidative stress can directly induce many types of genotoxic damage including double 
strand breaks (Karanjawala et al., 2002). Defects in copper homeostasis are directly 
responsible for human diseases and are implicated in pathophysiologies such as cancer 
(Kim et al., 2008). Since copper-metabolism genes were differentially regulated 
following arsenite-induced damage, we attempted to see if copper metabolism may 
directly have a role in the DNA damage response in mammalian cells.  We treated normal 
MEFs with copper in doses ranging from 0 to 100 µM prior to arsenic treatment. At these 
doses, the levels of DSB were significantly reduced as compared to cells without copper 
pre-treatment. In support of this, supplementation with copper has been shown to protect 
both normal and mutant bacteria deficient in CopA (bacterial homolog of Wilson disease 
ATPase) against hydrogen peroxide induced damage (Macomber et al., 2007). Possible 
reasons for this protective action of copper are an increase in expression of antioxidant 
enzymes as well as chelating factors such as metallothionine, induced in response to 
rising intracellular copper levels.  Higher doses of copper however, have been shown to 
be toxic and induce increased cellular damage (Gutteridge and Wilkins, 1983; Rowley 
and Halliwell, 1983). Increased copper can also induce oxidative stress in cells (Campo et 
al., 2004). High levels of copper have also been demonstrated to be able to inhibit PARP-
1 induced repair of oxidative damage (Schwerdtle et al., 2007). So while these studies 
point to the importance of copper regulation for genomic integrity, we are currently 
unsure of the biological significance of the variable expression of copper binding genes 
in PARP-1 deficient cells. This is thus an area that warrants further study. 
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Expectedly, lymphoblastoid cells from patients with copper metabolism disease 
conditions, Menkes and Wilson’s diseases, displayed increased levels of DSBs and 
genomic instability. Menkes disease cells were particularly more sensitive to DSBs upon 
arsenite and hydrogen peroxide exposure as compared to the normal cells and the 
Wilson’s disease cells. A reason for this observation would be that Menkes ATPases is a 
primary channel expressed in all cell types for the uptake of copper to incorporate into 
secretory enzymes. When mutated in Menkes disease, it induces the accumulation of 
intracellular copper, allowing copper’s redox activity to exacerbate the oxidative damage 
to DNA rendered by agents such as arsenic and hydrogen peroxide. Defects in Menkes 
ATPases may result in extensive impairment of other processes such as the inactivation 
of various secretory cuproenzymes and copper dependent process that are involved in the 
protection of the cells against oxidative damage. Wilson’s disease proteins play similar 
roles and are the only biological route for excretion of excess copper. However, Wilson 
ATPase is expressed only in the liver. This may explain why lymphoblastoid cells from 
Wilson’s disease patients did not reflect the increased levels of damage observed in 
Menkes disease lymphoblastoid cells. It would thus be of interest to directly investigate 
the effect of damage on liver cells derived from Wilson’s disease patients. Interestingly, 
the type of genotoxicant appears to be important in determining the levels of DSB 
sustained. With radiation, which primarily induces DSBs, the levels of damage were 
similar among all 3 cell types at 2 Gy. In contrast, Menkes disease cells had augmented 
levels of damage compared to normal and Wilson’s disease lymphoblastoid cells 




In Menkes disease cells, the addition of copper increased the levels of γH2AX 
foci with all three genotoxicants. This may be attributed to the disease cells having high 
intracellular copper levels, which are further elevated by copper supplementation. In 
support, when copper chelator is added to Menkes disease cells, the levels of DSB are 
reduced. Hence, copper supplementation may exacerbate the copper imbalance causing 
increased toxicity. Although a similar deficiency in copper metabolism exists in Wilson’s 
disease, all cell types (excluding hepatic cells) have functional Menkes ATPases that can 
allow copper transport. This can explain why Wilson’s disease lymphoblastoid cells did 
not exhibit increased sensitivity to copper supplementation unlike Menkes disease cells.  
Copper chelation followed by arsenite and H2O2 treatment, induced heightened 
DSB formation in normal cells. This observation can be explained by the inhibition of 
critical copper containing proteins involved in protective roles such as antioxidant 
defense that are rendered dysfunctional when copper is absent. Yet, in Menkes disease 
cells, copper chelation proved to be useful in reducing the levels of damage. Elevated 
copper levels have been found in many types of human cancers (Chan et al., 1993; Kubo 
et al., 2005; Scanni et al., 1977; Zowczak et al., 2001). Furthermore, excess of copper 
appears to be an essential co-factor for angiogenesis. On this basis, the employment of 
copper chelators has been reported to be of therapeutic value in the treatment of several 
types of cancers as anti-angiogenic molecules (Brewer, 2005; Redman et al., 2003). 
Mixtures of copper chelators with copper salts were also demonstrated to be proteasome 
inhibitors and apoptosis inducers, specifically in cancer cells [(Chan et al., 1993); 
reviewed in (Marzano et al., 2009)]. In a similar vein, copper chelation therapy has been 
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employed for various neurodegenerative disorders such as Alzheimer, Parkinson and 
Creutzfeldt-Jakob [reviewed in (Gaeta and Hider, 2005)].  
DSBs can result in chromosomal instability in cells. To identify if copper 
metabolism diseases rendered cells more genomically unstable, we undertook 
micronucleus analysis. Correlating with the increased DSB formation, Menkes disease 
cells also displayed the highest levels of micronuclei formation with arsenite and 
radiation exposure. Wilson’s disease lymphoblastoid cells exhibited lower levels of 
micronuclei than Menkes disease cells, probably owing to the cell types tested having 
functional Menkes ATPase. While chromosomal instability have long been associated 
with neoplastic transformation (Foijer et al., 2008). We cannot ascertain whether Menkes 
disease patients show increased susceptiblity to cancer as the majority of patients die in 
infancy. With Wilson’s disease patients, who do not succumb to early mortality, liver 
cancer is extremely rare but are vulnerable to aggressive malignant intra-abdominal 
tumours during long term follow-up, irrespective of treatment (Walshe et al., 2003).  
4.3 ATOX1 is important for the maintenance of chromosomal 
stability in the presence of DNA damaging agents. 
 
Next, we explored if specific factors in the copper metabolism pathway may 
affect the susceptibility to DNA damage. Microarray analysis and PCR indicated that 
Atox1 mRNA levels were reduced in PARP-1 deficient MEFs. ATOX1, a copper 
chaperone, was recently established to be a copper-dependent transcription factor. 
Additionally, ATOX1 functions as an antioxidant factor in yeast (Lin and Culotta, 1995). 
Furthermore, neuronal cell lines transfected with rat Atox1 were significantly protected 
from oxidative injury (Kelner et al., 2000). However, its role in DNA damage response or 
the maintenance of genomic stability has not been clearly elucidated. Studies have 
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identified that oxidative stress accompanies DNA repair deficiencies, such as in the 
absence of ATM (reviewed in (Barzilai et al., 2002). It has also been suggested that 
continuous presence of unrepaired damage may constantly activate components of the 
DNA damage response that are dependent on NAD (Barzilai et al., 2002). NAD depletion 
increases oxidative stress (Kirsch and De Groot, 2001). NAD is also the major substrate 
for PARP-1 (Szabo et al., 1996). The absence of PARP-1 has been demonstrated to 
protect MEFs from oxidative stress-induced cell death (Du et al., 2003). Given the role of 
ATOX1 as an antioxidant, it is possible to speculate that Atox1 down regulation in 
PARP-1 deficient MEFs may be a consequence of reduced NAD depletion causing 
reduced oxidative levels, in turn stimulating lower ATOX1 expression. However, PARP-
1 absence can also cause the loss of activity of stress-activated transcription factors (Ha et 
al., 2002). Since ATOX1 can also function as a transcription factor, further enquiry is 
warranted into the interaction of PARP-1 and ATOX1 in response to oxidative stress.  
We found that Atox1 mRNA levels were increased in response to hydrogen peroxide in 
normal MEFs. Although, Atox1 mRNA levels were reduced upon radiation in normal 
human lymphocytes, culturing in atmospheric oxygen conditions led to increased Atox1 
levels. The protective role of Atox1 in antioxidant defense has been demonstrated 
previously in yeast (Lin and Culotta, 1995). Changes in Atox1 levels may thus have 
occurred in response to oxidative stress induced by arsenite, H2O2 and in vitro culture 
conditions.  The significance of reduced Atox1 expression upon radiation exposure should 
be further studied.   
Since Atox1 levels rose in response to oxidative agents, we further investigated 
the effects of genotoxicants on Atox1 deficiency in mouse cells. Atox1 deficient MEFs 
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displayed heightened DNA damage when challenged with sodium arsenite and radiation. 
In the absence of ATOX1, increased superoxide levels were also observed. This was 
positively correlated to an increase in DSB. Increased oxidative levels can directly induce 
DSBs in cells (Karanjawala et al., 2002). Paradoxically, upon H2O2 treatment in Atox1-/- 
MEFs, lower levels of superoxide were detected. This may point to underlying 
differences in the metabolism of H2O2 when Atox1 is absent. Hence, the levels of other 
ROS species have to be investigated to further understand this observation. As with the 
normal human cells, copper supplementation prior to the addition of arsenite, peroxide 
and radiation induced significant reduction in DSBs in both Atox1 proficient and deficient 
MEFs. This phenomenon has been earlier observed in SOD1 deficient yeast where the 
aerobic defects were reversed by the addition of copper (Chang and Kosman, 1989; 
Tamai et al., 1993). It is possible that the dose of copper used may activate compensatory 
mechanisms such as the expression of metallothionine to chelate copper and hence 
protecting cells from damage. It is also possible that doses higher than those tested in this 
study may inflict increased damage when the threshold for compensatory mechanisms is 
exceeded.  
Elevated levels of chronic, unrepaired oxidative DNA damage can result in a gain 
of chromosomal instability (Degtyareva et al., 2008). Lack of ATOX1 may thus create a 
condition of chronic oxidative stress, inducing oxidative damage, including DSB which 
eventually lead to chromosomal instability. We observed increased chromosomal 
aberrations and micronuclei formation, an indication of increased genomic instability in 
the Atox1 deficient cells upon DNA damage. Studies have suggested that oxidative DNA 
damage is likely to be involved in the aetiology of cancer and that it is likely to accelerate 
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tumourigenesis by increasing mutation rates [reviewed in (Toyokuni, 2006)]. In addition 
to causing genomic instability, ROS can directly increase tumourigenicity by activating 
signalling pathways that regulate cellular proliferation (Arnold et al., 2001; Burdon et al., 
1996), angiogenesis (Brown and Bicknell, 2001; Milligan et al., 1996) and cell death 
(Chung et al., 2003; Simon et al., 2000). In support of this role of ROS in carcinogenicity 
and the capacity of ATOX1 as an antioxidant factor, a study has found that ATOX1 was 
significantly down regulated in metastatic colorectal cancer cell lines comparing primary 
tumours (Humar et al., 2002). ATOX1 was found to be part of a battery of 
hypermethylated gene loci which were indicative of increased cancer recurrence 
following chemotherapy in a study evaluating biomarkers for cancer diagnosis and 
monitoring of disease progression (Wei et al., 2006). With implications to therapy, in 
clinical trials using selomethionine for treatment against colon polyp recurrence, ATOX1 
levels were found to increase following treatment in colorectal cancer cell lines (Goulet 
et al., 2007) compared to primary tumours. Interestingly, PARP-1 deficiency has also 
been implicated in tumourigenesis (Nozaki et al., 2003; Tong et al., 2007). Hence, while 
these evidences allude to a role of PARP-1 and ATOX1 in tumourigenesis, the mechanics 
of this interaction are yet to be elucidated.  
Apart from directly affecting ROS levels as an antioxidant, ATOX1 may impact 
downstream processes through its role as a transcription factor (Itoh et al., 2008; Itoh et 
al., 2009). Copper stimulated the binding of ATOX1 to the cyclin D1 promoter. In Atox1-
/- MEFs, defective copper-induced proliferation is rescued by re-expression of nuclear 
targeted ATOX1 (Itoh et al., 2008). This decrease in proliferation was also evident in our 
cell viability data from Atox1-/- MEFs supplemented with copper at 2 hours of arsenite 
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treatment. Copper has been shown to stimulate cellular proliferation but the underlying 
mechanisms have not been demonstrated (Hu, 1998). In our study, at 24 hours of arsenite 
treatment, normal MEFs also displayed increased viability as compared to normal cells 
without copper supplement while copper chelator treatment resulted in the lowest cell 
survival rates. We also observed that when ATOX1 is absent, copper addition reduces the 
proliferation of cells. Interestingly, copper addition to bacteria with aberrant copper 
metabolism has also been found to reduce proliferation (Grass and Rensing, 2001; 
Macomber et al., 2007). This reduced growth may be attributed to the accumulation of 
copper in the cytosol of Atox1-/- cells due to aberrant copper transport (Macomber et al., 
2007). At 24 hours of arsenite exposure, Atox1-/- MEFs with arsenite survive better 
despite increased damage. This may be attributed to the cyclin D1 defect present in 
Atox1-/- mice. Thus this allows for progression through the cell cycle despite damage. The 
nuclear function of ATOX1 has been suggested to contribute to hyper proliferative 
conditions such as cancer, angiogenesis and atherosclerosis (Itoh et al., 2008). 
To further evaluate whether ATOX1 could differentially express genes that 
coordinate the response to DNA damage, a PCR-based array was used. Genes in the 
DNA damage signalling as well as oxidative stress and anti-oxidant defence pathways 
were differentially expressed in the absence of ATOX1. Superoxide Dismutase 3 (SOD3) 
has been established to be transcriptionally activated by ATOX1. In addition, ATOX1 
acts as the copper chaperone for SOD3 (Jeney et al., 2005). In agreement with this 
finding, SOD3 was down regulated by more than 30 fold in Atox1 deficient cells 
compared to Atox1 proficient cells in our PCRarray data. While SOD1 and SOD2 are 
located intracellularly in the cytosol and mitochondrial membrane respectively, SOD3 is 
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an extracellular protein. It has been found that copper chaperone for superoxide 
dismutase (Ccs) is the copper chaperone for SOD1 (Culotta et al., 1997). Thus regulation 
of the SOD1 and SOD2 is likely to be independent of ATOX1. Correlatively, the other 
isoforms of SOD (SOD1 and SOD2) did not show a significant change in gene 
expression levels between the Atox1 proficient and deficient MEFs tested. 
Several genes involved in DNA double strand break processing were significantly 
up-regulated in Atox1 deficient MEFs. Prkdc, Mre11a, Xrcc3, Trp53, Atm, Brca1, Brca2, 
Rad51, Rad51c and Rad52 were genes that play a role in processing DSBs and were up-
regulated upon arsenite treatment to a greater extent in Atox1 deficient MEFs as 
compared to the Atox1 proficient cell types. Similarly, Prkdc, Xrcc3 and Mre11a were 
significantly up-regulated upon radiation exposure. This upregulation in genes correlated 
to an increase in DSB detected by γH2AX assay. Hence, the increased expression may be 
a consequence of repair of the damage induced in cells in response to DSBs. However, it 
is not known if the repair of DSBs over time is affected as a result of ATOX1 deficiency. 
O6-methylguanine–DNA methyltransferase (Mgmt) is an ubiquitous DNA repair 
protein involved in repairing alkylated DNA adducts (Biswas et al., 1999) and has been 
implicated in cancer types such as brain and breast cancer (Mollemann et al., 2005). 
Mgmt was consistently down-regulated in the Atox1 deficient cell types with and without 
arsenite and radiation induced damage as compared to the Atox1 proficient cell types. 
Down regulation of Mgmt in Atox1 negative cells suggests an increased sensitivity to 
DNA alkylating agents, thus becoming sensitive to mutagenesis processes (Mollemann et 
al., 2005). Mgmt also possessed the Atox1 consensus motif in its promoter regions. 
Hence, Mgmt is a worthy target for further evaluation of whether it could be a direct 
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transcriptional target of ATOX1. The sensitivity of Atox1 deficient cells to alkylating 
agents should also be investigated. 
ATOX1 has been suggested to have an important role in antioxidant defense. 
Expectedly, a significant number of genes in this pathway were differentially expressed 
upon DNA damage when ATOX1 was absent. Majority of the genes were up-regulated 
with and without arsenite and radiation exposure (Table 2). These included glutathione 
peroxidases, peroxiredoxins, peroxidases, other antioxidants, other genes involved in 
superoxide metabolism, oxidative stress responsive genes and oxygen transporters. 
Accordingly, superoxide levels were found to be higher in Atox1 deficient MEFs. 
Upregulation of antioxidant defense genes may be due to increased superoxide levels. 
How the other ROS species may be affected by Atox1 deficiency remains to be studied. 
A gene that was significantly down-regulated in both untreated, As3+ treated and 
radiation exposed Atox1 deficient MEFs was solute carrier 38 family a 1 (Slc38a1), an 
oxygen transporter that encodes for a neutral amino acid transporter.  Bioinformatics 
analysis revealed that Slc38a1 possessed both the Atox1 consensus motif and Atox1 
response element in its promoter sequences. Further studies are in order to establish if is 
transcriptionally regulated by ATOX1. Interestingly, it has been previously reported that 
Slc38a1 is down regulated with age and hence an indicator of the aging phenotype (Giresi 
et al., 2005). It also should be noted that Slc38a1 was the best predictor of the young 
versus older class distinction and is thus likely to be of importance in defining the aging 
phenotype (Giresi et al., 2005). Thus the down regulation of this gene in the Atox1 
deficient cells compared to the Atox1 proficient cells may imply a role of ATOX1 and 
associated proteins in the ageing process. 
152 
 
Apart from this, up regulation of thioredoxin interacting protein (Txnip) in 
untreated Atox1-/- cells compared to Atox1+/+ cells was evident. Very recently, it has been 
found that increased Txnip contributes to the impaired function of thioredoxin activity 
and increased ROS level in glucose treated endothelial cells (Li et al., 2009). This also 
supports the observation of higher superoxide levels in the untreated Atox1-/- cells 
compared to Atox1+/+ MEFs. Other genes that contribute to an increase in ROS levels 
were found to be up regulated in Atox1 deficient MEFs. NADPH Oxidase 4 (NOX4), a 
known inducer of ROS (Martyn et al., 2006; Serrander et al., 2007), was up regulated 10 
fold in our study. CYBA, part of the complex formed by NOX4, was also up regulated. 
From our data, ATOX1 deficiency contributed to increased superoxide levels. Copper 
chelation and supplementation did not induce a significant increase in ROS in the 
absence of ATOX1. However, challenging cells with hydrogen peroxide under reduced 
copper conditions significantly increased the superoxide production in the Atox1-/- cells 
possibly because copper chelation also inhibits SOD1, which has an additive effect along 





Conclusions and future directions 
 
5.1 Conclusions 
PARP-1 is important for DNA damage response, telomere maintenance and 
genomic stability following arsenite-induced oxidative damage. In PARP-1 deficient 
MEFs, we demonstrate that copper regulating proteins were differentially regulated. In 
particular, copper chaperone and known antioxidant, ATOX1, was significantly down 
regulated. We determined that ATOX1 deficiency increased the levels of genomic 
instability. Since oxygen metabolism is critical for genomic stability, we thus propose 
that ATOX1 may be one of the important factors to keep oxidative levels in check in 
mammals. This, in turn, may prevent genomic instability. Although the nature of PARP-1 
and ATOX1 interaction has not yet been elucidated, this study highlights the new 
understanding of how copper metabolism may affect oxidative levels and the genomic 
integrity of the cells. 
5.2 Future directions: 
In this study, the relationship of PARP-1 to copper metabolism has not yet been 
fully explored. Furthermore, the physiological significance of the differential regulation 
of copper containing genes in PARP-1 MEFs is not yet clear. Although the study points 
to a link between PARP-1 and ATOX1, it is not known how PARP-1 may regulate 
ATOX1 expression. Protein-protein interaction studies are in order to identify if PARP-1 
and ATOX1 protein may bind directly to each other. In addition, chromatin 
immunoprecipitation experiments are needed to evaluate if these proteins may bind to the 
promoter region of the genes to transcriptionally affect expression.  
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The effect of copper supplementation on decreasing the damage inflicted by 
genotoxicants was demonstrated in this study. However, the threshold of effect for copper 
supplementation must be determined. Apart from this, the study has uncovered important 
actions of ATOX1 in aspects which are critical in cancer. More studies are required to 
evaluate how ATOX1 may be differentially expressed in cancers and what implications 
they may have on tumourigenesis. The effects of other genotoxicants on ATOX1 should 
also be investigated. Potential new target genes which may be regulated by ATOX1 have 
been identified in this study. To further assess the effects, DNA-protein and protein-






Figure 44: Model of how PARP-1 and ATOX1deficiency may affect tumourigenesis. 
The flow chart highlights how PARP-1 and ATOX1 may play a significant role in the maintenance 
chromosome-genomic stability. Atox1 deficiency has been associated with abnormal copper 
metabolism. Increased copper levels and deficiencies in copper metabolism proteins may cause 
increased oxidative stress. Increased oxidative stress can lead to heightened levels of oxidative damage 
in cells, which can accumulate to cause chromosomal and genomic instability in the cell. Chronic 
hypoxia can also directly cause chromosomal instability. Chromosomal instability is also thought to be 
critical for tumourigenic progression. Our study showed that modifying the levels of copper can affect 
the response to genotoxicants in the levels of DNA damage and chromosomal instability induced. Solid 
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Abstract
Arsenite (As3+) has long been known to induce cancer and
other degenerative diseases. Arsenite exerts its toxicity in part
by generating reactive oxygen species. Identification of genetic
factors that contribute to arsenic mutagenicity and carcino-
genicity is critical for the treatment and prevention of arsenic
exposure in human population. As poly(ADP-ribose) polymer-
ase (PARP) is critical for genomic DNA stability, role of PARP-1
was evaluated in arsenic-induced cytotoxic and genotoxic
effects. Our study revealed that telomere attrition, probably
owing to arsenite-induced oxidative stress, was much more
pronounced in PARP-1/ mouse embryonic fibroblasts (MEF;
40%) compared with PARP-1+/+ MEFs (10-20%). Correlation
observed between telomere reduction and apoptotic death in
PARP-1 null cells strongly indicates that the telomere attrition
might be a trigger for enhanced apoptotic death after arsenite
treatment. Elevated DNA damage detected by alkaline comet
assay points to an impaired repair ability of arsenite-induced
DNA lesions in PARP-1/ MEFs. Consistent with elevated
DNA damage, increased micronuclei induction reflecting gross
genomic instability was also observed in arsenite-treated
PARP-1/ MEFs. Microarray analysis has revealed that
arsenite treatment altered the expression of about 311 genes
majority of which have known functions in cellular responses
to stress/external stimulus and cell growth and/or mainte-
nance. Our results suggest an important role for PARP-1 gene
product in the maintenance of chromosome-genome stability
in response to arsenite-induced DNA damage. (Cancer Res 2005;
65(23): 10977-83)
Introduction
Poly(ADP-ribose) polymerase-1 (PARP-1), the best-characterized
member of the PARP family is an abundant nuclear zinc finger
protein found in most eukaryotes. PARP-1 primarily functions as a
DNA damage sensor (1, 2) by recognizing and binding with high
affinity to both ssDNA and dsDNA breaks that arise directly or
indirectly as byproducts of ongoing DNA repair process (1, 2).
Further PARP-1 also facilitates the access of other DNA repair factors
to the sites of DNA damage (3, 4). PARP-1 is also known for its ability
to modulate the cellular responses either to survive or to undergo
apoptotic death, depending on the extent of DNA damage (5).
Arsenite is a significant environmental concern worldwide
especially in some parts of the United States as well as in
Argentina, Canada, India, Japan, Thailand, Taiwan, and Bangladesh.
Chronic exposure to inorganic arsenite is associated with hepatic
injury, peripheral neuropathy, and a wide variety of cancers (6).
Many different modes of arsenite-induced genotoxicity have been
identified, including oxidative stress, altered DNA repair and
methylation mechanisms, altered cell proliferation, and abnormal
gene amplification (6). Recently, very low concentrations of
arsenite have been shown to inhibit poly(ADP) ribosylation of
proteins in mammalian cells (7).
Our previous study showed that the PARP-1-deficient mice had
drastically shortened telomeres with high chromosomal instability
(8). In addition, PARP-1 deficiency also induced telomere
dysfunction and tumor development in mice with a p53 mutant
background (9). PARP-1 thus seems to function in regulating
telomere length as well as telomeric end capping. In view of its
importance in both DNA repair and chromosome stability, the
present study was undertaken to determine whether PARP-1 is an
important genetic factor responsible for arsenic-induced cytotox-
icity in mammalian cells. Our study indicates that arsenite-induced
cell death, telomere attrition, and genomic instability are greatly
enhanced in PARP-1 null cells, and that PARP-1 is required for
cellular resistance to arsenite exposure.
Materials and Methods
Cell culture and sodium arsenite treatment. PARP-1+/+ and PARP-1/
mouse embryonic fibroblasts (MEFs; kindly provided by Dr. Zhao-Qi Wang)
were cultured following the procedure described earlier (10). Cells in
exponential growth phase (at about 70% confluence) were exposed to doses
of sodium arsenite [As3+; Sigma, St. Louis, MO; 1.5 Ag/mL (11.5 Amol/L) or
3.0 Ag/mL (23 Amol/L)], and the cells were treated for 24 or 48 hours. These
same doses were used for all the experiments described below. Several
earlier studies have shown that doses in the range of 5 to 20 Amol/L of
sodium arsenite were found to show moderate effect level for the induction
of sister chromatid exchanges and micronuclei in mammalian systems (11).
Doses in the range of 1.5 and 10 Ag/mL were required to induce
chromosome aberrations in mouse lymphoma cells (12). Additionally, a
dose of 1.5 Ag/mL is considered pertinent to our study, as the arsenic level
is quite high in some Asian countries. A higher dose of 3.0 Ag/mL was used
to induce sufficient oxidative damage (13, 14) for enabling us to show the
effect in a DNA repair–deficient system. Two independent sets of MEFs for
each genotype were used in the experiments. The data were pooled and
presented.
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Flow fluorescence in situ hybridization for telomere measurement.
After a continuous treatment with As3+ for 24 or 48 hours, cells were
trypsinized and washed with 1 PBS/0.1% bovine serum albumin (BSA).
Cells were then probed with a telomere sequence–specific peptide nucleic
acid (PNA) by fluorescence in situ hybridization (FISH). Telomere length
was measured by flow cytometry as explained elsewhere (15).
Alkaline single-cell gel electrophoresis (Comet) assay. Cells were
treated with As3+ for 30 minutes and 24 hours with the doses mentioned
earlier. The treated cells were harvested by trypsinization, washed in ice-
cold 1 PBS, and resuspended in HBSS with 10% DMSO with EDTA. The
cells were then suspended in (0.75%) molten low melting point agarose
(at 37jC) and immediately pipetted onto the comet slides (Trevigen,
Gaithersburg, MD). Electrophoresis was done as per vendor’s suggestions.
After electrophoresis, slides were briefly rinsed in neutralization buffer
(500 mmol/L Tris-HCl, pH 7.5), air-dried, and stained with SYBR green dye.
The tail moment of the comets was generated using the Metasystems
(Altlussheim, Germany) analysis software ‘‘Comet imager version 1.2.’’ Fifty
randomly chosen comets were analyzed per sample. The extent of DNA
damage observed was expressed as tail moment, which corresponded to the
fraction of the DNA in the tail of the comet.
Fluorescence in situ hybridization analysis of chromosomes. After
As3+ treatment for the specified time intervals, cells were released from
the treatment and allowed to grow for 24 hours in the absence of arsenite.
Cells were arrested at mitosis by treatment with colcemid (0.1 Ag/mL).
The cells were then incubated with a hypotonic solution of sodium citrate
at 37jC for 20 minutes followed by fixation in Carnoy’s fixative. FISH was
done using telomere-specific PNA probe labeled with Cy3, and the cells
were counterstained with 4V,6-diamidino-2-phenylindole (Vectashield;
refs. 8, 15). Fifty metaphases were captured using the Zeiss Axioplan 2
imaging fluorescence microscope and analyzed using the in situ imaging
software (Metasystems).
Cytokinesis-blocked micronucleus assay. Cells, after treatment for 24
and 48 hours with As3+, were incubated with cytochalasin B (Sigma, 5 Ag/
mL) for an additional 22 hours. The cells were then trypsinized and
subsequently fixed using a combination of both Carnoy’s fixative (acetic
acid/methanol, 1:3) and three to four drops of formaldehyde (to fix the
cytoplasm). Fixed cells were dropped onto clean slides and stained with
3 Ag/mL of acridine orange, which differentially stains cytoplasm and
nucleus (16, 17). One thousand binucleated cells were scored for each
sample.
Cell cycle analysis. Control and As3+-treated cells were washed with 1
PBS/0.1% BSA and fixed in 70% ethanol. The fixed cells were later stained
with propidium iodide/RNase A. Samples were then analyzed by flow
cytometry at 488-nm excitation E and 610-nm emission E. Approximately
10,000 events per sample were collected, and the data was analyzed using
WINMDI software.
Microarray gene chip analysis. PARP-1+/+ and PARP-1/ cells were
treated with 1.5 Ag/mL of As3+ for 24 hours. Total RNA was extracted
(RNeasy kit, Qiagen, Hilden, Germany), and double-stranded cDNA was
synthesized from 5 Ag of total RNA using Superscript system (Invitrogen,
Carlsbad, CA) primed with T7-(dT)-24 primer. For biotin-labeled cRNA
synthesis, in vitro transcription reaction was done in the presence of T7
RNA polymerase and biotinylated ribonucleotides (Enzo Diagnostics,
Farmingdale, NY). The cRNA product was purified (RNeasy kit, Qiagen),
fragmented, and hybridized to Affymetrix GeneChip Mouse Genome 430
2.0 in a Gene chip hybridization oven 640 (Affymetrix, Inc., Santa Clara,
CA) as per the Gene Chip Expression Analysis manual (Affymetrix). After
16 hours of hybridization, the gene chips were washed and stained using
the Affymetrix Fluidic station and scanned by Gene Array Scanner
(Affymetrix). Image data were normalized and statistically analyzed
using Gene Spring 7.2 (Silicon Genetics, Redwood City, CA). There were
311 differentially (P < 0.05, one-way ANOVA) expressed genes, and they
were annotated according to Gene Ontology: Biological Process.
Subsequent data analysis involved agglomerative average-linkage hier-
archical clustering for finding different patterns and levels of gene
expression.
Statistical analysis. Statistical comparisons between and among the
groups were made using two-way ANOVA, Student’s t test, and contingency
tables analysis (m2 test and Fisher’s exact test) using Microsoft Excel 2003
(Microsoft Corp., Redmond, WA). The difference was considered to be
statistically significant when P < 0.05.
Figure 1. Telomere length measurements by flow FISH in PARP-1+/+
(white columns ) and PARP-1/ (black columns) MEFs treated with sodium
arsenite for (A) 24 hours and (B ) 48 hours. Cells were treated with two different
doses of arsenite [11.5 Amol/L (1.5 Ag/mL) and 23 Amol/L (3.0 Ag/mL)].
Sham-treated cells served as control. Columns, means of two experiments;
bars, SD. There is greater telomere loss (P < 0.05) in PARP-1/ MEFs (f40%)
compared with the normal MEFs (f10-20%) at 48 hr after treatment with
arsenite. MESF, molecules equivalent of soluble fluorochromes. *, P < 0.05,
statistically significant when comparing the response of PARP-1/ cells with the
PARP-1+/+ cells (two-way ANOVA test and Student’s t test).
Figure 2. Histogram of micronuclei induction measured by the
cytokinesis-blocked micronucleus assay after 24 hours (A ) and 48 hours (B ) of
sodium arsenite treatment. The micronuclei formation, a biomarker of
chromosomal instability, is shown in PARP-1+/+ MEFs (white columns) and
PARP-1/ MEFs (black columns): 11.5 Amol/L (1.5 Ag/mL) and 23 Amol/L
(3.0 Ag/mL) of sodium arsenite treatment for both cell lines compared with the
untreated samples. A total of 1,000 binucleated cells were scored. The
micronuclei containing binucleated cells after arsenite treatment showed a 2-fold
increase in PARP-1/ cells compared with PARP-1+/+ cells. *, P < 0.05, m2 test
and Fisher’s exact test. **, P < 0.05, statistically significant when compared with
respective untreated samples as well as with As3+-treated PARP-1+/+ MEFs.
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Results
Arsenite-induced telomere attrition was greater in
PARP-1/ mouse embryonic fibroblasts. Arsenite has been
suggested to be a potent inducer of oxidative stress and DNA
damage (14), and telomere shortening has been attributed to
oxidative stress (18, 19). Our earlier studies have implicated
PARP-1 in telomere maintenance (8, 9). We therefore investigated
the effect of arsenite treatment on telomere length in the absence
of the PARP-1 gene product. There was no significant difference
in telomere length in both the cell types studied (Fig. 1A and B)
at 24 hours after treatment, but the extent of telomere attrition
was significantly (P < 0.05, two-way ANOVA) greater in PARP-1/
cells (30-40% loss) compared with the PARP-1+/+ cells (10-20%
loss; Fig. 1A and B) at 48 hours after treatment. This interesting
observation led us further to examine whether the telomere loss
triggered by As3+ treatment enhances the chromosome instability.
To test this possibility, micronuclei analysis was done because it
is a reliable indicator of chromosomal damage and genomic
instability (20, 21). Micronuclei formation is due to the exclusion
of chromosomes or chromosomal fragments from the daughter
nuclei. Consistent with telomere loss, PARP-1/ cells exhibited a
2- to 3-fold increase (P < 0.05, m2/Fisher’s exact test) in the
number of micronuclei containing binucleated cells at 24 and 48
hours after sodium arsenite treatment compared with PARP-1+/+
cells (Fig. 2A and B). FISH using telomeric PNA probe was
employed to analyze the chromosomal aberrations, particularly
chromosome end-to-end fusions. Chromosomes with critically
short telomeres are unstable and often result in end-to-end
Figure 3. Telomere PNA-FISH analysis on metaphase chromosomal spreads
from PARP-1+/+ and PARP-1/ MEFs. A, chromosomal DNA was stained with
DAPI (gray ) and telomeres were hybridized with Cy3-labeled telomere probe
(white ). Arrow points to a Robertsonian fusion-like configuration without
telomeres at the fusion point in PARP-1/ MEFs following arsenic treatment.
Partial metaphase spread. B, in a partial metaphase spread from PARP-1/
MEFs, arrow points to a ring-like structure resulting from loss of telomeres on
sister chromatids in a chromosome. C and D, compilation of chromosome
analysis from PARP-1+/+ and PARP-1/ MEFs with or without arsenic
treatment. C, chromosome aberrations detected in PARP-1+/+ and PARP-1/
MEFs following arsenic treatment for 24 hours. Frequency of chromosome
aberrations per cell is given. D, chromosome aberrations detected in PARP-1+/+
and PARP-1/ MEFs following arsenic treatment for 48 hours. Frequency of
chromosome aberrations per cell is given. Chromosome alterations detected
include fragments, breaks, and end-to-end fusions. *, P < 0.05, C 2 test and
Fisher’s exact test.
Figure 4. DNA damage as measured by the comet assay in PARP-1+/+
(white columns ) and PARP-1/ (black columns ) MEFs after 11.5 Amol/L
(1.5 Ag/mL) and 23 Amol/L (3.0 Ag/mL) of sodium arsenite treatment.
Representative of SYBR Green–stained comets prepared from control (A ) and
arsenic-treated PARP-1 null cells (B). The extent of DNA damage measured as
tail moment (product of tail length and fraction of DNA) differed between
PARP-1-deficient and PARP-1proficient cells. Columns, mean; bars, SD. Data
for tail moment for PARP-1+/+ and PARP-1/MEFs after treatment with arsenite
for 30 minutes (C ) and for 24 hours (D ). *P, < 0.05, two-way ANOVA test
and Student’s t test. **, P < 0.05, statistically significant when compared with
respective untreated samples as well as with As3+-treated PARP-1+/+ MEFs.
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fusions and chromosomal aberrations. Higher numbers of chromo-
some aberrations were detected in PARP-1/ MEFs at 1.5 Ag/mL
dose at both the time points. Typical fusions, such as Robertsonian
fusion-like structures and ring like structures (Fig. 3A and B), were
detected in the As3+ -treated PARP-1/ MEFs, which are best
indicators of telomere loss and dysfunction. However, arsenite
treatment did not increase the frequency of chromosome end-
to-end fusions in PARP-1 null cells as expected, but the frequency of
gross chromosome aberrations (which includes end-to-end fusions,
chromosome breaks, and fragments) observed was higher in
PARP-1/ cells than PARP-1+/+ cells (Fig. 3C and D). Statistically
significant increase (P < 0.05, m2 test) in the total number of
chromosome aberrations was observed at a dose of 1.5 Ag/mL
in PARP-1/ MEFs at both 24 and 48 hours following treatment.
Cells lacking PARP-1 displayed elevated DNA damage. The
extent of arsenic induced DNA damage and repair was estimated
by alkaline single-cell gel electrophoresis popularly known as
comet assay (Fig. 4A and B). The comet assay was done under
alkaline condition (pH >13), to estimate all types of DNA damage,
including double-strand breaks, single-strand breaks, and alkali
labile sites. PARP-1/ cells reflected enhanced DNA damage
induction compared with PARP-1+/+ cells after arsenite treatment
(Fig. 4C and D). DNA damage induced by 30 minutes of treatment
of As3+ was 5- to 6-fold (P < 0.001, two-way ANOVA test and
Student’s t test) more in PARP-1/cells than PARP-1+/+ cells.
Similarly, arsenic exposure for 24 hours resulted in an increased tail
moment, indicating the impaired repair efficiency of arsenite-
induced DNA damage in PARP-1 null cells (Fig. 4D).
PARP-1/ mouse embryonic fibroblasts are more sensitive
to arsenite induced cell death. The dependence of elevated
persistent DNA damage and telomere attrition on cell viability
was next evaluated by flow cytometry. Although no marked
differences were observed between the two cell types at 24 hours
after arsenic treatment, PARP-1 null cells showed a 2-fold increase
over PARP-1-proficient cells in apoptotic death at 48 hours after
arsenite treatment (P < 0.05, m2 Testand Fisher’s exact test; Fig. 5A
and B) illustrative of a delayed cell killing effect. This increased
cell death was further verified by 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide assay and crystal violet assay
(data not shown). Cell cycle analysis is useful for detecting early
events of DNA damage/repair response, and cells deficient in DNA
repair invariably exhibit abnormal cell cycle checkpoint regulation.
To determine whether the increased cell death of PARP-1/
cells is due to loss or abnormal checkpoint regulation, cell cycle
analysis was done after arsenic treatment in both PARP-1+/+ and
PARP-1/ cells. Both cell lines showed a dose-dependent increase
(P < 0.05) in apoptosis visualized as sub-G1 population of cells
and the fraction of sub-G1 population being higher in PARP-1
/
cells than PARP-1+/+ cells. There was a corresponding decrease
(P < 0.05) in G1 cell population in both PARP-1-proficient and
PARP-1-deficient MEFs at 24 and 48 hours of treatment (Fig. 5A
and B). At 48 hours after treatment with As3+, the percentage of
G2-M phase cells had greatly reduced (P < 0.05) in PARP-1
/
MEFs compared with PARP-1+/+ MEFs. It is likely that mitotic
Figure 5. Cell cycle profile and cell viability were assessed by flow cytometry in
both genotypes [PARP-1+/+ (first three columns ) and PARP-1/ (last three
columns )] after arsenite treatment with different doses (1.5 and 3.0 Ag/mL) for 24
hours (A ) and 48 hours (B). Arsenite-treated PARP-1/ MEFs showed more
cell death as indicated by the sub-G1 population of cells in a time-dependent
manner compared with the normal MEFs. Percentage of cells in different cell
cycle stages after arsenic treatment in PARP-1-proficient and PARP-1-deficient
cells (histograms ). Percentage of cells in each phase of cell cycle was
compared with the respective phase in treated samples. *, P < 0.05, compared
with respective untreated sample (m2 test and Fisher’s exact test). **, P < 0.05,
compared with respective untreated sample as well as with As3+-treated
PARP-1+/+ MEFs.
Figure 6. Gene expression data were obtained using Affymetrix Mouse
Genome 430 2.0 GeneChip. Cluster diagram, 311 differentially expressed
probes with P < 0.05 and fold change of >2.0 in one of the experimental
conditions. Column, a single experiment condition; row, a single gene.
Expression levels (red) for up-regulation and (blue ) for down-regulation
according to the color scale.
Cancer Research
Cancer Res 2005; 65: (23). December 1, 2005 10980 www.aacrjournals.org
catastrophe occurs increasingly in PARP-1/ cells, leading to increased
apoptotic death detected by an increase in sub-G1 cell population.
Differential gene expression patterns in PARP-1+/+ and
PARP-1/ cells after arsenite treatment. To study the
differential gene expression patterns in PARP-1+/+ and PARP-1/
MEFs with or without arsenite treatment, microarray technology
was employed. Using this technology, the expression pattern of
over 34,000 genes was analyzed and compared with untreated
controls. PARP-1+/+ and PARP-1/ MEFs were treated with
1.5 Ag/mL of As+3 for 24 hours and then subjected to gene
expression studies. Microarray analysis was focused on genes that
were altered with a >2-fold change with P < 0.05. A one-way
ANOVA test was done to find distinct groups of genes that were
significantly changed. Analysis has indicated that there are about
311 genes, which are differentially expressed among the different
groups (control versus treated, PARP-1/ versus PARP-1+/+). These
genes belong to different biological processes, such as apoptosis/
cell death, physiologic processes, and response to stress/external
agents. The data are presented as a hierarchical clustering in
Fig. 6 for the genes with differential expression in arsenic-treated
Table 1. Functional categorization of differentially expressed genes in PARP-1+/+ and PARP-1/ MEFs after arsenite
treatment










Response to stress and external stimuli
Prdx1 NM_011034 8.78 1.53 3.7 49.71
Hspcb BI154147 5.86 1.3 4.25 19.09
Daf1 NM_010016 41.28 5.84 3.45 69.9
Gadd45a NM_007836 5.29 1.52 1.67 5.79
Sod1 BC002066 5.96 1.52 1.81 16.4
Hspa1b M12573 2.47 9.08 2.35 1.56
Hspa1a AW763765 17.88 230.82 14.21 1.1
Ifi30 NM_023065 4.51 2.39 1.83 5.89
Ii BC003476 3.42 15.5 4.51 1.01
Cell growth and maintenance
Afp NM_007423 10.16 48.71 100 30.34
Ube1c NM_011666 4.71 2.58 1.73 21.08
Calm1 AU079514 4.84 1.98 4.59 11.22
Ets1 BC010588 2.17 4.69 1.15 8.86
Ube2b AK010432 4.63 6.53 1.32 39.99
Arhgap5 BM248774 4.8 1.23 3.49 1.12
Btg1 L16846 4.59 2.1 1.35 13.01
Mt2 AA796766 11.85 1.84 1.82 3.53
Prkar1b BB274009 7.27 3.91 82.96 44.58
Ikbkg BB821318 5.17 1.08 1.71 9.56
Slc9a3r1 BB805362 7.34 1.25 5.72 1.6
Rab3d BB349707 1.67 60.42 47.56 2.12
Myrip BB429683 11.03 1.12 19.61 1.59
Cell death
Mcl1 BC003839 4.52 1.02 1.22 3.65
Hspa1b M12573 27.13 24.35 1.43 1.28
Elmo3 AI481208 4.17 1.21 4.21 1.19
Sod1 BC002066 5.96 1.52 1.81 16.4
DNA metabolism
Foxc1 BB759833 0.85 9.41 11.5 1.03
Uox M27695 0.95 10.66 6.9 1.63
Rfx3 BC017598 0.04 2.06 1.49 32.13
Lbh AK007400 4.27 1.08 3.32 1.39
Hoxd8 BF785056 2.21 24.02 7.5 7.08
Ncor1 BM239260 7.93 1.63 7.42 1.52
Ash1l BG694892 2.12 1.94 6.76 1.64
Zfp99 AK009842 4.38 1.35 4.27 1.39
Prps2 BM934034 4.16 2.06 6.68 1.28
NOTE: Expression profile of selected genes, which were differentially expressed to a fold change of z2.0 in one of the treatments is given. Data indicate
the fold increase (positive values) or decrease (negative values) in treated samples compared with corresponding controls.
*Compared with untreated PARP-1+/+ MEFs.
cCompared with untreated PARP-1/ MEFs.
bCompared with untreated PARP-1+/+ MEFs.
xCompared with treated PARP-1+/+ MEFs.
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samples. It is clear from the data that there are several genes,
which are up-regulated in both PARP-1+/+ and PARP-1/
following arsenic treatment. Differentially expressed genes were
classified according to Gene Ontology: Biological Process.
Expression profile of selected genes, which were differentially
expressed to a fold change of z2.0 in one of the treatments, is
given in Table 1. We have also identified candidate genes, which
are in apoptosis and cell cycle pathways following treatment
with arsenic. Differences observed in the expression patterns of
these genes (data not shown) between the PARP-1-proficient and
PARP-1-deficient cells warrant further investigation.
Discussion
In this study, PARP-1-deficient cells showed a greater telomere
attrition than in PARP-1-proficient cell lines at doses of 11.5 and
23 Amol/L. Use of low concentrations (<1.0 Amol/L) of arsenite
have been shown to promote telomerase activity with or without
an increment in telomere length (22). High concentrations of
arsenite (>1.0 Amol/L) used in this study have shown a rapid and
dramatic loss of telomeric DNA, leading to apoptotic cell death.
Although inhibition of telomerase alone by arsenite may cause
telomere shortening over numerous population doublings, rapid
telomere loss was observed in PARP-1/ cells after only 24 to 48
hours of sodium arsenite treatment. There are several possible
explanations for this observation. Rapid telomere loss may be due
to the susceptibility of the hexametric repeat structure of
telomeric DNA (triple-G-containing structures) to oxidative
damage (23, 24), as available evidences indicate that oxidative
stress has the potency to break polyguanosine sequences in
telomeric repeats, leading to telomere loss (19, 25). Arsenite, being
one of the efficient inducers of oxidative stress (13, 14, 26), can
also break polyguanosine sequences in telomeric repeats, result-
ing in rapid telomere loss (27). Additionally, DNA repair in the
telomeric DNA was shown to be less efficient than the rest of
the genome (25), further exacerbating the telomere attrition in
the absence of the PARP-1 gene product. In view of the
interactions of PARP-1 with the participants of the base excision
repair pathway (BER; refs. 28, 29), it is likely that PARP-1
deficiency may be a contributing factor to the rapid telomere
shortening due to perturbations in the cellular processes of DNA
damage recognition and repair. Consistent with this, deficiencies
in both shortlong- and long-patch BER pathways have been
reported in PARP-1-deficient cells (28). This study (28) shows that
both uracil and 8-oxoguanine are poorly repaired in PARP-1-
deficient cells compared with wild-type cells. Arsenite has been
shown to induce a wide variety of oxidized base lesions, including
8-hydroxyguanine (30). Furthermore, acute arsenic treatment
inhibits the activity of human 8-hydroxyguanine glycosylase
(OGG1) enzyme (30). Hence, a fundamental BER deficiency in
the absence of PARP-1 is presumably responsible for the
enhanced sensitivity of PARP-1 null cells to arsenite treatment.
Recently, arsenic mutagenicity has been shown to involve mito-
chondrial DNA damage (31), and it is presently unclear whether
PARP-1 is also involved in BER process in mitochondrial DNA.
Earlier studies have implicated telomere shortening as an
important checkpoint to limit the potential of human cells to
proliferate (32). Shortening of telomeres triggers an apoptotic
response in a p53-dependent manner (33). Telomere dysfunction
coupled with chromosome instability due to inefficient DNA repair
might be responsible for increased cell death in PARP-1-deficient
cells. The cellular hypersensitivity of PARP-1 null cells therefore
unequivocally projects the role of PARP-1 as a survival factor
against arsenic exposure. One of the earliest responses to ionizing
radiation– and alkylating agent–induced DNA damage is the
poly(ADP) ribosylation of many nuclear proteins, which is
mediated chiefly by PARP-1 and to a lesser extent by the PARP
family of proteins (2, 34). Arsenite was shown to inhibit poly(ADP)
ribosylation of proteins (7) in mammalian cells, and it is presently
unclear whether the lack of poly(ADP) ribosylation of proteins
affects the DNA repair process. As PARP-1 is implicated in diverse
repair pathways, particularly BER, it is reasonable to assume that
the increased cell death, telomere attrition, and genomic instability
observed in PARP-1 null cells is due to inefficient repair of oxidized
base lesions.
Telomere length maintenance has also been implicated in cancer
development due to reactivation of telomerase in tumor cells.
Telomerase inhibition is therefore emerging as a promising
approach in cancer chemotherapy (35, 36). Treatment of cancer
cell lines with telomerase inhibitors induces telomere shortening
and halts cellular proliferation (35). The importance of PARP-1 in
telomere integrity suggests that PARP-1 inhibitors may present a
myriad of potential therapeutic applications, especially in cancer
treatment (37, 38). Seimiya et al. (37) showed that the combination
of inhibitors to the PARP family protein found at the telomeres,
tankyrase, might serve as an effective anticancer therapy approach
(36, 37). Because PARP-1 deficiency increases the cytotoxicity of
arsenite treatment, PARP-1 inhibitors could also be used in
combination with other DNA-damaging agents to increase the
cytotoxicity of cancer cells (39).
Gene expression studies have revealed differential expression of
>300 genes following arsenic treatment in PARP-1+/+ and PARP-1/
MEFs. Genes that are up-regulated or down-regulated following
treatment with arsenic in both cell types include genes that
participate in diverse biological processes, such as cell death, signal
transduction, response to stress/external stimulus, and cell growth
and/or maintenance. As many as 36 genes involved in response to
external stimulus were differentially expressed in the treated
samples. More importantly, about 39 genes, which are important
for cell growth and/or maintenance, were altered in their
expression profiles. This clearly indicates that PARP-1 has a role
in the above cellular processes, which warrants further validation
and investigation. Differential expression in these genes may
provide biomarkers for gaining insights into mode of arsenic
toxicity. Efforts are under way to identify and characterize specific
DNA repair and cell cycle pathway(s) in the pathobiology of arsenic
exposure. Taken together, our study identifies PARP-1 as one of
the important genetic factors responsible for mediating the toxic
effects of arsenite.
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